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Abstract 
Hypercholesterolemia is a classical risk factor for cardiovascular disease 
development. The genetic etiology of hypercholesterolemia in familial combined 
hyperlipidemia (FCH), one of the most common genetic dyslipidemias, is poorly 
understood. We aimed at understanding the genetic etiology of hypercholesterolemia 
in FCH. 
Sequencing, genotyping and computational analyses were performed in a case-
control setting to better understand the ‘nature’ aspect of hypercholesterolemia in 
FCH. My findings suggest that FCH more likely has a polygenic basis. 
All my findings have shown that the genetic definition of a disease, especially 
relatively common diseases like FCH that have been previously considered to be 
monogenic, may need to be reconsidered. Thus findings from my studies of FCH 
support a new direction in thinking about the genetic etiology of this common human 
hyperlipidemia. 
 
Key Words: Hypercholesterolemia, Familial Combined Hyperlipidemia, Rare 
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Chapter 1: Introduction 
1.1 Cardiovascular Disease 
 
1.1.1 Definition of cardiovascular disease (CVD) and current statistics  on 
Cardiovascular Disease 
Cardiovascular disease (CVD) is the generic term that describes any disease 
that affects the cardiovascular system, including the heart and blood vessels. Many 
diseases fall under the classification of CVD. Ischemic heart disease and stroke are 
common examples of CVD. In ischemic heart disease, there is reduced supply of 
blood to the heart muscle; in stroke there is reduced blood flow to the brain. Some of 
the various types of CVD are shown in Table 1.1. 
CVD is the leading cause of mortality in North America. Even though the 
relative rates of mortality due to CVD have declined due to improvements in disease 
management and prevention, the absolute numbers of patients are rising due to the 
aging of the “baby boomer” generation and CVD in absolute terms still remains the 
leading cause of death and disability (1, 2). Figure 1.1 summarizes the statistics of 
mortality rates of CVD in North America over time. 
CVD is also becoming the leading cause of death worldwide because of the 
changes in diet and lifestyle of individuals in developing countries. Individuals from 
developing countries are adopting the stereotypical Western lifestyle of low physical 
activity and unhealthy diet, causing CVD to become the leading cause of death 
globally. Table 1.2 summarizes global CVD statistics.  
 
2 
 
 
 
 
 
 
1.1.2 Risk Factors for CVD according to the Framingham Heart Study  
Epidemiological studies, such as the Framingham Heart Study and its derived 
risk score, have shown that there are certain common factors that put an individual at 
risk for developing CVD (3). These Framingham risk factors are diabetes, 
hypertension, age, sex, obesity, cigarette smoking, elevated plasma low density 
lipoprotein cholesterol (LDL-C) levels and depressed high density lipoprotein 
cholesterol (HDL-C) levels (3, 4). Table 1.3 briefly describes how each risk factor 
contributes to increased CVD 
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Table 1.1 Brief description of the some of the different types of cardiovascular 
diseases. Information in this table was taken from  (5), (6) 
Type of CVD Brief Description 
Coronary Heart 
Disease 
Coronary Heart Disease (CHD) is also known as coronary artery 
disease (CAD) and Ischemic Heart Disease (IHD). In CHD 
there is blockage in the coronary artery of the heart. This 
blockage deprives the heart muscle of oxygen and vital 
nutrients, which could result in myocardial infarction (7) 
Stroke Impairment of brain functions due to reduced blood flow to the 
brain. Lack of blood flow may be due to rupture of vessel wall 
(hemorrhagic) or due to block (ischemic) (5) 
Hypertensive heart 
disease 
The abnormal regulation of systemic blood pressure due to 
higher than normal arterial blood pressure (6) 
Rheumatic heart 
disease 
Heart disease where there is inflammation of the heart muscle 
due to rheumatic fever.  Rheumatic fever is brought about by 
infection with the streptococcus bacteria (6) 
Congenital heart 
disease 
Heart disease in which there is malformation in the heart organ 
from birth. These malformation may be due to genetic defects or 
may be due to environmental exposure to teratogens during 
gestation (6) 
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Figure 1.1 North American Mortality rates of cardiovascular disease from 
1970 to 2002. Information from this table was taken from (2, 8, 9) 
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Type of CVD   
Global deaths due to type of 
CVD Proportion of deaths  
Coronary Heart Disease 7.2 million 43% 
Stroke 5.5 million 33% 
Other forms of Heart Disease 2.4 million 14% 
Hypertensive Heart Disease 0.9 million 5% 
Inflammatory Heart Disease 0.4 million 3% 
Rheumatic Heart Disease 0.3 million 2% 
Total number of deaths 16.7 million 100% 
Note: Proportion of death refers to proportion of global deaths due to CVD that result from a 
particular type of CVD. Information in this table was taken from World Health Organization 
(WHO) (http://www.who.int/cardiovascular_diseases/en/cvd_atlas_01_types.pdf Accessed July 
1st 2013). 
 
Table 1.2 Number of global deaths, in 2002, due to various types of cardiovascular 
diseases.  
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Risk Factor Brief Description of association 
Age CVD risk increases with age (3) 
Sex Males and postmenopausal women are at greater risk than 
premenopausal women(3) 
BMI Overweight individuals are at a greater risk of CVD development(3) 
Diabetes Diabetes increases risk(3) 
Smoking Smoking increases risk of CVD(3) 
Hypertension High systolic blood pressure increases CVD risk(3) 
Total 
Cholesterol 
High cholesterol due to elevated LDL-C increases risk(3) 
High Density 
Lipoprotein 
Cholesterol 
(HDL-C) 
HDL-C is a negative risk factor – high levels of HDL-C reduce the 
risk of CHD(3) 
Table 1.3. Cardiovascular Disease risk factors according to the Framingham 
Heart Study with brief explanation of each risk factor(3). 
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1.2 Hypercholesterolemia  
Cholesterol belongs to the family of organic compounds called steroids (10). A  
steroid can be defined as a compound that has 17 carbon atoms arranged in 4 rings 
(11). Steroids fall under a large group of macromolecules called lipids; so cholesterol 
is a lipid. A lipid can be defined as an organic molecule that does not chemically 
interact with water (12). However this definition of a lipid is contextual as many 
lipids are amphipathic and the majority of the structure of amphipathic lipids is still 
hydrophobic. Cholesterol is a good example of an amphipathic lipid, in which a 
majority of its structure is hydrophobic, while a minority of its structure is hydrophilic 
(i.e. the hydroxyl group). The structure of cholesterol is shown in Figure 1.2  
Cholesterol is essential to life. Cholesterol is required for the formation of cell 
membrane, bile acids, steroid hormones and formation of vitamin D. Humans have 
endogenous and exogenous sources of cholesterol. Cholesterol is synthesized by the 
liver in humans (endogenous source). Cholesterol is also obtained from the diet 
(exogenous source) (10).  
Hypercholesterolemia is a condition where there is an aberrantly elevated 
concentration of cholesterol in the blood. As alluded to in Section 1.1.2, 
hypercholesterolemia increases an individual’s risk for CVD. Section 1.2.4 will 
discuss how hypercholesterolemia increases CVD risk. An individual’s cholesterol 
levels can be somewhat influenced by environmental factors such as dietary intake of 
cholesterol. However, genetic factors account for over 50%, and perhaps up to 80% of 
inter-individual variation in cholesterol levels in the human population (13). 
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Figure 1.2 Chemical Structure of Cholesterol. It is a general steroid with some 
odd hydrocarbon side chain.  Cholesterol is an organic molecule that is a steroid. 
Cholesterol has 17 carbon atoms arranged in 4 ring structures. Even though the 
definition of a lipid is a molecule that is hydrophobic, there are many lipids, like 
cholesterol, that are amphipathic with a majority of its structure being 
hydrophobic. The hydroxyl (OH) group of cholesterol is the only hydrophilic 
portion of the molecule and that hydrophilic portion of the molecule is still not 
enough to make it soluble in the aqueous blood. This figure shows the entire 
molecule soluble in aqueous blood. This is why cholesterol must be transported in 
the form of a lipoprotein. This figure is taken and modified from Food and Health 
Communications, Inc. 
(http://dev.foodandhealth.com/clipart.php?cat=9&img=Cholesterol_Structure.jpg ) 
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1.2.1 Lipoprotein metabolism in general  
 Lipids such as cholesterol are insoluble in the aqueous blood. So, cholesterol 
needs to be transported within macromolecular complexes called lipoproteins that 
contain specific biological transporter proteins called apolipoproteins (or 
apoproteins). A lipoprotein can be defined as the assembly of a lipid and a protein (i.e. 
apolipoprotein) as a single unit. An apo-protein also refers to a protein in the state 
where it is unbound to its ligand (14). Within a lipoprotein, lipids such as cholesterol 
are bound to and held within the surface apolipoproteins and thus can be transported 
through the bloodstream (14). Cholesterol is transported as two main types of 
lipoproteins; the cholesterol within these particles is identical, but it is the 
biochemical behaviour of the particle which determines whether the cholesterol is 
“good” or “bad” in popular parlance. Cholesterol is transported from its site of 
synthesis (i.e. the liver) to other parts of the body within low density lipoprotein 
(LDL) particles. Excess or unused cholesterol is transported from body tissues back to 
the liver with high density lipoprotein (HDL) particles (14). There are various types of 
lipoproteins in human blood and they all have one main function, which is the 
transportation of lipids in the blood. Other types of lipids such as triglycerides are 
transported in the blood as very low density lipoprotein (VLDL) or chylomicrons. 
Cholesterol carried within LDL particles can become embedded within the 
interior wall of the arteries, which with repeated deposition over time leads to 
atherosclerosis (which shall be explained in section 1.2.4). That is why LDL-C is 
colloquially referred to as ‘bad cholesterol’; as mentioned, the cholesterol is identical 
to the substance found inside HDL particles, but by virtue of the fact that LDL 
particles (but not HDL particles) can become deposited within the arterial wall, the 
cholesterol within them gets its “bad” reputation. Hypercholesterolemia is usually the 
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result of abnormally elevated plasma LDL particles and excess LDL-C. In other 
words, aberrantly elevated LDL corresponds to excess cholesterol because cholesterol 
in the blood is mainly carried within LDL particles (10)   
A minor proportion of cholesterol in the blood is carried within HDL particles: 
the cholesterol within HDL particles has been extracted from peripheral tissues, is 
transported back into the liver and metabolized for bile acid synthesis. Because 
cholesterol inside the HDL particle has been removed from peripheral cells and the 
arterial wall, and is ultimately cleared from the blood, the identical cholesterol inside 
the HDL particle is referred to by lay people as “good cholesterol” based not on the 
properties of the cholesterol molecules, but rather based on the biochemical behaviour 
of the HDL particles (10).  The Framingham study showed that high levels of HDL-C 
are associated with reduced CVD risk in patients, which is consistent with what is 
understood about the action of HDL particles biochemically and physiologically. 
 
1.2.2 Low Density Lipoprotein Cholesterol (LDL-C) metabolism  
Two thirds of the body’s cholesterol is contained within LDL (15) and this is 
mainly endogenous cholesterol made in the liver (16). Cholesterol is synthesized in a 
multi-step biochemical process from acetyl-CoA and hydroxymethylglutaryl-CoA 
(HMG-CoA) reductase, which is the enzyme that catalyzes the rate determining step 
in the process (16). LDL particle formation can be either the result of direct release 
into circulation from the liver, or through conversion of circulating VLDL to LDL in 
bloodstream.  The proportion of LDL produced via VLDL varies from individual to 
individual. On average about two-thirds of circulating LDL is derived from 
conversion from VLDL and about one-third is derived from direct synthesis by the 
liver (17).  
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 Catabolism of LDL is brought about by the LDL receptor pathway, whereby 
LDL is internalized in the cell through receptor mediated endocytosis (15). After 
receptor-mediated endocytosis, LDL is degraded within the lysosomes, and the 
cholesterol released suppresses HMG-CoA reductase; thus cholesterol regulates its 
own synthesis through negative feedback (18).  Cholesterol within the cell is 
esterified and can be used for a variety of important functions depending on the cell 
type.  The LDL receptor is then recycled back to the cell surface, and the process of 
receptor mediated endocytosis can resume.  It is very important to appreciate that the 
LDL receptor is the main regulator of LDL-C levels in the blood.  Exogenous 
cholesterol is absorbed into the blood and transported in chylomicrons, and through 
breakdown, this cholesterol finally reaches the liver and is repackaged within VLDL 
and LDL particles (16). Figure 1.3 summarizes LDL-C metabolism. 
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Figure 1.3 LDL metabolism. Most of the LDL in blood is derived from VLDL catabolism. 
When the triglycerides in VLDL are hydrolyzed, the remnants are referred to as IDL. Some 
IDL gets cleared from plasma by the liver. The remaining IDL that does not get cleared 
undergoes further triglyceride hydrolysis and becomes LDL. Some LDL found in plasma is 
also produced directly from the liver. LDL gets cleared from the blood through the LDL 
receptor pathway. In the LDL receptor pathway, LDL binds to its receptor, LDLR, which is 
expressed on the cell surface of most cells especially the liver. The complex of LDL-and 
LDLR enters the coated pit and is internalized. The coated vesicle loses its clathrin coat and 
becomes an endosome, which is the site of lipoprotein and receptor dissociation. The LDL 
receptor recycles to the cell surface, and the lipoproteins are degraded in the lysosomes. 
HDL transports cholesterol from peripheral tissues back into the liver. This figures was 
taken and modified from http://health-7.com/imgs/15/947.jpg  
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1.2.3 High Density Lipoprotein Cholesterol (HDL-C) metabolism  
 HDL transports cholesterol from peripheral tissues, including the arterial wall, 
back into liver (19), which is a process referred to as “reverse cholesterol transport”. 
HDL-cholesterol is known as the ‘good cholesterol’ because it has been removed 
from potentially dangerous sites by the process of reverse cholesterol transport. HDL 
also has beneficial properties: for instance it blocks the proatherogenic oxidation of 
LDL in the vessel wall (19). HDL has been seen as cardio-protective. HDL-C levels 
had consistently shown an inverse relationship with CVD risk (19). Researchers have 
questioned whether or not there is direct causality between HDL and CVD risk; 
specifically, is HDL directly protective or is it merely a marker of some other entity or 
process that is directly protecting the heart and arteries (19)? Thus the precise role and 
mechanism of action of HDL are currently controversial in the field (20).  
1.2.4 Mechanism of atherosclerotic plaque formation due to elevated plasma 
LDL-C levels  
 The arterial wall is made up of three layers, namely, (i) tunica intima, (ii) 
tunica media and (iii) tunica adventitia (21). A schematic figure of an artery is shown 
in Figure 1.4.  Atherosclerosis can be said to start with a lesion that occurs in the 
endothelium of the arterial wall; this can be due to a toxin from cigarette smoke, or 
chemical or physical stress, such as high blood pressure. This initial injury or lesion 
then causes LDL to enter the arterial wall and accumulate in between the endothelium 
and tunica intima. When the LDL-C level is high in the plasma and remains in plasma 
for long,, it is more likely to become oxidized.  
 The properties of oxidized LDL are different from that of regular (i.e. native) 
LDL (22). Oxidized LDL is an immunogen, i.e. it triggers an immune response. As a 
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result of the immune response (23), monocytes from the bloodstream come to the site 
of oxidized LDL as the monocytes recognize oxidized LDL as a foreign substance. As 
the monocytes enter and take up residence within the arterial wall, they ingest the 
oxidized LDL and become macrophages. When the macrophages become filled up 
with oxidized lipids, they enlarge and take on a “foamy” appearance, which is why 
they are referred to as “foam cells”. These foam cells eventually die, leaving the 
cholesterol permanently embedded within the arterial wall.  As the process repeats 
over time, the cholesterol within the wall builds up into structures called “plaques” 
which can begin to cause narrowing and eventually occlusions of the artery. Larger 
and more mature plaques narrow the lumen of the artery; they are also prone to 
bursting or rupture and these unpredictable and dramatic events can suddenly 
completely block the artery, leading to a heart attack (myocardial infarction) or a 
stroke, depending on the anatomical location of the artery (23, 24). Figure 1.5 
visually summarizes the process of atherosclerosis. 
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Figure 1.4 Structure of the artery. The artery is made up of a three layers and an 
innermost endothelium. From the endothelium, the three layers are: tunica intima, 
tunica media and tunica adventitia, respectively. Atherosclerosis occurs between 
the endothelium and tunica intima (or essentially the tunica intima). This figure 
was taken from Encyclopedia Britannica (21).  
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Figure 1.5 Atherosclerotic plaque formation. Native LDL becomes trapped 
between endothelium and tunica intima and undergoes oxidation. Then the 
resident monocytes transform into macrophages that take up oxidized LDL. After 
the macrophages consume oxidized LDL, they becoming foam cells. The foam 
cells enlarge and die, which leads to cholesterol being permanently embedded in 
these foam cells. This buildup of cholesterol leads to formation of structures 
called plaque. Plaque formation leads to narrowing of the lumen and thus reduces 
blood flow in the artery. This figure was taken and modified from Rochester 
Institute of Technology ( http://cias.rit.edu/faculty-staff/101/student/287 ) 
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1.2.5 Low Density Lipoprotein (LDL): Structure and Function  
 LDL is the lipoprotein through which cholesterol and esters of cholesterol are 
transported in blood (25). LDL is a spherical amphipathic assembly, where the 
hydrophilic portion is outwards facing and interacting with aqueous blood and the 
hydrophobic portion is inwards. Figure 1.6 shows the structure of LDL (25). The 
hydrophobic core of LDL consists of esterified cholesterol (or cholesteryl ester) and 
some triglyceride. The phospholipid and apolipoprotein are found on the particle 
surface. The main apolipoprotein in LDL is apolipoprotein (apo) B-100 (25). 
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Figure 1.6 (a) Structure of LDL (25) Low Density Lipoprotein (LDL) is an 
assembly of proteins and lipids. LDL is the most abundant cholesterol carrying 
lipoprotein. The unesterified cholesterol and phospholipid faces outward that is 
surrounded by aqueous blood. The hydrophilic portion of the phospholipids faces 
the aqueous blood and thus makes up the polar surface of LDL. The esterified 
cholesterol (or cholesteryl ester) is the inner portion and makes up the 
hydrophobic (non-polar core). Esterified cholesterol is cholesterol with its 
hydroxyl group esterified. Esterification of cholesterol ensures efficient 
transportation of cholesterol because more cholesterol can be packed into the non-
polar core when it is esterified (b) (Top) Representation of ApoB-100 of LDL(26) 
The large circle represents the lipids portion of LDL (i.e. the lipid core), 70% of which is 
cholesterol.  ApoB is believed to wrap around the lipid core as shown. The dark circles 
represents the cysteine residues and the unshaded circles on ApoB represent the N-
glycosylated carbohydrates. Part of ApoB is exposed to the surface and part of ApoB is 
buried in the lipid core. (Below) (27) Another representation of ApoB. The LDLR 
binding region is believed to be included in residues 3000 to 4000.  
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1.2.6 Proteins that normally control LDL-C levels: HMG CoA reductase,   
LDLR, ApoB, PSCK9, ARH, and IDOL  
Cholesterol is a highly regulated molecule, especially within cells.  Proteins 
that normally control plasma LDL Cholesterol (LDL-C) levels are: HMG CoA 
reductase, Low Density Lipoprotein Receptor (LDLR) (18), Apolipoprotein B-100 
(ApoB) (28), PCSK9 proprotein convertase subtilisin/kexin type 9 (PSCK9) (29), 
LDLR adaptor protein (LDLRAP1) also called the Autosomal Recessive 
Hypercholesterolemia gene (ARH), and Inducible Degrader of LDLR (IDOL) (30). 
All of these proteins, except for HMG CoA reductase and ARH will be focused on in 
this thesis. The downstream effect of  defective LDLR and ApoB is increased plasma 
LDL-C and total cholesterol levels (18, 31), while the downstream effect of defective 
PCSK9 function is decreased plasma LDL-C and total cholesterol levels (29, 30). 
Section 1.2.2 discussed HMG-CoA reductase, while section 1.4 will discuss the other 
proteins. Figure 1.7 is a visual representation of how all six proteins interact to affect 
LDL metabolism. 
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Figure 1.7 Schematic of how LDLR, ApoB, PCSK9, ARH, HMG CoA and 
IDOL affect cholesterol levels. Normal functioning of HMG-CoA reductase 
(written as HMG-CoA in the diagram), IDOL and PCSK9 increase LDL-
cholesterol levels. Normal functioning of LDLR, ApoB and ARH decrease 
LDL-cholesterol levels. 
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1.3 Dyslipidemias  
Dyslipidemia is the term used to describe abnormal levels of lipids in the blood. 
As alluded to in Section 1.2, lipids are macromolecules that are vital to many 
functions within the human body, and show a range of normal levels in the blood. So, 
just like water, too much or too little cholesterol can be pathogenic. Most pathogenic 
human dyslipidemias are hyperlipidemias, so literature focuses on hyperlipidemia 
(32). 
 
1.3.1 Fredrickson’s classification of hyperlipidemia  
 Lipids and lipoproteins have been described in detail in section 1.2. The 
Fredrickson classification system describes the various hyperlipidemias that can affect 
patients based on the lipoprotein that is increased in the plasma. The Fredrickson 
classification says nothing about the etiology of the phenotype; it simply describes the 
phenotype based on the pattern of lipoprotein elevation. So, a particular Fredrickson 
phenotype may result from multiple genetic defects. The Fredrickson scheme does not 
include a description of any human hypolipidemia. Table 1.4 summarizes the 
Fredrickson classification (33). Because an individual’s plasma lipid levels normally 
rise after a meal, hyperlipidemia is defined after a 12-16 hour fast (33) (34). The 
World Health Organization (WHO) uses the Fredrickson classification to describe 
hyperlipidemia (34). Most, but not all human hyperlipidemias are described using the 
Fredrickson system (34). 
In Table 1.4, the word “Familial Hyperlipidemia” is used. However, usage of 
the word ‘Familial’ needs to be clarified here. In the field and colloquially, ‘Familial’ 
often implies a monogenic etiology (35). However, familial does not necessarily need 
to be monogenic because the familial hyperlipidemias in Table 1.4 are primary 
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hyperlipidemias in that they cluster in families but do not necessarily follow a specific 
Mendelian pattern of inheritance (35). 
 Another way of classifying hyperlipidemia is using "primary" or "secondary" 
nomenclature. Primary hyperlipidemias usually result from a genetic defect of some 
sort, while secondary hyperlipidemias result from other existing diseases in an 
individual. For instance, a poor diet, excessive alcohol intake, obesity, diabetes, 
thyroid disease, liver disease, kidney disease, autoimmune disease and certain 
medications such as corticosteroids or drugs that target the human immunodeficiency 
virus, can each cause secondary hyperlipidemia (34). 
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Fredrickson 
classification 
Familial  
Hyperlipidemia 
Elevated 
Lipoproteins 
Elevated 
Lipids 
Type  1 Chylomicronemia CM TG 
Type 2A Hypercholesterolemia LDL TC 
Type 2B Combined hyperlipidemia VLDL, LDL TC, TG 
Type  3 Dysbetalipoproteinemia IDL TC, TG 
Type  4 Hypertriglyceridemia VLDL TC 
Type 5 Mixed Hyperlipidemia VLDL, CM TC, TG 
Note: Abbreviations: CM, Chylomicron; LDL, Low Density Lipoprotein; VLDL, 
Very Low Density Lipoprotein; IDL, Intermediate Density Lipoprotein; TC, Total 
Cholesterol, TG, Triglyceride. Information in this table was taken from Fredrickson et 
al (33) 
 
Table 1.4 Fredrickson classification of hyperlipidemia.  
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1.3.1.1 Focus on Fredrickson types 2A and 2B (FH and FCH) 
Fredrickson Type 2A and Type 2B are the only phenotypes that include 
hypercholesterolemia in its phenotypic description. The diseases Familial 
Hypercholesterolemia (FH) and Familial Combined Hyperlipidemia (FCH) are 
designated as Type 2A (elevated LDL only) and Type 2B (elevated LDL and VLDL 
both) Fredrickson phenotype classes, respectively. The disease Familial 
Hypertriglyceridemia (FHTG) is identical with the Fredrickson Type 4 (elevated 
VLDL) phenotype. Previous work from our lab has shown that the FCH and FHTG 
have a common genetic etiology for elevated triglyceride (TG), which is a 
combination of many single nucleotide polymorphisms (or SNPs) that each contribute 
a small amount to raise levels of, but which cumulatively act to raise TG to a 
clinically relevant level. My hypothesis was that FCH may be a condition that is due 
to the co-existence of FH (a disease that is due to rare mutations in the LDLR that 
raise LDL-C levels) and FHTG (a disease that is due to common polymorphisms that 
raise TG levels) (Figure 1.8).  
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Figure 1.8 Venn diagram suggesting a genetic model for Familial Combined 
Hyperlipidemia (FCH). Elevated LDL occurs in FH and elevated VLDL occurs 
in FHTG. Elevated LDL and elevated VLDL occurs in FCH. Previous work from 
Hegele lab has shown that the TG (essentially VLDL) elevation in FCH and 
FHTG is due to similar genetic etiology, namely the accumulation of many 
common SNPs, each with a small effect on risk. So I hypothesized that FCH 
could reflect the coexistence of FH (rare variants that raise LDL-C) and FHTG 
(common variants that raise VLDL). 
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1.3.2 Role of genetics in dyslipidemia 
 
1.3.2.1 Genetic Variation and Disease  
Most complex diseases have both an environmental etiology and genetic 
etiology. The ratio of environmental factors to genetic factors in the causation of a 
disease varies from disease to disease and from individual to individual. There are 
various types of genetic variation. I define genetic variation can be defined as any 
change in the DNA sequence in an individual’s DNA. This change in sequence can be 
brought about, for instance, either by small substitutions of nucleotide or by larger 
gains or loss of DNA, such as insertions and deletions. Sometimes the word ‘genetic 
variation’ is considered to be synonymous with ‘mutation’. The meaning of the word 
mutation depends on the context in which it is used. In a clinical setting, mutation 
usually refers to a rare genetic variation that leads to a dysfunctional gene product, 
which consequently leads to lack of wellbeing. So, in clinical terms, every mutation is 
a genetic variation but not every genetic variation is a mutation. The definition of 
mutation in this thesis is that of the clinical setting, in which it refers to a rare 
molecular event that likely affects the normal function of the gene product and could 
lead to an abnormal phenotype or disease. 
Cystic Fibrosis (CF) and phenylketonuria (PKU) are examples of diseases that 
result mainly from genetic variation in a single gene that is sufficient to cause the 
disease.  These are referred to as “monogenic diseases” and are individually rare in 
the population.  For instance, the prevalence of CF in North America is about 1 out of 
2500 live births, which makes CF the most common recessive disorder in individuals 
of European descent (36). Phenylketonuria is also another monogenic disorder (37)  
Cystic fibrosis (CF) is an autosomal recessive disease where individuals have a 
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homozygous (or compound heterozygous) mutation in the cystic fibrosis 
transmembrane conductance regulator gene (CFTR). In CF, individuals have 
pathological changes in tissues that express CFTR including secretory cells, sinuses, 
lungs, pancreas and reproductive tracts. CF is most pronounced in the airways. The 
deletion of  the amino acid phenylalanine at amino acid position 508 occurs in more 
than half of Caucasian CF cases (38) (36).  
Similarly, PKU is a rare disorder whose prevalence varies from population to 
population but generally affects ~1 in 10000 live births.  Even so, PKU is the most 
common inborn error of amino acid metabolism (37).  PKU is an autosomal recessive 
disease where individuals do not metabolize the amino acid phenylalanine, which 
leads to elevated levels in the blood and toxic levels in the brain (37). The genetic 
defect is in the phenylalanine hydroxylase gene (PAH) and missense mutations occur 
in majority of cases in PKU. 
Identifying causal mutations in a monogenic disease helps unraveling 
pathways in various biochemical processes. For instance, identifying the casual LDL 
receptor gene (LDLR) mutation in FH (39) increased the understanding of the 
biochemistry of cholesterol metabolism through LDLR and knowledge of receptor 
mediated endocytosis, which is a mechanism used by many proteins and not just 
LDLR. 
Diseases can be categorized, based on their prevalence in the population, as 
common diseases or rare diseases. According to the World Health Organization 
(WHO) a rare disease, also known as an orphan disease, is a disease defined as 
affecting individuals at a frequency of 65 to 100 in 100,000 (40). In contrast, a 
common disease can be defined as a disease that is found much more frequently in the 
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population, like cancer and CVD, which together affect one-third to one-half of all 
people.  
There have been various models for explaining genetic etiology of common 
diseases. The Common Disease-Common Variant (CDCV) Hypothesis is a model 
whereby common diseases are said to result from accumulation of  a moderate 
number of common variants, each of which contributes to a certain small percent of 
the disease risk (41). However, common variants identified by GWAS so far explain 
only a small portion of the genetic component of most common diseases, which has 
given rise to the ‘missing heritability’ problem.  
In the field of genomics/genetics, the missing heritability problem essentially 
refers to the proportion of genetic susceptibility that is not explained by GWAS 
identified loci such as common variants (41). To solve the missing heritability 
problem, the missing genetic component has been attributed to either of three models, 
namely, (i) the infinitesimal model, (ii) the rare allele model and (iii) the broad sense 
heritability model.   
In the infinitesimal model, the genetic component is explained by numerous 
amounts of common variants (each of small effect size) each contributing a small 
percent to disease risk.  In the rare allele model, the genetic component is explained 
by many rare variants (each of large effect size) each contributing to disease risk. In 
the broad sense heritability model, the genetic component is explained by a 
combination of environmental, genotypic and epigenetic interactions. Also, some 
propose that other mechanism, such as gene X gene interactions, gene X environment 
interactions or epigenetic factors can help explain the “missing heritability” for many 
common diseases. 
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GWAS are not sufficiently powered to detect variants under any of these three 
models. (41). So, researchers have a choice of which model best fits their hypothesis/ 
experiments as none of the models has been shown to be better over the other (41).  
1.3.2.1.1 Common Variants  
Common variants are defined as variants with a minor allele frequency (MAF) 
of greater than 5% in the general population (42). There are various types of common 
variants including SNPs. SNPs have been used for studying complex diseases/traits 
such as dyslipidemia (43), but also many other traits. SNPs have been used to identify 
loci that were later discovered to be involved in lipid metabolism (44). Common 
variants that predispose individuals to disease are normally non-disease causing in 
and of themselves.  
The effect size is the statistic that refers to the magnitude of an effect such as 
magnitude of regression coefficient and mean difference (45). Effect size can be 
represented as an Odds Ratio. The Odds Ratio is the ratio the odds of an event 
occurring case cohort to odds of an event occurring in the control cohort (45). The 
effect size of a variant essentially refers to the increase in risk that is conferred by the 
variant. Common variants usually have small effect sizes. Common variants do not 
cause disease; they increase susceptibility to disease. However, there are exceptions; 
for instance, a common SNP is associated with a huge risk (odds ratio of almost 7-
fold) for developing the eye disease macular degeneration (46).  However, the effect 
sizes for most SNPs so far discovered in GWAS of common diseases and phenotypes 
ranges from 1.2- to 2-fold.   
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1.2.3.1.2  Rare Variants  
 A rare variant is defined as a variant with a minor allele frequency (MAF) of 
less than 1% in the population; variants with a MAF of 1%-5% are called uncommon 
variants (42). Mutations (defined in section 1.3.2.1) are usually rare variants. 
Mutations can often have large effect sizes. However, there are exceptions, because 
next generation sequencing of the genomes of completely healthy people has now 
revealed hundreds of thousands of new rare variants, but because most of these people 
were essentially healthy, all these mutations cannot be assumed to have large effects 
on disease risk. Nevertheless, the general notion is that mutations are rare variants that 
can have large effects on disease risk. 
 Under the rare variant model (which was briefly described in Section 1.3.2.1), 
mutations are likely to be rare variants because of evolutionary theory. In 
evolutionary theory, variants that are deleterious to fitness such as disease causing 
variants (i.e. mutations) are selected against and therefore cannot be common in the 
population. This phenomenon is called purifying selection and it refers to selection 
against fitness-reducing variants (such as disease causing variants) such that their 
frequency is kept low in the population or even eliminated in the population. So, 
existence of rare variants in the population is a balance between purifying selection 
and high mutation rates that give rise to susceptibility variants, such that the balance 
leads to the frequency of such variants being 1% or slightly more if it has a moderate 
effect on fitness. Evolutionary theory is one of the strongest supports for the rare 
allele model (41). The hypothesis of our resequencing study, which was our first 
study, (explained in Section 1.8.1 of the thesis) was made in light of the rare allele 
model. 
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1.3.2.2 Monogenic dyslipidemias  
 Monogenic dyslipidemias refer to dyslipidemias in which the genetic etiology 
can be narrowed down to one gene. Thus monogenic dyslipidemias typically follow a 
Mendelian pattern of inheritance. Table 1.5 gives a list of dyslipidemias that are 
considered to follow a Mendelian pattern of inheritance(47) their OMIM numbers (i.e. 
Online Mendelian Inheritance in Man in The NCBI database)  have also be given for 
reference. FH is a classic example of a monogenic dyslipidemia. However, recent 
research in the field has shown that an alternate etiology for a proportion of cases of 
FH – perhaps 20%, can actually be polygenic (48). 
 
1.3.2.3 Polygenic dyslipidemias  
 Polygenic dyslipidemia refers to dyslipidemia where multiple genes contribute 
to the disease phenotype. Polygenic dyslipidemia would fit the infinitesimal model 
(which was briefly described in Section 1.3.2.1 of the thesis). Diseases where etiology 
cannot be narrowed down to a single or few genes are by default categorized as 
polygenic. However, not finding a single particular gene (or few genes) involved in 
disease etiology may sometimes reflect the science or technology involved in 
unraveling disease etiology.  
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OMIM, Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/omim/) 
Abbreviations:  
LDLR, low density lipoprotein receptor 
APOB, Apolipoprotein B 
PCSK9, proprotein convertase subtilisin/kexin type 9 
ARH, low density lipoprotein receptor adaptor protein 1 
LIPA, lipase A 
SLC10A2, solute carrier family 10 (sodium/bile acid cotransporter family), member 2 
APOA1, apolipoprotein A-I 
LCAT, lecithin-cholesterol acyltransferase 
ABCA1, ATP-binding cassette, sub-family A (ABC1), member 1 
LIPC, lipase 
APOC2, apolipoprotein C-II 
LPL, lipoprotein lipase 
APOE, apolipoprotein E 
ABCG5, ATP-binding cassette, sub-family G (WHITE), member 5 
ABCG8, ATP-binding cassette, sub-family G (WHITE), member 8 
CETP, cholesteryl ester transfer protein, plasma 
MTP, microsomal triglyceride transfer protein 
ANGPTL3, angiopoietin-like 3 
APOA5, apolipoprotein A-V 
CYP7A1, cholesterol 7-alpha-hydroxylase 
SAR1B, SAR1 homolog B 
 
Monogenic Dyslipidemia Gene 
OMIM 
number  
1-Autosomal dominant Familial Hypercholesterolemia due to defective  LDLR 606945 
2-Autosomal dominant Familial Hypercholesterolemia due to defective  APOB 107730 
3-Autosomal dominant Familial Hypercholesterolemia due to defective  PCSK9 607786 
4-Autosomal Recessive Familial Hypercholesterolemia due defective  ARH 605747 
5- Cholesteryl ester storage disease due to defective  LIPA 613497 
6-Hypobetalipoproteinemia due to defective  APOB 107730 
7-Primary Bile Acid malabsorption due to defective  SLC10A2 601295 
8-Analphalipoproteinemia due to defective  APOA1 107680 
9-Familial LCAT deficiency due to defective  LCAT 606967 
10-FamilialHypoalphalipoproteinemia due to defective  ABCA1 600046 
11-Hepatic Lipase deficiency due to defective  LIPC 151670 
12-Hyperchylomicronemia due to defective  APOC2 608083 
13-Hyperchylomicronemia due to defective  LPL 609708 
14-Dysbetalipoproteinemia due to defective  APOE 107741 
15- Hypobetalipoproteinemia due to defective  PCSK9 607786 
16-Sitosterolemia due defective  ABCG5 605459 
17-Sitosterolemia due to defective  ABCG8 605460 
18-CETP deficiency due to defective  CETP 118470 
19-Abetalipoproteinemia (ABL) due to defective  MTP 157147 
20-Familial Combined Hypolipidemia due to defective  ANGPTL3 604774 
21-Fredrickson’s Type V Hypertriglyceridemia due to defective  APOA5 606368 
22- Cholesterol 7α-hydroxylase deficiency due to defective  CYP7A1 118455 
23- Chylomicron retention disease due to defective  SAR1B 607690 
Table 1.5 Brief descriptions of monogenic dyslipidemias and their OMIM 
number for reference 
reference 
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1.4 Familial Hypercholesterolemia 
1.4.1 Characterization, clinical features, diagnosis and clinical genetics of 
Familial Hypercholesterolemia  
In the disease Familial Hypercholesterolemia (FH), individuals have 
abnormally elevated LDL-C levels. FH typically shows a Mendelian pattern of 
inheritance, as it is usually a single gene disorder. FH can be inherited in an 
autosomal dominant manner (in which case is referred to as Autosomal Dominant 
Hypercholesterolemia) and an autosomal recessive manner (in which case it can be 
referred to as Autosomal Recessive Hypercholesterolemia). The prevalence of the 
heterozygous form of FH is 1in 500 and the prevalence of the homozygous form of 
FH is 1 in 1,000,000 (49).  
In FH, there is reduced clearance of LDL-C from plasma because of defective 
activity of LDLR. FH heterozygotes have a 2- to 3-fold increase in LDL cholesterol 
levels. Approximately half of FH heterozygotes develop tendon xanthomas, 
xanthelasmas, premature corneal arcus and CHD by the 4
th
 or 5
th
 decade of life. FH 
homozygotes have a 5- to 8-fold increase in LDL-C levels and develop CHD in the 
2
nd
 decade of life. 
The way FH is diagnosed can vary from clinician to clinician, but there are 
standard clinical methods for diagnosis mainly that involve observation of  elevated 
plasma LDL-C levels (that is unexplained by secondary causes), a personal history or 
family history of CHD or myocardial infarction, and the presence of xanthomas on 
physical examination (50). 
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1.4.2 Genetic Etiology of Familial Hypercholesterolemia  
Autosomal Dominant Hypercholesterolemia (ADH) can be caused by a 
mutation in any one of three genes, namely LDLR (Low Density Lipoprotein Receptor 
gene), APOB (Apolipoprotein B-100 gene) and PCSK9 (Proprotein Convertase 
Subtilisin/kexin Type 9 gene). Autosomal Recessive Hypercholesterolemia (ARH) is 
caused by a mutation in the two copies of the LDLR gene, or the Autosomal 
Recessive Hypercholesterolemia gene (ARH). The autosomal dominant form of FH is 
much more common than the autosomal recessive form of FH. The frequency of  FH 
due to LDLR, APOB, PCSK9 and ARH is 52%-76%, 2-10%, 2% and 2%, respectively. 
Thus, mutation in LDLR is the most common cause of heterozygous FH (49). 
 
1.4.2.1 Low Density Lipoprotein Receptor gene LDLR: Structure and function  
LDLR codes for the Low Density Lipoprotein Receptor (LDLR) and this gene 
is mainly expressed in the in liver. LDLR is an ~860-amino acid cell surface 
glycoprotein (51). The most important physiological ligand for the LDLR is LDL, 
which carries ~70% of cholesterol in humans (51) (LDL has been described in Section 
1.2.5). LDLR plays an important role in cholesterol homeostasis because its main 
function is to clear LDL from plasma.  
LDLR has five domains, namely: (i) Ligand Binding Domain, (ii) EGF 
Precursor Homology, (iii) O-linked Sugar Domain, (iv) Membrane Spanning Domain 
and (v) Cytoplasmic Domain. The schematic figure of mature LDLR (i.e. LDLR with 
the 21 amino acid signal peptide sequence removed) is shown in Figure 1.9  (39) 
shows the structure of cholesterol. Figure 1.3 shows how LDLR is involved in 
clearance of LDL from blood. 
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The first 21 amino acids of LDLR is the signal peptide sequence which gets 
cleaved soon after the protein is translated. The 21 amino acid signal directs location 
of translation on the membrane of the Endoplasmic Reticulum (ER) as the protein is 
getting translated (39). 
The ligand binding domain as its name implies, is the domain that binds LDL. 
It is a cysteine rich domain and many disulphide bonds are present in this domain. 
This extensive disulphide structure gives this domain stability. This domain is 
negatively charged and this negative charge is complementary to the charge of regions 
of apo E (39). The second domain is the Epidermal Growth Factor (EGF) precursor 
homology domain and the name was given because this domain of LDLR resembles 
the part of the extracellular domain of EGF (39). The third domain is called O-linked 
sugar domain because of the clustering of O-linked sugar chains (39). The fourth 
domain, which is the membrane spanning domain, is rich in hydrophobic amino acid 
residues so that it can interact with the hydrophobic cell membrane (39). The fifth 
domain is the cytoplasmic domain and this domain is important for the clustering of 
LDLR in clathrin-coated pits that occurs in LDL clearance by LDLR. LDLR clusters 
and then internalizes LDL. This clathrin is important for this clustering of LDLR (39). 
In clearance of LDL from blood (Figure 1.3), receptor-ligand complexes 
occurs in clathrin coated pits. LDLR clusters in clathrin coated pits. The receptor-
ligand complex is internalized into the cell within the clathrin coated pits. This 
complex is delivered to the endosomes where the pH is low (i.e. acidic). At this low 
pH, the receptor dissociates from the ligand; the receptor gets recycled back to the cell 
surface and the ligand moves from the endosome to the lysosome. In the lysosome, 
LDL is hydrolysed and cholesterol is released into the cell (51). This entire process is 
referred to as receptor-mediated endocytosis. 
37 
 
 
 
A loss-of-function mutation in the LDLR gene leads to less or no clearance of 
LDL, thus resulting in hypercholesterolemia. For the LDLR, mutations have been 
classified into 4 classes (39). In Class I mutations, no receptor is synthesized due to a 
major deletion mutation that results in no protein product expressed. In Class II 
mutations, LDLR is synthesized but does not undergo its normal post translational 
modification, which occurs in the ER. So, LDLR does not get to the cell surface; 
LDLR remains in ER until it is degraded. In Class III mutations, LDLR is synthesized 
and reaches the cell surface but fails to bind its ligand. In Class IV mutations, LDLR 
is synthesized, reaches cell surface, binds to LDL but fails to cluster and clustering of 
LDLR (which occurs in clathrin coated pits), is vital for receptor mediated 
endocytosis. So, for LDLR, the mutations are classified based on the aspect of 
receptor mediated endocytosis it is affecting and not the type of mutation. The 
downstream effect of all the classes is reduced clearance of LDL. LDLR mutations are 
the most common cause of FH as alluded to earlier. 
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Figure 1.9 Structure of  LDLR (a) The multidomain LDLR. LDLR has five domains. The 
Ligand binding domain is for binding of LDL and the cytoplasmic domain is important for 
internalization of LDLR –LDL complex into the cell. The membrane spanning domain is 
rich is hydrophobic residues so that it can interact with the hydrophobic layer of the cell 
membrane. The EGF (Epidermal Growth Factor) precursor homology domain is 
homologous to part of EGF. Figure 1.9 was modified from (39). Figure 1.3 shows the 
mechanism of LDLR action. The main function of LDLR is to clear LDL from the blood. 
LDLR clears LDL from the blood through receptor mediated endocytosis. In receptor 
mediated endocytosis, LDLR binds LDL. The LDLR-LDL complex gets internalized into 
the cell. The LDLR-LDL complex enters the endosome. In the endosome the pH drops 
which dissociates the LDLR-LDL complex. LDLR gets recycles back to the cell surface, 
while LDL is transported to the lysosome and gets metabolized in the lysosome. In the 
lysosome, cholesterol is released from LDL.  
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
 
 
1.4.2.2 Apolipoprotein B-100 gene APOB: Structure and function  
 APOB codes for both Apolipoprotein B-48 (ApoB-48) and Apolipoprotein B-
100 (ApoB-100). The difference between the two isoforms of the protein is that the 
ApoB-48 isoform, which is 48% of the length of the full-length ApoB-100 isoform, is 
expressed in the small intestine.  In contrast, the ApoB-100 isoform is expressed in 
the liver.  ApoB is the ligand that LDLR recognizes in LDL (52) (Apolipoproteins 
and LDL were discussed in Section 1.2). ApoB, which is one of the largest 
monomeric proteins known (53) is the apolipoprotein of LDL (52). Because of the 
insoluble nature of ApoB, it has been difficult to completely study its tertiary structure 
(26) (53). So researchers have used experimental and in silico data to predict the three 
dimensional structure of ApoB. Figure 1.6b is also a diagram for ApoB structure. 
Some cases of FH result from a perfectly normal LDLR but a  mutation in APOB; 
these mutations disrupt the ApoB structure such that it cannot bind with LDLR and 
thus clearance of LDL from plasma gets disrupted (27). APOB mutation is the second 
most common cause of FH as alluded to earlier. 
 Figure 1.6b (Top) was modified from (26) and Figure 1.6 b (Bottom)  was 
modified from (27.) ApoB, which is made up of  4536 amino acids, is believed to 
wrap around the spherical lipid core The Receptor binding region of the ApoB protein 
is believed to span amino acid residues 3000 to 4000 (27) .  
 
1.4.2.3 Proprotein Convertase Subtilisin/kexin Type 9 gene PCSK9: Structure 
and function  
PCSK9 codes for Proprotein Convertase Subtilisin/kexin Type 9 protein 
(PCSK9). PCSK9, which is a 692 amino acid protein that normally degrades LDLR. 
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A loss of function mutation in PCSK9 leads to less degradation of LDLR and thus 
increases clearance of LDL by LDLR. A gain of function mutation in PCSK9 leads to 
less clearance of LDL by LDLR. Thus, gain of function mutations are causative of 
Familial Hypercholesterolemia (54, 55). 
The mature PCSK9 is shown is Figure 1.11a PCSK9 has three domains, 
namely the prodomain, the catalytic domain and lastly the C-terminal domain. PCSK9 
binds the cell surface LDLR by directly interacting with the EGF Precursor 
Homology Domain of LDLR and PCSK9 binds LDLR with its catalytic domain (56). 
This interaction of PCSK9 with LDLR targets LDLR for lysosomal degradation (57). 
 
1.4.2.4 Autosomal Recessive Hypercholesterolemia gene ARH: Structure and 
function  
ARH (Autosomal Recessive Hypercholesterolemia protein), also called LDLR 
associated protein (LDLRAP1) interacts with the cytoplasmic tail of LDLR. The 
Phosphotyrosine binding (PTB) domain of ARH interacts with the NPXY consensus 
in LDLR cytoplasmic tail domain and the consensus of NPXY is required for 
internalization of LDLR-ligand complex (58). ARH, which is a 308 amino acid 
protein, is required for the internalization of LDL-LDLR complex and ARH is 
haploinsufficient; mutation in both copies of ARH causes FH (59).  Figure 1.11b is a 
simple diagram of ARH and was modified from (58).  As mentioned earlier, 
autosomal recessive mutation in ARH is fourth most common cause of FH. 
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Figure 1.10 Structure of PCSK9 and ARH  (a) Simple diagram of PCSK9. From N-
terminus to C-terminus, PCSK9 has the prodomain, the catalytic domain and the C-
terminal domain. PCSK9 degrades LDLR through its interaction with its catalytic 
domain. The catalytic domain of PCSK9 interacts with EGF Precursor homology of 
LDLR Figure 1.11a was taken and modified from Abifadel et al  (55) (b) Simple 
Diagram of ARH. ARH has a PTB (phosphotyrosine binding) domain. This PTB 
domain interacts with the NPXY consensus sequence of the cytoplasmic tail 
domain if LDLR and this interaction is necessary for the internalization of 
LDLR-LDL complex into the cell. Figure 1.11b was modified from (58) 
(a) PCSK9 
 
 
(b)  ARH 
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1.4.2.5 Role of polygenic susceptibility in FH - Humphries 2013 Lancet paper (48) 
A minority of FH patients – perhaps 10 to 20% depending on the population - 
do not have mutations in any of the four known FH–causing genes (i.e. LDLR, APOB, 
PCSK9 and ARH). These patients are known as Mutation Negative Familial 
Hypercholesterolemia (FH/M-ve) patients (48).  
According to the Global Lipid Genetics Consortium (GLGC), there are 37 
SNPs that have been shown to be associated with LDL-C levels (43). Researchers 
(48) used 12 of the 37 SNPs to test for accumulation of risk alleles in FH/M-ve 
patients to see if FH/M-ve could have an alternate polygenic etiology (48). 
Researchers tested this hypothesis in the British population and found that FH/M-ve 
patients have a greater accumulation of the 12 GLGC-identified risk alleles than in 
FH patient with mutation in any of the four known FH-causing genes. Thus FH can 
also be a polygenic disease, particularly when mutations in the genes that cause the 
monogenic form are absent (48). 
 
1.4.2.6 Role of APOE in FH 
 Recent studies have shown that a mutation in the apo E gene (APOE) 
segregates with Familial Hypercholesterolemia (60). Marduel et al (60) was the first 
to report segregation of an APOE deletion mutation, the APOE Leu 167 del mutation.  
The APOE Leu 167 del mutation was also found in another family where the mutation 
segregated with FH (data yet to be published). In both cases, the APOE mutation 
segregated with Autosomal dominant form of FH. 
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1.4.3 Treatment of Familial Hypercholesterolemia 
 
1.4.3.1 Statin treatment: Brief explanation of cholesterol lowering by diet, statins 
and other drugs - ezetimibe, bile acid sequestrants  
Hypercholesterolemia can be reduced by lowering the amount of cholesterol in 
the diet. Hypercholesterolemia can also be reduced by exercise (61). This change in 
lifestyle is often the first step in lipid lowering. As a result of knowledge of 
cholesterol metabolism, certain drugs have been developed to lower cholesterol. 
Acetyl CoA is a precursor in cholesterol biosynthesis and statins are structural 
analogues of acetyl CoA. So, statins lower cholesterol by preventing HMG CoA 
reductase from metabolizing its natural substrate (61). Statins also lower cholesterol 
because the effect of reduced cholesterol biosynthesis is upregulation of LDLR such 
that more LDLR are expressed on the cell surface (61). 
There are other drugs that lower cholesterol by targeting various aspects of 
cholesterol biochemistry. For instance, ezetimibe blocks the absorption of cholesterol 
from the small intestine (61) and bile acid sequestrants increase the conversion of 
cholesterol to bile acids thus depleting liver cholesterol levels leading to upregulation 
of the LDLR (62). 
 
 
1.4.3.2 Kaplan-Meier survival curve for Familial Hypercholesterolemia  
Kaplan-Meier curves are survival curves that can display differences due to 
various interventions carried out in the population. Survival curves show rates of 
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survival (i.e. percent of patients that are living) of individuals as a function of time. 
Figure 1.12 shows a Kaplan-Meier survival curve for FH patients on statin and those 
not on statin treatment. The FH patients on statin treatment had much greater survival 
rates than FH patients who were not on statin treatment (63). Thus Kaplan-Meier 
survival curves emphasize the importance of early treatment with statins leading to 
better prognosis. 
 
1.4.4 IDOL, PSMD9 and cholesterol metabolism 
Expression of LDLR is highly regulated. Myosin regulatory light chain 
interacting protein (IDOL) has been identified as an Inducible Degrader of LDR 
(IDOL) protein; thus IDOL is sometimes referred to as IDOL. IDOL degrades LDLR 
through a pathway independent of PCSK9. IDOL mediates ubiquitination and 
degradation of LDLR (30, 64). Thus a gain of function mutation in IDOL will lead to 
less LDL clearance and loss of function mutation will lead to more LDL clearance. 
This function makes IDOL a suitable gene to study in diseases where 
hypercholesterolemia occurs such as FH and FCH. 
The gene for Proteasome Modulator 9 (PSMD9) is localized 12q24 (65). 
Linkage of PSMD9 locus to primary hypercholesterolemia while studying a rare 
family and suggested that this locus be tested in disease where primary 
hypercholesterolemia occurs.  Thus PSMD9 is also a candidate gene for 
hypercholesterolemia based on chromosomal localization. 
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Figure 1.11 Kaplan-Meier Survival Curve for FH patients on statin treatment 
and not on statin treatment (63). The survival rate is represented on the vertical 
axis. The survival rate essentially shows the percentage of FH patients that are still 
living over the course of time (which is represented on the horizontal axis). FH 
patients on statin treatment have much better survival rates over time compared to FH 
patients who are not statin treatment. (63). 
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1.5 Familial Combined Hyperlipidemia 
 FCH has a prevalence of 1% in the Western population, making it the most 
common genetic dyslipidemia. Because of the hypercholesterolemia that is 
characteristic of FCH, having FCH puts an individual at risk for CVD; FCH has been 
estimated to occur in 20% of individuals with Coronary Heart Disease (CHD), which 
is a form of CVD (66, 67).  
Familial Combined Hyperlipidemia (FCH) disease was characterized by an 
affected proband having both elevated plasma cholesterol and triglyceride levels due 
to elevated LDL and VLDL, respectively (68). Other affected family members can 
either have elevated cholesterol, or elevated TG or both, thus making FCH distinct 
from FH and Familial Hypertriglyceridemia (FHTG). FCH is distinct from FH and 
FHTG because (i) in FH, a clear vertical pattern of inheritance is observed and 
triglyceride levels are normal in affect family members and (ii) in FHTG, cholesterol 
levels are always normal in affected family members (68). Interestingly, it was 
suggested that the primary metabolic defect in FCH is in TG metabolism with 
secondary effects on cholesterol metabolism and that FCH could be a monogenic 
disorder.  
The genetic etiology of FCH is currently considered to be polygenic (69). 
Previous work from our the Hegele lab has explained genetic basis for primary 
hypertriglyceridemia, including FCH and FHTG, with a combination of both common 
variants and rare variants (70, 71) explaining 42% of variation in HTG. 
The genetic etiology of hypercholesterolemia in FCH is poorly understood. 
Many genes have been implicated through large linkage association studies (66), yet 
the genetic basis for hypercholesterolemia is still unknown. Part of this thesis focused 
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on unraveling the genetic etiology of hypercholesterolemia in FCH, more so 
hypercholesterolemia is a classical risk factor for CVD development.  
 
1.6 DIET1 and dyslipidemia 
 DIET1 was first discovered in mice over a decade ago. The gene is located on 
chromosome 2 in the mouse genome (72). DIET1 has not been fully annotated in the 
human genome. Recently, DIET1 has been shown to affect lipid metabolism in mice 
and cultured human cells (73). Thus the gene is now becoming a subject of interest in 
the field (74). 
 DIET1 was somewhat serendipitously discovered. A particular strain of mice 
was used as a model to study genes involved in lipid metabolism. DIET1 was 
discovered when a de novo (i.e. spontaneous) mutation occurred in this particular 
strain of mice and gave rise to a new strain of mice (72). So, there was now the old 
strain (i.e. the original strain) and a new strain that was phenotypically different. 
When both the old strain and new strain were given an atherogenic diet (i.e. a diet 
high in cholesterol), the old strain of mice showed increased cholesterol levels and 
formation of atherosclerosis but the new strain did not. The new strain did not show 
any increased cholesterol levels and did not develop atherosclerosis. So the phenotype 
of this new strain was described as ‘resistant to diet-induced hypercholesterolemia 
and atherosclerosis’ (72).  
  Because both the old and new strains of mice had extensive genetic identity, 
the new phenotype had to be a result of a gene or a few genes. Using various genetic 
approaches, such as genetic crosses and linkage analyses, a mutation in DIET1 in 
mice was associated with the phenotype (72)  
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 Further studies were aimed at understanding the metabolic role and gene 
expression of DIET1 (13). Phan et al used the genetic approach of gene expression 
profiling to unravel the metabolism of DIET1. DIET1 is involved with increased bile 
acid synthesis and excretion. Thus the mutation at the DIET1 locus caused the new 
strain of mice to be resistant to diet-induced hypercholesterolemia and atherosclerosis 
because plasma cholesterol concentration decreases when there is increased bile acid 
synthesis and bile acid excretion (13) 
 There have been some human studies on DIET1. The chromosomal location of 
DIET1 in humans is 10p12 and DIET1 encodes a predicted protein of 2156 amino 
acids (73). Human and mice DIET1 share 70% similarity (73). DIET1 is expressed in 
the small intestine in humans and mice (73). The role of DIET1 at the metabolic level 
in both human and mice has been reported (73). 
 Cultured human and mouse intestinal cells were examined to further explain 
DIET1 metabolism (73). Bile acid synthesis is controlled by negative feedback 
regulation. Bile acid synthesis upregulates a protein called fibroblast growth factor 
(FGF) 15 in mice (or FGF-19 in humans). The downstream effect of FGF-15/19 is 
inhibited bile acid synthesis (73). DIET1 upregulates FGF-15/19. So mice and 
cultured human intestinal cells deficient in DIET1 do not express FGF-15/19 do not 
have repression of bile acid synthesis. Increased bile acid synthesis and increased bile 
acid excretion are ways of lowering cholesterol in body. Thus, DIET1 deficiency 
leads to hypocholesterolemia (73, 74). 
 DIET1 was shown to recently be associated with TG levels in mice (data yet to 
be published, communicated from Professor Karen Reue, Department of Genetics, 
University of California, Los Angeles). Since the Hegele lab has examined genetic 
factors accounting for variation hypertriglyceridemia more than any other group (70, 
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71, 75) I wanted to test for associations between common variants in DIET1 region 
and hypertriglyceridemia.  
 
1.7 Genetic approaches to identifying disease etiology 
There are various approaches —in the terms of study design and techniques —
to identifying disease etiology in the field of genetics/genomics and the repertoire of 
approaches increases with advancing technologies. Various designs employed in 
identifying disease etiology include family studies, case-control studies and 
population studies. Various techniques used in identifying disease etiology include 
resequencing and genotyping.  
In a family study design, genetic variation is evaluated in family members 
affected with a particular disease. Various analyses, essentially referred to as pedigree 
analyses, are performed to identify whether the genetic variation segregates with the 
disease in the disease affected family. Linkage analyses and autozygosity mapping are 
ways of analyzing pedigree information. In linkage analyses the LOD Score is 
essentially measure of likelihood of linkage divided b likelihood of no linkage; LOD 
score is calculated from pedigree information (76).  Autozygosity mapping, which is 
another form of linkage analyses, can be used in identifying genes involved in 
autosomal recessive disorders (77) . These approaches are also used for better 
understanding genetic etiology of traits that are non-disease related (78) such as 
height and hair colour. 
The advent of advanced technologies, such as next generation sequencing, has 
birthed various genetic/genomic approaches including Genome Wide Association 
Studies (GWAS) in large epidemiological settings, and resequencing of candidate 
(suspect) genes in smaller well –defined phenotypic extremes or case-control settings. 
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So, researchers in the field have a variety of approaches, in terms of study design and 
technique, to choose from to understand genetic etiologies of diseases. For GWASs, 
chip-based microarray technology is used for assaying millions of SNPs. Illumina and 
Affymetrix are two common platforms used for most GWASs (79).  
Genotyping can be defined as any technique that enables identification of 
genetic variation in an individual. The difference between genotyping and sequencing 
is that genotyping requires prior knowledge of the genetic variation so novel genetic 
variations cannot be discovered. However sequencing does not require any knowledge 
of prior genetic variation, so novel genetic variation can be discovered. Genotyping 
can be accomplished by various techniques such as restriction enzyme length 
polymorphism and TaqMan assays. Sanger sequencing can also be employed for 
genotyping. When using the resequencing technique, the DNA sequence of the gene is 
sequenced.  
In Genome Wide Association Studies (GWASs), common genetic variants, 
such as SNPs, are genotyped all across the genome to see if there is an association 
between genetic variation and a trait (including disease) (80). GWASs are employed 
for identifying susceptibility loci for complex traits (80). In GWASs, the difference in 
frequency of genetic variation between cases and controls is tested to see if the gene 
variation is associated with susceptibility to the complex disease. 
 
1.7.1 Resequencing candidate genes to test for accumulation of rare variants in 
case-control cohorts  
 Our context of a mutation is a genetic variation that leads to protein 
dysfunction which eventually leads to lack of individuals’ well-being. So, missense 
rare variants are likely to be mutations. If rare missense variants occur significantly 
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more frequently in a gene of a diseased individual relative to the non-disease 
individual, it indicates that the gene is associated with disease etiology directly or 
indirectly. Given that functional verification of a genetic variant consumes a lot of 
time and resources, it is reasonable to verify rare missense variants that significantly 
accumulate in disease individuals. 
Previous work from the Hegele lab has used the approach of resequencing 
candidate genes in better understanding disease etiology. The Hegele lab used the 
resequencing approach to test for significant accumulation of rare missense variants in 
candidate genes for hypertriglyceridemia (71, 75).  
 
1.7.2 Using genotyping to compare Genetic risk score in case-control cohorts  
 Sometimes selected common variants such as SNPs are genotyped in cases 
and controls to create a genetic risk score. An individual’s genetic risk score is a 
measure of the sum of risk alleles present in an individual. The SNPs are genotyped to 
see if cases have more of the risk allele relative to controls. If the mean genetic risk 
score is higher in cases relative to controls, it shows that those sets of SNPs genotyped 
or the set of risk alleles increase disease susceptibility 
 
1.8  In silico analyses  
 The effect of all rare missense  variants on function of gene products of the 
four candidate gene were predicted using the in silico tools Polymorphism 
Phenotyping version 2 (PolyPhen-2) and Sorting Intolerant from Tolerant (SIFT). 
SIFT bases its prediction on multiple sequence alignments and amino acid 
conservation to determine whether a missense mutation is deleterious or not (81, 82). 
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PolyPhen-2 bases its prediction on amino acid sequence alignment and structural 
alignment of the protein (83).  
PolyPhen-2 is a free online computational tool that is very commonly used to 
predict the effect(s) of missense variants on protein function. PolyPhen-2 uses 8 
sequence-based predictive features and 3-structure based predictive features in its 
prediction model, where these predictive features essentially compare the wild type 
protein with the mutant protein (i.e. protein with the missense rare variant). PolyPhen-
2 also reports estimates of false positive rate and true positive rate (84) . PolyPhen-2 
qualitatively appraises a mutation to be either ‘benign’, ‘probably damaging’ or 
‘possibly damaging’ depending on the false positive rate of the prediction model. The 
‘Possibly damaging’ appraisal is a less confident prediction than ‘probably damaging’ 
because the false positive rate is higher in ‘possibly damaging’(84). 
SIFT is another free online computational tool that is commonly used for 
predicting the effect of missense variants. Using query sequences, SIFT compiles 
sequences of functionally related protein and calculates the probability of finding all 
20 amino acid at each amino acid position, where the probabilities are recorded in a 
scaled probability matrix.  A mutation is said to affect the protein if the scaled 
probability, or ‘SIFT score’, is below a certain threshold. An amino acid that is 
conserved throughout evolution is more likely to be intolerant to substitution than an 
amino acid that is not conserved. SIFT also gives a conservation value for each 
position, where 0 is the conservation value if all amino acids are seen and 4.25 is the 
conservation value if only one amino acid is seen throughout the homologous family 
of proteins at that position. SIFT ensures that the final set of aligned sequences has a 
median conservation value of approximately 3.00, because a median conservation 
value of 3.25 produces predictions with low confidence (85). The only limitation of 
54 
 
 
 
SIFT is that it does not use structural predictions — although structural predictions 
are said to marginally improve predictions (85). 
 Multiple sequence alignment was also performed for each of the 4 candidate 
genes to visually observe conservation of amino acid position of the detected 
missense rare variants. In a multiple sequence alignment, amino acid sequences of a 
particular protein from different species are aligned to derive potential evolutionary or 
functional significance of each amino acid residue (86). So in a multiple sequence 
alignment, each single row represents the amino acid sequence of a protein from one 
species, with gaps inserted so that homologous residues appear in the same positions 
across the species used for the alignment,  Here, homologous is context dependent 
(86). In the evolutionary context, homology refers to the amino acid residues having 
common evolutionary ancestry.  In the context of structural biology, equivalence 
refers to the analogous amino acid residues belonging to the homologous fold in the 
set of proteins.  In the context of molecular biology, equivalence refers to the amino 
acid residues having similar functional roles in the set of proteins (86). Clustal Omega 
was the multiple sequence alignment tool used for multiple sequence alignments for 
the  4 candidate genes of the first project (87). Jalview 2.8 was used to analyze the 
multiple sequence alignments (88). 
 
 
1.9 General Thesis Project Aims  
 The overall theme of this thesis was to better understand the genetic etiology 
of hypercholesterolemia in Familial Combined Hyperlipidemia (FCH). There were 
three main studies in this thesis. Each study was composed of various projects. Even 
though the second study and part of the last study focused on Familial 
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Hypercholesterolemia and hypertriglyceridemia, respectively, the studies still 
converge towards understanding the two phenotypes characteristic of FCH, namely 
hypercholesterolemia and hypertriglyceridemia. 
 In all the thesis projects, whenever FCH patients were used as cases, their 
controls were individuals with FHTG. This is because previous work from the Hegele 
lab has shown that individuals with FCH and FHTG share a common genetic 
architecture for hypertriglyceridemia. To understand hypercholesterolemia in FCH, 
we needed to control for the hypertriglyceridemia phenotype of FCH, by using 
individuals with FHTG as controls. 
 
1.9.1 Study I- Resequencing candidate genes in FCH  
 I hypothesized that there is an accumulation of rare missense variants in the 
LDLR, APOB, PCSK9 and IDOL in FCH cases relative to controls. I tested this 
hypothesis using Sanger Sequencing to see if hypercholesterolemia in FCH is a result 
of FH-causing mutations. The gene responsible for the autosomal recessive form of 
Familial Hypercholesterolemia, ARH, was not sequenced because FCH does not show 
an autosomal recessive pattern and the frequency of FH dues to ARH mutations is 
extremely low, meaning that I was less likely to detect any ARH mutation. 
 
1.9.2 Study II- Understanding hypercholesterolemia in Mutation Negative 
Familial Hypercholesterolemia  
 There were two projects for this study and both studies were collaborations. 
Project I 
 In the  first collaboration project, I tested the hypothesis that Mutation 
Negative Familial Hypercholesterolemia patients (FH/M-ve) have a higher mean 
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LDL-C genetic risk score than Mutation Positive Familial Hypercholesterolemia 
(FH/M+ve) controls. The genetic risk score was determined by calculating how many 
risk alleles of 12 SNPs were present in FH/M-ve patients. These 12 SNPs (See 
Section 1.4.2.5)  were identified in Global Lipids Genetics Consortium (GLGC)(43). 
This has already been studied in the British population (48). So my project was a 
replication study in the Canadian Population. 
 
Project II 
 In the second collaboration project, APOE was sequenced in all our FH/M-ve 
patients because our collaborators found an  APOE FH-causing mutation, namely the 
APOE Leu 167 del (data yet to be published). Thus, all the FH/M-ve patients were 
sequenced for  the APOE Leu 167 del,  as well as any novel mutations.  
 
1.9.3. Study III – Use of laboratory GWAS data for further understanding 
hypercholesterolemia and hypertriglyceridemia  
  Three projects composed the third study. In all three projects the same GWAS 
data from the Hegele lab (70) were used. The GWAS data were analyzed using a 
Unix-based program called PLINK (89). PLINK can be defined as a program that 
allows analyses of various types of genomic and genetic data. The GWAS data was 
genotyped SNPs across the entire human genome; more information on the GWAS 
data can be found in Johansen et al (70).In general, GWAS data are a wealth of 
genetic information and thus makes GWAS data a useful resource for testing new 
hypotheses, performing new analyses and consequently generating new findings. 
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Project I 
The Hegele lab identified many, but not all, of the genetic variation in HTG. 
In the first project of my third study, I tested the hypothesis that DIET1 is associated 
with hypertriglyceridemia. As mentioned in Section 1.6 of this thesis, DIET1 has 
shown association with HTG in mice. So, I questioned whether genetic variation in 
DIET1 could further explain genetic variation in HTG, which is a component 
phenotype characteristic of FCH. The key experiment was logistic regression to see if 
there was an accumulation of risk alleles in DIET1 region in HTG patients. 
 
Project II 
 In the second study of my third project, I wanted to see if there is an 
accumulation of SNPs in the PSMD9 region in FCH cases relative to controls since 
because PSMD9 locus has been associated with hypercholesterolemia. The key 
experiment was performing logistic regression for the PSMD9 region in FCH cases 
and FHTG controls. 
 
Project III 
 The Global Lipids Genetic Consortium (GLGC) identified 37 SNPs to affect 
LDL cholesterol level in the general population (43). In the third project of my third 
study, I studied the 37 GLGC identified LDL-C SNPs for association with 
hypercholesterolemia in FCH. Then I tested whether FCH cases have a greater LDL-
genetic risk score, where the genetic risk score was a measure of risk alleles of the 37 
SNPs. 
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Figure 1.12 Summary of Thesis projects 
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Chapter 2: Materials and Methods 
 
2.1 Study subjects 
All study subjects provided informed consent for use of their DNA for 
research purposes, including DNA extraction, sequencing and analyses. This study 
was approved by the University of Western Ontario Institutional Review Board 
(protocol number 07920E) (Ethics Approval notice attached in the Appendix). The 
study subjects involved in all the three projects were of self-declared European 
ancestry. 
 
2.1.1 Familial Combined Hyperlipidemia patients (Fredrickson Type 2B 
Phenotype) 
For the first project, a total of 138 cases were Familial Combined 
Hyperlipidemia (FCH) patients (MIM 144250). FCH patients were unrelated and of 
self-declared European ethnicity. FCH patients were diagnosed as the affected 
individual having plasma total cholesterol concentration above the 90th percentile 
(>7.7 mmol/L) in addition to having plasma triglyceride concentration above the 90th 
percentile (>3.4 mmol/L), controlled for age and sex, according to reference levels for 
the North American population. All the FCH cases were patients from the Lipid 
Genetics Clinic in London, Ontario. 
 
2.1.2 Familial Hypercholesterolemia patients (Fredrickson Type 2A Phenotype) 
For the second project, a total of 44 cases were Mutation Negative Familial 
Hypercholesterolemia (FH/M-ve). 44 controls were Mutation Positive Familial 
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Hypercholesterolemia (FH/M+ve) patients. All of these 88 Familial 
Hypercholesterolemia patients (MIM 143890) were from the Lipid Genetics Clinic in 
London, Ontario. Familial Hypercholesterolemia was diagnosed as having Low 
Density Lipoprotein cholesterol (LDL-C) above the 95
th
 percentile (>5.2 mmol/L), 
controlled for age and sex, according to reference levels for the North American 
population. Cases and control were matched for age and sex. 
 
2.1.3 Hypertriglyceridemia patients 
 
2.1.3.1 Familial Hypertriglyceridemia patients (Fredrickson Type 4 phenotype) 
For the first project, there were 94 Hypertriglyceridemia patients of the 
Fredrickson Type 4 phenotype classification (Familial Hypertriglyceridemia) used as 
controls. Familial Hypertriglyceridemia (FHTG) was diagnosed as having 
triglycerides above the 90
th
 percentile (>3.7 mmol/L), controlled for age and sex, in 
the North American population. All the Type 4 controls were patients from the Lipid 
Genetics Clinic in London, Ontario. FHTG patients were used as for the 
hypertriglyceridemia component of FCH. 
 
2.1.3.2 Polygenic Hypertriglyceridemia patients (Fredrickson Types 2B, 3, 4 and 
5)  
For the third project, hypertriglyceridemia (HTG) patients were cases who 
constituted individuals clinically diagnosed with of all the 4 Fredrickson polygenic 
hypertriglyceridemia phenotypic classification, namely: Type 2B (MIM 144250), 
Type 3 (MIM 107741), Type 4 (MIM 144600) and Type 5 (MIM 144650). HTG was 
diagnosed as having an untreated 12 hour fasting plasma triglyceride concentration 
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above the 90
th
 percentile (>3.4 mmol/L) on at least two occasions. These polygenic 
HTG cases were patients from the Lipid Genetics Clinic in London, Ontario. In total 
there were 504 HTG patients (cases) and 1254 mostly normolipidemic controls.  
Familial Hypercholesterolemia (Fredrickson Type 2A phenotype) patients 
constituted 4% of controls; healthy Canadian individuals of European descent 
ascertained through the Study of Health Assessment and Risk in Ethnic Groups (90) 
constituted 18% of controls; healthy individuals from the Myocardial Infarction 
Genetics Consortium (91) constituted 78% of controls. Familial Hypercholesterolemia 
patients were used as controls to counterbalance the increased cholesterol phenotype 
that is seen in HTG patients. 
 
2.2 DNA samples of study subjects 
2.2.1 DNA extraction  
 Genomic DNA (gDNA) samples were collected from whole blood that was 
drawn from study subjects. gDNA was isolated from whole blood of study subjects 
using the Puregene DNA isolation kit (Gentra Systems, QIAGEN Inc, Mississauga, 
ON, Canada) according to manufacturer’s instructions. 
 
2.2.2 Whole genome amplification  
Whole genome amplification was performed, according to manufacturer’s 
instructions, on extracted gDNA using the Illustra GenomiPhi HY DNA 
Amplification Kit (GE Healthcare Life Sciences, Mississauga, ON, Canada). WGA 
was performed for FCH and FHTG gDNA samples because gDNA samples were 
limited. The number of gDNA samples was limited as those samples that had been 
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collected over the course of 15 years and had been used to varying degrees in earlier 
studies. 
 
2.2.3 DNA quantification  
For the second project, gDNA was quantified to a final concentration of 
approximately 50ng/µL for genotyping. DNA quantification was performed by 
measuring the concentration of 1µL gDNA on the ND-1000 Spectrophotometer 
(Nanodrop, Thermo Scientific, Mississauga, ON, Canada) for each gDNA FH sample. 
88 FH gDNA samples were diluted to a concentration of y 50ng/µL, which is 
considered optimal for subsequent procedures, including genotyping. 
 
 
2.3 DNA amplification by Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was performed to amplify target regions 
of WGA DNA of the 4 candidate genes in cases and controls of the first project. 
Target regions in LDLR were the 18 coding regions, 100bp outside each exon and the 
promoter. Target regions in APOB were exons 26 and 29 since 90% of reported 
hyperlipidemia-associated mutations reside within these regions. The target region in 
PCSK9 for sequencing was exon 7, since more than 60% of disease-associated 
variants have been shown to reside in this exon (92). The target regions in IDOL were 
7 exons, since no disease-causing mutations have yet been reported in this gene. 
 
2.3.1 Primer list for candidate genes  
Tables 2.1 to 2. 4 represent the forward (F) and reverse (R) primers of the target 
regions for the first project and annealing temperature for each target region. Primers 
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were designed using the free online software, Primer3 The length of both forward and 
reverse primers had to be between 18 to 22 bp; the difference in length of the primers 
was not more than 1 nucleotide; the GC content of each  primer must be between 
40%-60%; the forward and reverse primer must have similar melting temperatures 
(Tm ) (i.e. not more than 1 C difference )and repeat sequences in primers were avoided 
(93). Factors that affect the melting temperature include  GC content, concentration of 
ions and DNA length (http://www.entelechon.com/2008/08/dna-melting-temperature/ 
). 
Figures 2.1 to 2.4 represents the gene structure of each candidate gene and the 
regions of the genes that were sequenced. Figures were generated by mainly using 
GenomeGraphs software package (94) in R statistical programming environment (95).  
Ensemble ID (ENSG ID) of all genes were required for generation of figures: 
LDLR:   ENSG00000130164,  
 APOB:  ENSG00000084674,    
PCSK9: ENSG00000169174    
IDOL:  ENSG00000007944 
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Table  2.1.  Primer sequence and annealing temperature of the 18 exons and 
promoter of LDLR 
Exon 
 
 
Annealing 
temperatur
e (  C) 
Amplico
n size 
(bp) 
 
Primer sequence (5' to 3') 
 
 
Promote
r 58 410 F: CAGGAGGATCTTTCAGAAGATGCG 
 
  R: AGGAGCAAGGCGACGGTCCAG 
1 58 438 F: GGACTGGAGTGGGAATCAGA 
 
  R: TTACCCCACAAGTCTCCCAG 
2 58 486 F: GTGCTTGCTTAATTCCCTGG 
 
  R: TCAAAATCCACTGGCCAC 
3 58 501 F: GAGACAGGGTTTCACTATATTGGC 
 
  R: ACAAACCCGAAGAGGTAGCA 
4 58 609 F: GCAGTGGTTCAGAGTCCATGG 
 
  R: TCCCAATAAGCTAACAGCAACCATCGG 
5 58 520 F: CTCAAGCAGTTGGAACCACA 
 
  R: GCGAGACTCCGTCTCAAAAC 
6 58 357 F: GTGCTGGGATTACAGGCACAAAC 
 
  R: CCTACAGCACTCATGTCTCAGTC 
7 60 470 F: ACATGCCTGTAGTCCCAGCTACTT 
 
  R: CAAGAAACTCTGGCCAGCCAATGA 
8 58 362 F: TTACATCTCCCGAGAGGCTGG 
 
  R: GGTCAGGGGATATGAGTCTGTG 
9 58 400 F: GGAGGTCTTTTCCACCCTCT 
 
  R: CTGAGGCAGGAGGAGAGAAG 
10 58 498 F: AGCGAGTACACCAGCCTCATC 
 
  R: GCCCACTAACCAGTTCCTGA 
11 58 467 
F: 
CCCAAACAAGCCACATTTGGAGTTTGGGGTTC 
 
  R: AAAGAGGGAAACCTTCAGGGAGCAGCTTGG 
12 58 467 F: TGTGACCTGCAACTCCCCTAC 
 
  R: CTCAGGTCTAAGACCTCCTCC 
13 61 526 F: AGGCTGAAGCAAGAGAATCG 
 
  R: GGTGGTCCTCTCACACCAG 
14 58 502 F: TCTCTTCCACAACCTCACCC 
 
  R: CATCAAAGGGGAACTGGGTA 
15 61 500 F: AGAGATGGTATTTTGCCATGTTG 
 
  R: GATAGGGAAACTGAGGGCCCAGAG 
16 58 508 F: CCGGAATTGAGTCCTACAACC 
 
  R: TCTCGGTGAGGCTATTCCAC 
17 58 440 F: GTCAAGGTTATGGTACGATGC 
 
  R: TTCCTCTACACCACCAAGGC 
18 58 574 F: ACTGAATCCGGTACTCACCG 
    R: GTGCCATCTGCTGTTGTGTG 
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Table 2.2 Primer sequence and annealing temperature of the 19 amplicons of 
exon 26 and 3 amplicons of exon 29 of APOB 
 
Exon 
Annealing   
temperature 
( ̊ C) 
Amplicon 
size (bp) Primer Sequence (5’ to 3’) 
26-1 60 580 F:TGCATTACAGATGGAGGAGTC 
 
    R:TTTGCAGATCAGAGGTGGAGG 
26-2 60 590 F:TTCGTTCTATGCTAAAGGCACA 
 
    R:AGCGGCCATTTGTTGTTAAT 
26-3 60 581 F:AAAATTAATAGTGGTGCTCACAAGG 
 
    R:TTTAGGTTACCAGCCACATGC 
26-4 60 590 F:CAGCTCTGACAAGTTTTATAAGCAA 
 
    R:GGGCACTGACTTTGTGTTCA 
26-5 60 557 F:CGCTCTCTGGGGAGAACATA 
 
    R:TGATGTGCTTCAGGTTTCTCTG 
26-6 60 556 F:ACCAAGATGTTCACTCCATTAACC 
 
    R:CAGGATGCAGTACTACTTCCAC 
26-7 60 512 F:TTGATGAGCACTATCATATCCGTG 
 
    R:TTGTAGGACATTGCTTAGCTTCTG 
26-8 60 589 F:ATCCTTCAGAGCCAAAGTC 
 
    R:TCCTGCTGAATGTCCATTTG 
26-9 60 580 F:AAGGCCACAGTTGCAGTGTA 
 
    R:CTACAAAGTCAATTGTAAAGGAAGGA 
26-10 60 510 F:CAGATTTGAGGATTCCATCAGTTCAG 
 
    R:AAGCTGCGATACCTGCTTCGTTTG 
26-11 60 580 F:TACCTACTTTTGGCAAGCTATACA 
 
    R:TGTGATTCATGTGTTCCCTCA 
26-12 60 593 F:ATTGAACATCCCCAAACTGG 
 
    R:TTACTTGCCAACTTGCTTGC 
26-13 60 487 F:TTTGAGATCACGGCATCCACAAAC 
 
    R:TGTCAAAGGATTTGATGCTCTGAC 
26-14 60 580 F:AAGAAAAACAAACACAGGCATTC 
 
    R:AAGATGAAGAAAGGAGATGAGCA 
26-15 60 557 F:CTCTTCCAGATTTCAAGGAATTGTG 
 
    R:CTTGACATCTCCTTTGGTAGATG 
26-16 60 544 F:CAATTCTTCAATGCTGTACTCTACC 
 
    R:GACCTGGCTCTGGAAAGACC 
26-17 60 582 F:TCAGCTCTTGTTCAGGTCCA 
 
    R:TTTTACCTCGGGGAGTGTTG 
26-18 60 549 F:TCAGTTCTTGTCATGCCTACG 
 
    R:TAGGAACTGTACGGTTGAGCTG 
26-19 60 580 F:TCCTTCCTTTCAAGCACTGAC 
 
    R:TTTTGTGTGTTCCCAAAACTG 
29-1A 60 580 F:TTGTGTAATTGGAGTAATTGAAAACA 
 
    R:GAAACTGGAATCTGGGGAAG 
29-2 60 613 F:CCATATGAAAGTCAAGCATCTGA 
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    R:TTCACGAAGGGCCATAATGT 
29-3A 60 657 F:ATTCAAAACGAGCTTCAGGA 
 
    R:TGTGAAAGTTCAATTGGAAAAGA 
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Table 2.3.  Primer sequence and annealing temperature of exon 7 of PCSK9 
Exon 
 
Annealing 
temperature  
( ̊C) 
 
Amplicon 
size (bp) Primer Sequence 
 
 
7 59 
451 F: 
CAGAGTTCTGCCTGGGCAGTC 
 
 
 R: 
GAGTGTCCTTGAAGGCACCATC 
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Table 2.4 .  Primer sequence and annealing temperature of the 7 exons of IDOL 
Exon 
 
 
Annealing 
temperature 
( ̊ C) 
Amplicon 
Size (bp) 
 
Primer Sequence (5’ to 3’) 
 
 
1 62 286 F:GAGGGCCAGCCCTCTCCGAGTCCG 
 
  R:TAGTAGGGGGCGCGCCAGAGTGCC 
2 60 413 F:TGGTATCATTGGAGCCGTGGAACT 
 
  R:CACTCAGACCAAGTAGGTAGCTCC 
3 60 346 F:GCTGAGATTGATGTCAGGTTATCC 
 
  R:TGCCTCGAACATCAGAGAGCTCAA 
4 58 324 F:TGAGATCCCAGTGTCTTAGACGTT 
 
  R:GAGCTGACTGTCGAGTAAATCCCT 
5 60 311 F:CCACAAAGGCACACACATGGTGAA 
 
  R:ACCGTAGAAACCTGGTTGTCACCT 
6 60 602 F:GGAGATGTTAGAGAAACAGAGGTG 
 
  R:ACAAAGACCCTTTCCGGGTGAAGA 
7 60 340 F:TGTGAGACGGCAAAGATCTCTACC 
 
  R:TGGTCCCATGACTGGAGTTGTTGA 
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2.3.2 Polymerase Chain Reaction  
WGA DNA samples of FCH and FHTG patients were used for Polymerase 
Chain Reaction (PCR). The PCR kit used was Life Technologies Platinum® Taq (Life 
Technologies Inc., Burlington, ON, Canada). WGA DNA Samples and PCR reaction 
mixtures were placed in 96-well plates in a DNA Thermocycler (Life Technologies 
Inc. Burlington, ON, Canada). Every reaction well contained 1µL of WGA DNA, 2µL 
10x MgCl2 PCR buffer, 3.2µL of 10mM of each of the 4 dNTPs , 0.33µL of 
0.6pmol/µL of the forward primer, 0.33µL of 0.6pmol/µL of the reverse primer, 
0.6µL of 50mM MgCl2 and 0.1µL of 5U/µL Taq Polymerase, yielding a final volume 
of 20µL PCR reaction mixture. The thermocycler conditions were comprised of 3 
stages. The first stage was the initial denaturing stage for 5 minutes at 95  C to 
separate DNA strands, followed by second stage that was composed of 30 cycles of 3 
steps. The first step was denaturation for 30 seconds at 95  C, the second step was 
annealing for 30 seconds at 60  C and the third step was elongation for 30 seconds at 
72  C. The final stage was the final elongation stage, carried out at 72  C for 10 minutes 
to ensure that every amplified DNA strand was fully extended. 
For some target regions, the PCR reaction mixture and Thermocycler 
conditions were slightly different as those target regions required addition of  99.9% 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich®, Oakville, ON, Canada) to ease double 
strand separation. Table 2.5 contains details of those PCR reaction conditions. Only 
differences in PCR conditions are displayed in the table — otherwise PCR reaction 
conditions are as stated in this section. 
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Gene Exon Reaction Mixture 
LDLR 4 1.5uL DMSO, 10.8uL distilled water, extension time 45 seconds 
 
7,13,15 1.5uL DMSO, 10.8uL distilled water, 0.2uL Taq Polymerase, 2.0uL WGA DNA 
IDOL 1 1.5uL DMSO, 10.8uL distilled water, 0.2uL Taq Polymerase 
Table 2.5. PCR reaction mixture for target regions that required DMSO 
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2.3.3 Gel electrophoresis  
A 1% agarose gel was used to visualize PCR products under UV light to 
confirm satisfactory amplification of PCR products before sending samples to 
sequencing. The agarose gel was made by dissolving 1g of agarose powder 
(Bioshop® Canada Inc., Burlington, ON, Canada) in 100mL of distilled water and 
boiling for 5 minutes.  PCR products containing loading dye were loaded on to the 
agarose gel and Loading dye contained glycerol. In all cases, negative control 
reactions showed no bands which confirmed no contamination; if negative controls 
had been positive for a PCR product (i.e. showed band on agarose gel), it would have 
meant that our experimental WGA DNA samples had been contaminated with other 
DNA samples from other sources, such as bacteria and PCR for contaminated samples 
was repeated. 
 
2.3.4 Calf intestinal phosphatase (CIP)- Exonuclease (Exo) I treatment and 
preparation of sample for Sanger sequencing  
Contaminants such as single strands, primers and free dNTPs were removed 
from PCR product using calf intestinal phosphatase – exonuclease I (CIP-ExoI) 
treatment on PCR product in a thermocycler. CIP-ExoI treatment was performed to 
ensure that only PCR products, and no contaminants, had been sequenced. In each 
case, 6µL of CIP-ExoI treatment was added to 6µL of PCR product in a reaction well. 
CIP-ExoI treatment was made up of 5.7µL of distilled water, 2 Units of Exonuclease I 
(New England BioLabs ® Inc., Ipswich, Massachusetts, United States ) and 2 Units 
Calf Intestinal Phosphatase (New England BioLabs ® Inc., Ipswich, Massachusetts, 
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United States ). The thermocycler conditions for CIP-ExoI treatment were 37  C for 1 
hour, to activate the CIP-ExoI enzyme, followed by 72  C for 15 minutes to stop all 
enzyme activity. 
Reactions containing 2.5µL of CIP- ExoI treated PCR product, 2.5µL of 
distilled water and 2.5 uL of the sequencing primer, yielding a total of 7.5uL, were 
sent to the London Regional Genomic Centre (LRGC) (London, Ontario, Canada) for 
sequencing. The sequencing primer was a ¼ dilution of either of the forward or 
reverse PCR primer from stock solution, so that two 7.5uL PCR products were sent to 
sequencing for each DNA sample, where one 7.5uL PCR product contained the 
forward primer and the second 7.5uL PCR product contained the reverse primer. 
Automated chain termination Sanger sequencing was performed on PCR products at 
LRGC using the ABI 3730 (Life Technologies, Burlington, Ontario, Canada). For 
each PCR product sent to sequencing, electropherograms, which were the hard copies 
of the DNA sequence of target region of each sample, were produced. 
 
2.3.5 Sanger Sequencing 
 In the London Regional Genomic Centre (LRGC), the 7.5µL CIP-ExoI treated 
PCR products of all target regions were Sanger Sequenced by the involvement of four 
steps, namely, denaturation, chain termination of  PCR amplification, purification and 
sequencing, respectively. In total, there were 11,368 target regions that were 
sequenced for the first project. 
 The samples of PCR amplicons were centrifuged at 1000g for one minute on 
the Beckman Coulter TJ-25 Centrifuge (Biotech Equipment Sales Inc., San Francisco, 
California, United States). After centrifugation, the samples are placed on an Applied 
Biosystems GeneAMP 9700 Thermocycler (Life Technologies Inc., Burlington, 
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Ontario, Canada) at 98 C for 5 minutes for denaturing of samples. The samples were 
held at 4  C in the thermocycler to keep the double stranded PCR product unwound.  
After the denaturing, the samples were again centrifuged at 1000g for one minute. 
After centrifugation, the samples were placed on an ice pack to maintain the unwound 
structure. 
4µL of Applied Biosystems BigDye® Terminator Master Mix (Life 
Technologies Inc., Burlington, Ontario, Canada) was added to 7.5µL denatured PCR 
product. The Master Mix was made up of 12.5% BigDye Terminator, 25% 5 x Buffer 
AB and 62.5% distilled water. The positive control had the 4µL BDT Master Mix, 
2µL pGEM (Promega Corporation, Madison, Wisconsin, United States), 2µL Applied 
Biosystems® Control Primer (M13F) (Life Technologies, Burlington, Ontario, 
Canada), and 2µL distilled water. The PCR product and positive control containing 
Master Mix, making a total volume of 11.5µL in each well, were each centrifuged at 
1000g for one minute. After centrifugation, the samples were placed on the Applied 
Biosystems GeneAMP 9700 Thermocycler for chain termination PCR. A hot start 
PCR was performed at 80  C. The thermocycler conditions comprised 2 stages. The 
first stage was an initial denaturing stage for 5 minutes at 96  C to separate DNA 
strands, followed by the second stage that was composed of 30 cycles of 3 steps. The 
first step of these was denaturation for 20 seconds at 96  C, the second step was 
annealing for 15 seconds at 50  C and third step was elongation for 4 minutes at 60  C. 
After the second stage, the samples were stored at 4  C in the thermocycler.  
The samples were then purified to remove contaminants such as free dNTPs, 
proteins, salts and unincorporated dye. Purification was carried out using an Edge 
Plate (Edge BioSystems, Gaithersburg, Maryland, United States). 
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The purified samples were then placed on Applied Biosystems 3730 Analyzer 
(Life technologies Inc., Burlington, Ontario, Canada) for sequencing.  
The raw data from the Applied Biosystems 3730 Analyzer was processed 
using the Applied Biosystems DNA Sequencing Analysis Software version 5.3.1 (Life 
Technologies Inc., Burlington, Ontario, Canada). After processing of raw data, 
electropherograms, which were the hard copies of the DNA sequence of target region, 
were generated. Electronic versions of the electropherograms were also available.  
The samples were denatured to unwind the double-stranded PCR products so 
that there would be ease of access of sequencing reagents. 
Hot Start PCR minimizes amplification of non-specific sequences because it 
prevents non-specific primer annealing, which typically occurs at lower temperatures 
(i.e. below 65  C) (96). 
In chain termination PCR, fluorescently labeled dideoxy nucleotides are used. 
Each of the 4 dideoxy nucleotides fluoresces at a different colour. The rationale for 
using dideoxy nucleotide was to generate PCR products that end with the 
fluorescently labeled dideoxy nucleotide and generate chain terminated PCR products 
that differ from each other by one nucleotide. The fluorescently labeled dideoxy 
nucleotides is able to terminate PCR reaction because the Dideoxy NTPs lack the 3’ 
hydroxyl group, which prevents incorporation of another nucleotide as no 
phosphodiester bond can be created (97, 98). Figure 2.5 is a simplified visual 
representation of the reactions that occur in Sanger Sequencing. 
Within the 3730 sequencer, the fluorescently labeled PCR products pass 
through a capillary tube that separates chain terminated PCR products on the basis of 
size. The smallest PCR product is read first, the next PCR product that is 1bp longer is 
read next and so on. The colour of each fluorescent dye corresponds to a particular  
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nucleotide, which essentially leads to each nucleotide position of the PCR product 
being read as a sequence.  
80 
 
 
 
 
 
 
F
ig
u
re
 2
.5
 S
im
p
li
fi
ed
 v
is
u
al
 r
ep
re
se
n
ta
ti
o
n
 o
f 
es
se
n
ti
al
ly
 w
h
at
 o
cc
u
rs
 i
n
 S
an
g
er
 S
eq
u
en
ci
n
g
. 
81 
 
 
 
 
 
2.3.6 DNA sequence analyses  
Electropherograms of all target regions were analyzed using SeqScape® 
software version 2.6 (Applied Biosystems), which is a standard software for mutation 
detection and analysis. Reference genomes (hg19) were obtained from the National 
Center for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov/ ) and target regions were compared with reference 
genomes. All genotype information was entered into the lab database and genotype 
information was used for statistical analyses. The NCBI reference genomic DNA (the 
NC number) and cDNA (the NM number) for the candidate genes were as follows: 
LDLR: NC_000019.9 and NM_000527.4;  
APOB: NC_000002.11 and NM_000384.2;   
PCSK9: NC_000001.10 and NM_174936.3  
IDOL NC_000006.11 and NM_013262.3 
 
2.3.7 Power Calculations 
 Power calculations were performed using the free software PS-Power and 
Sample Size Calculation (99). Power was determined after calculating rare variant 
accumulation and obtaining Odds Ratios for the risk alleles of all the candidate genes. 
Significance level used was 5% in power calculation for all candidate genes. 
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2.4 SNP genotyping for Mutation Negative Familial Hypercholesterolemia 
patients and Mutation Positive Familial Hypercholesterolemia patients 
(Fredrickson Type 2A phenotype) 
As part of a collaboration to study patients with clinical FH who were negative 
for mutations in known genes, 44 Mutation Negative Familial Hypercholesterolemia 
(FH/M-) patients (cases) and 44 Mutation Positive Familial Hypercholesterolemia 
(FH/M+) patients (age- and sex-matched controls) were selected.  Samples were sent 
to the British Heart Foundation (BHF) Laboratories, Institute Cardiovascular Science, 
University College London, England United Kingdom to obtain an LDL-C genetic 
risk score using the top 12 Global Lipids Genetic Consortium (GLGC) identified 
SNPs (reference). We hypothesized that FH/M-ve patients would have a significantly 
greater accumulation of LDL-C raising SNPs than FH/M+ve patients. This hypothesis 
was first evaluated and proven in a British study of patients predominantly resident in 
the United Kingdom (48). This study was the first study to test this hypothesis in a 
Canadian population; our study also served as an independent replication study for the 
work spear-headed by our collaborators. 
The GLGC was an international project that identified 95 loci associated with 
lipid traits at the genome wide level (43). 37 loci were associated with LDL-C and 12 
of those 37 were selected for SNP genotyping on the 88 Canadian FH/M+ve and 
FH/M-ve samples. These 12 SNPs were chosen for genotyping because a previous 
study, preformed in a British population, showed that that FH/M- patients have a 
significantly higher LDL-C genetic risk score, where those 12 SNPs were used for 
constructing LDL-C genetic risk score (48).  
  SNP genotyping was the key experiment of the second project of the thesis. 
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Genotyping was performed on gDNA samples that were diluted to 50ng/uL as 
this was the optimal concentration for subsequent procedures for genotyping. 
 
 
2.4.1 List of GLGC identified SNPs  
Table  2.6 shows the 12 GLGC identified SNPs that were genotyped to 
calculate the LDL-C genetic risk score for all 88 FH patients. The risk alleles (bolded) 
are the LDL-C raising alleles.  
 
2.4.2 Calculation of LDL-C genetic risk score  
12 common LDL-C raising alleles identified by GLGC were used to construct 
a weighted LDL-C-raising genetic risk score. For each individual, LDL-C genetic risk 
score was calculated by calculating the weighted sum of the risk alleles. The weights 
used corresponded to the weight of the allele effect size as determined in GLGC (43). 
 
2.4.3 APOE gene resequencing in Mutation Negative Familial 
Hypercholesterolemia patients 
 All 3 coding regions of APOE were sequenced in 95 FH/M-ve patients. APOE 
was sequenced to identify any potential FH-causing mutations as a recent 
collaborative study has showed an APOE amino acid deletion variant namely, APOE 
Leu 167 del to be FH-causing.  
APOE was sequenced to screen for this particular amino acid deletion variant 
and for possible novel FH-causing or FH-associated variants. APOE was sequenced 
by following identical procedures of sections 2.3.2 to 2.3.5 of the Materials and 
Methods section. For the 3 coding regions of APOE, the PCR reaction mixture and 
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thermocyler conditions were slightly different, as the 3 coding regions required 
addition of  99.9% dimethyl sulfoxide (DMSO) (Sigma-Aldrich®, Oakville, ON, 
Canada) to ease double strand separation.  PCR reaction conditions for all three 
coding regions of APOE were identical to those for the first exon of IDOL, shown in 
Table 2.5. Only differences in PCR conditions for the three coding regions are 
displayed in Table 2.7— otherwise PCR reaction conditions for all three coding 
regions are as stated in section 2.3.2. 
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*LDL-C raising alleles are indicated in bold. Effect sizes taken from (48) 
Note: Abbreviations: CHR: Chromosome, SNP: single nucleotide polymorphism 
ψ 
APOE weights were based on haplotypic effects taken from (100) as described in 
Methods. 
For calculating the effect size of APOE, the APOE genotype was first determined and 
then given an APOE risk score calculation. 
 
 
 
 
 
 
 
CHR 
 
SNP 
 
Gene 
 
Minor* 
 
Common* 
 
GLGC Weight for Score 
Calculation 
1 rs2479409 PCSK9 G A 0.052 
1 rs629301 CELSR2 G T 0.15 
2 rs1367117 APOB A G 0.1 
2 rs4299376 ABCG8 G T 0.071 
6 rs1564348 SLC22A1 C T 0.014 
6 rs1800562 HFE A G 0.057 
6 rs3757354 IDOL T C 0.037 
11 rs11220462 ST3GAL4 A G 0.05 
14 rs8017377 KIAA1305 A G 0.029 
19 rs6511720 LDL-R T G 0.18 
19 rs429358 APOEψ C T 
 19 rs7412 APOEψ T C 
 19 ε2ε2 APOE 
  
-0.9 
19 ε2ε3 APOE 
  
-0.4 
19 ε2ε4 APOE 
  
0.2 
19 ε3ε3 APOE 
  
0 
19 ε3ε4 APOE 
  
0.1 
19 ε4ε4 APOE 
  
0.2 
Table 2.6. List of GLGC identified SNPs that were genotypes in the 88 Familial 
Hypercholesterolemia cohort and their effect sizes  
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2.5 SNP genotyping for patients with hypertriglyceridemia 
Genome wide association study (GWAS) data were obtained for the third 
project (70) and were used in genomic regions that were significantly associated with 
plasma triglyceride levels. To accomplish this, 463 HTG patients and 1197 healthy 
controls were genotyped for SNPs across the entire genome using the Affymetrix 
Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA)(70). HTG 
patients studied had Fredrickson types 2B, 3, 4 and 5. Controls were healthy 
normolipidemic individuals, as discussed in Section 2.1.3.2 of the Materials and 
Methods section. This data were used to evaluate the association between the DIET1 
region and hypertriglyceridemia in humans. 
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Exon 
 
 
Annealing 
temperature 
( ̊ C) 
Amplicon 
Size (bp) 
 
Primer Sequence (5’ to 3’) 
 
 
2 60 237 F: GGGAGGAGTCCTCACTGGCGGTTG 
 
  R: GCCAGGAGCAGCACAGAAGCCTC 
3 60 303 F: TGCCTGGACGGGGTCAGAAGGAC 
 
  R: CTGGGGAGGTATAGCCGCCCACCAG 
4 62 830 F: ATCAAGCTTTCGCCCGCCCCATCCCAGCCCTTC 
 
  R: CGTGAATTCGCATGGCTGCAGGCTTCGGCGTTC 
Table 2.7.  Primer sequence and annealing temperature of the 3 coding 
regions of APOE 
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2.6 DIET1 association analyses tested with PLINK  
 Single nucleotide polymorphisms (SNPs) in the DIET 1 region, which spans 
chromosome region 19 10:19,377,700-20,063,500 in the hg19 genome build, were 
compared in cases and controls to test for association between the DIET1 region and 
hypertriglyceridemia. The DIET1 region maps to the 10p12.31 chromosomal region. All 
analyses was done using the free whole genome association analysis toolset, PLINK (89). 
PLINK can perform large-scale analysis of phenotype/genotype data in a computationally 
efficient manner. The logistic regression command was used in all analyses; SNP 
association was performed using logistic regression adjusted for covariates such as sex 
and Body Mass Index (BMI). In logistic regression, a correlation between a dependent 
categorical variable and a continuous or categorical independent variable is tested for 
(101). In logistic regression, no assumption is made about the distribution of the 
independent variable (101). 
  
2.7 Statistical analyses 
For all three projects, statistical analyses were performed using various tools on 
data obtained. For the first project, analyses were performed on genotype data of cases 
and controls using subroutines within SAS version 9.3 (SAS Institute, Cary NC). For the 
second project, analyses were done on the LDL-C genetic risk scores of all 88 FH 
patients using subroutines within SAS version 9.3 (SAS Institute, Cary NC). For the third 
project, analyses were done on the GWAS genotype data from HTG patients and healthy 
controls subroutines within PLINK.  Significance in each case was set at a nominal P-
value < 0.05, with adjustment for multiple comparisons where appropriate. 
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2.7.1 Testing for rare variant accumulation using the chi-square test  
The general strategy for testing the first hypothesis was as follows: (i) record 
genotypes of all 138 cases and 94 controls, from Sanger sequencing into a database;  and 
(ii) rare variants were defined as variants with a minor allele frequency of <1% in the 
combined cohort of FCH cases and FHTG controls. Then we tested for accumulation of 
only missense rare variants. Chi- square analysis was used to test for  accumulation 
across each gene and across the four candidate genes together. Chi square tests were 
performed using SAS 9.3 statistical software. 
 
  
2.7.2 Comparing mean LDL-C genetic risk score using Wilcoxon’s signed rank test  
Normality tests showed that the LDL-C genetic risk scores of cases and controls 
were not normally distributed. So, non-parametric statistical analyses were performed. 
Since the samples were matched, Wilcoxon’s signed rank test was performed to see if 
there is any difference in the between means of LDL-C genetic risk scores in cases and 
controls. SAS Enterprise Guide 4.3 was used for Wilcoxon’s signed rank tests. 
 
2.7.3 Testing for SNP association between DIET1 locus and hypertriglyceridemia 
using logistic regression  
Logistic regression was performed to observe if there was any association 
between DIET 1 region and the dichotomous trait of disease status. All analyses were 
done with PLINK. First, SNPs in the region of interested were selected from the GWAS 
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data. There were a total of 4,808 SNPs were genotyped in the 10p12.31 region. Logistic 
regression was adjusted for covariates such as sex, diabetes status, population 
substructure and body mass index (BMI). (101) 
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Chapter 3: Results I— Resequencing candidate genes in Familial Combined 
Hyperlipidemia cases and Familial Hypertriglyceridemia controls 
 
 
3.1 Study subjects 
Cases were FCH patients whose biochemical phenotype  
3.1.1 Demographics of patients with Familial Combined Hyperlipidemia and 
Familial Hypertriglyceridemia  
Table 3.1 shows all the baseline clinical characteristics of 138 Familial Combined 
Hyperlipidemia (FCH) cases and 94 Familial Hypertriglyceridemia (FHTG) controls. The 
mean and standard error of body mass index (BMI), total cholesterol (TC), triglyceride 
(TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol 
(HDL-C) are given in Table 3.1. Where possible, cases and controls were matched for 
age, sex and BMI. 
 
3.2 Low Density Lipoprotein Receptor gene LDLR 
The DNA sequence of the 18 exons, 100 bp regions flanking each exon and about 
1000 bp of the promoter region of LDLR were sequenced and all detected variants were 
entered into the laboratory database. Silent variants, missense variants, intronic variants 
and splice site variants were found. Only rare missense variants were included for 
statistical analyses because of all types of variants, these are most likely to be disease 
causing. A list of all variants found in the LDLR gene in the case-control cohort is listed 
in the Appendix. 
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3.2.1 List of all LDLR missense rare variants found  
  I hypothesized that there is an accumulation of rare missense variants in the LDLR 
gene in cases relative to controls. Table 3.2 shows the list of missense rare variants that 
were found in the LDLR.  In total there were 7 rare missense variants in cases and 4 rare  
missense variants in controls. All the rare missense variants in LDLR, except for one 
,were exclusive to either cases or controls (Table 3.2). 
 
3.2.2 In silico analyses  
The effect of the amino acid substitutions on LDLR function was predicted using 
the in silico tools PolyPhen-2 and SIFT. Table 3.2 shows the in silico predicted effect of 
amino acid change on LDLR function. Rare missense variants that were predicted to be 
deleterious by both PolyPhen-2 and SIFT were found only in FCH cases for LDLR.  
 
3.2.3 Test for rare missense variant accumulation  
 Chi squared analysis was performed to test for differences in the frequency of 
missense rare variants in LDLR in FCH cases compared to FHTG controls. Table 3.3 
shows results of the Chi squared test. There was a greater accumulation of missense rare 
variants in cases, as shown by an odds ratio (OR) of 1.2 (Table 3.3).  However, this 
greater accumulation of missense rare variants was not significant because the confidence 
interval of the extended odds ratio included 1.0. In retrospect, the absence of statistical 
significance is not surprising given the sample size and statistical power.  The power to 
detect a difference of this magnitude, given the sample size of the LDLR resequencing 
project was 6%. 
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3.3 Apolipoprotein B-100 gene APOB 
The DNA sequence of the 19 amplicons of APOB exon 26, all 3 amplicons of 
APOB exon 29 and the 100 bp intronic regions flanking exons 26 and 29 were analyzed 
and variants were entered into the laboratory database. APOB exons 26 and 29 were 
chosen as target regions because these exons have each been shown to be a hotspot for 
FH-causing mutations. Silent variants, missense variants, deletion variants, intronic 
variants and splice site variants were found. As with the LDLR gene, only missense rare 
variants were included for statistical analyses. Only missense rare variants were included 
for statistical analyses because these variants, of all types of variants are most likely to be 
disease causing. All the variants found in exons 26 and 29 of APOB in the case-control 
cohort are listed in the Appendix. 
 
3.3.1 List of all APOB gene rare missense variants  
I hypothesized that there is an accumulation of rare missense variants in APOB 
exons 26 and 29 in cases relative to controls. APOB exons 26 and 29 were sequenced in 
138 cases and 94 controls. Table 3.4 shows the list of rare missense variants that were 
found in APOB. In total there were 10 rare missense variants in cases and 9 rare missense 
variants in controls. All rare missense variants in APOB were exclusive to either cases or 
controls (Table 3.4). 
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3.3.2 In silico analyses  
Effect of amino acid substitution on ApoB function was predicted using the in 
silico tools PolyPhen-2 and SIFT. Table 3.4 shows the in silico predicted effect of amino 
acid change on ApoB function. More missense rare variants were predicted to be 
deleterious by both PolyPhen-2 and SIFT in cases (Table 3.4). 
 
3.3.3 Test for rare missense variant accumulation  
 Chi square analysis was performed to determine whether the frequency of rare 
missense variants in APOB  differed between FCH cases and FHTG controls. The 
accumulation of rare variants in cases was not greater as shown by an OR of 0.74 and by 
an extended confidence interval that included 1.00 (P=0.63) (Table 3.5). . In retrospect, 
the absence of statistical significance is not surprising given the sample size and 
statistical power.  The power to detect a difference of this magnitude in APOB rare 
missense variants, given the sample size was 10% 
 
3.4 Proprotein Convertase Subtilisin/kexin Type 9 gene (PCSK9)  
The DNA sequence of exon 7 of PCSK9 was analyzed in 138 FCH cases and 94 
FHTG controls. Exon 7 of PCSK9 was chosen as target region as this exon has recently 
been considered a hotspot for FH-causing mutations. No variants were found in PCSK9 
in 138 FCH cases and 94 FHTG controls, so no further confidence or statistical analyses 
were performed. 
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3.5 Inducible degrader of Low Density Lipoprotein receptor gene (IDOL) 
The DNA sequence of all coding regions of IDOL was analyzed and patients’ 
genotypes were entered into the laboratory database. IDOL has recently been implicated 
in cholesterol metabolism as it is a degrader of LDLR. Only missense rare variants were 
included for statistical analyses. List of all variants found in the 7 exons of IDOL are 
found in the Appendix. 
 
 
3.5.1 List of all missense rare variants found  
We hypothesized that there is a greater accumulation of  rare missense variants in 
coding regions of IDOL in FCH cases relative to FHTG controls. The 7 exons of IDOL 
were sequenced in 138 cases and 94 controls. Table 3.6 shows the list of rare missense 
variants that were found in IDOL. In total there were 2 rare missense variants in cases 
and 2 rare missense variants in controls. All the rare missense variants except one were 
exclusive to either cases or controls in IDOL (Table 3.6). 
 
3.5.2 In silico analyses  
The effect of amino acid substitution on IDOL function was predicted using the in 
silico tools PolyPhen-2 and SIFT. Table 3.6 shows the in silico predicted effect of amino 
acid change on IDOL function. The rare missense variants that were exclusive to cases 
and controls were predicted to be deleterious by both PolyPhen-2 and SIFT (Table 3.6). 
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3.5.3 Test for rare missense variant accumulation  
Chi square analysis was performed to determine whether the frequency of 
missense rare variants in IDOL was different in FCH cases compared to FHTG controls. 
Table 3.7 shows results of the chi square analysis. There was no greater accumulation of 
rare missense variants in cases as shown by an OR of 0.69 and by a confidence interval 
that included 1.00 (P=1.00) (Table 3.7). . In retrospect, the absence of statistical 
significance is not surprising given the sample size and statistical power.  The power to 
detect a difference of this magnitude, given the sample size was 7.3%. 
 
3.6 Evaluating accumulation of functionally verified variants 
 
3.6.1 Test for rare missense variant accumulation across candidate genes (grand 
total)  
 There was no statistically significant accumulation of rare missense variants in the 
individual candidate genes. Therefore, statistical accumulation of missense rare variants 
across all 3 main candidate genes as a grand total was determined. 
Chi squared analysis was performed to determine whether the frequency of 
missense rare variants across LDLR, APOB and IDOL genes was different in FCH cases 
compared to FHTG controls. Table 3.8 shows results of the chi square analysis. There 
was no greater accumulation of rare missense variants in cases as shown by an OR of 
0.85 (Table 3.8). This indicates no enrichment of rare missense variants in FCH cases vs 
FHTG controls and that if anything, there is a non-significant trend that the frequency 
being higher in HTG patients. 
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3.6.2 Test for accumulation of functionally verified missense rare variants across 
candidate genes (grand total)  
The literature was searched to date (June 1st, 2013) to determine whether any of 
the rare missense rare variants found in cases and controls have been functionally 
verified. Interestingly, 4 functionally verified rare missense variants were found only in 
cases, namely: LDLR: p.G314S, p.D333V,  p.V806I and  APOB: p.R3500W variants, at a 
nominal level approaching statistical significance (P=0.09) (Table 3.9). Rare missense 
variants that were functionally verified in literature and/or predicted deleterious by both 
PolyPhen-2 and SIFT were also tested for significant accumulation using Fisher’s Exact 
test. There was a significant accumulation of rare variants as shown by an OR of 2.4, but 
the accumulation was non-significant (P=0.25) and included an OR of 1.00 (Table 3.10). 
 
 
3.7 Multiple sequence alignment analyses 
Multiple sequence alignment was done using Clustal Omega (87) and  Jalview 2.8 
(88) was used to analyze multiple sequence alignments.  
 
3.7.1 Multiple Sequence Alignments for LDLR 
 According to NCBI, LDLR is conserved in Humans (Homo Sapiens), Rhesus 
Monkey (Macca Mulata), House Mouse (Mus Musculus), Cattle (Bos Tarus), 
Chimpanzee (Pan troglodytes), Dog (Canis lupus familiaris), Rat (Rattus norvegicus) and 
Zebrafish (Danio rerio). Multiple sequence alignments (MSA) LDLR amino acid 
sequence was performed to observe whether the rare missense variants found in LDLR 
were conserved (Figure 3.1). 
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 The rare missense variants found in LDLR are marked by the red rectangles with 
the variant name on top. For the  p.G-2R variant, the residues marked by green rectangles 
represent electrostatic/ionic bonds that could be formed by the p.G-2R mutation.  For the 
p.D333V variant, the residues marked by blue rectangles represent possible 
electrostatic/ionic bond that may have been disrupted by the p.D333V mutation. For the 
p.C677G mutation, the residues marked by blue represent possible di-sulphide bonds that 
may be disrupted with p.C677G (Figure 3.1). 
 
3.7.2  Multiple Sequence Alignments for APOB 
 According to NCBI, APOB is conserved in Humans (Homo Sapiens), Rhesus 
Monkey (Macca Mulata), House Mouse (Mus Musculus), Cattle (Bos Tarus), 
Chimpanzee (Pan troglodytes), Dog (Canis lupus familiaris), Rat (Rattus norvegicus ) 
and Zebrafish (Danio rerio) and Chicken (Gallus gallus) . Multiple sequence alignment 
of the amino acid sequence of APOB was performed to observe whether or not the rare 
missense variants found in APOB were in conserved regions of the protein (Figure 3.2).  
 The rare missense variants found in APOB are marked by the red rectangles with 
the variant name on top. For the p.K1615R mutation, the residues marked by blue 
rectangles represent the electrostatic bonds may be strengthened and/ or weakened by the 
p.K1615R mutation. For the p.E2539K, p.R1662H, p.R2192C and p.R3500W, the 
residues marked by the blue rectangles represent electrostatic bonds that may be 
disrupted with the respective mutations. For the p.E2539K and p.T3020R mutations, the 
residues marked by green rectangles represent electrostatic bonds that may have formed 
with respective residues (Figure 3.2). 
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3.7.3 Multiple sequence alignments for IDOL 
 According to NCBI, IDOL is conserved in Humans (Homo Sapiens), Rhesus 
Monkey (Macca Mulata), House Mouse (Mus Musculus), Cattle (Bos Tarus), 
Chimpanzee (Pan troglodytes), Dog (Canis lupus familiaris),  Fruit fly (Drosophila 
melanogaster), Mosquito (Culicidae) and Zebrafish (Danio rerio) and Chicken (Gallus 
gallus) . Multiple sequence alignment of the amino acid sequence of IDOL was 
performed to observe whether the missense rare variants found in IDOL were in 
conserved regions of the protein. High conservation was an indication of importance of 
the residue (Figure 3.3). 
 The rare missense variants found in IDOL are marked by the red rectangles with 
the variant name on top. For the p.C31Y, the residues marked by blue rectangles 
represent residues that may disrupt disulphide bonds with the p.C31Y mutation. For the 
p.R372W mutation, the residues marked by blue rectangles represent electrostatic bonds 
that may be disrupted with an p.R372W mutation (Figure 3.3). 
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Table  3.3  Rare missense Variant accumulation  of non-
synonymous rare variants, in LDLR, in Cases and Controls 
   
Variant Selection   FCH Controls   OR(95% CI) P Value 
Missense <1%   7 4   1.20 (0.34-4.23) 1.00 
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Table 3.4 Missense rare variants found in the exons 26 and 29 of APOB in 138 
FCH cases and 94 FHTG controls and the predicted effect on protein function 
using in silico predictive tools PolyPhen-2  and SIFT. 
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Table 3.5  Rare  Missense  Variant accumulation  in exons26 and 29 of 
APOB, in Cases and Controls   
Variant Selection 
 
FCH Controls 
 
OR(95% CI) 
P -
Value 
Missense <1% 
 
10 9 
 
0.74(0.29-1.90) 0.63 
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Table 3.7.  Rare missense variant accumulation  of 7 exons of IDOL,  in Cases and 
Controls   
Variant Selection   FCH 
Control
s   
OR 
(95% CI) P -Value 
Missense<1%   2 2   
0.69  
(0.095-4.96) 1.00 
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Table  3.8  Rare missense variant accumulation  in LDLR, APOB and IDOL  
in Cases and Controls 
   
Variant Selection   FCH Controls   OR(95% CI) 
P -
Value 
Missense <1%   19 15   0.85 (0.39-1.90) 0.68 
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Table 3.9  Rare missense variant accumulation  functionally verified and/or 
predicted to be deleterious by both PolyPhen-2 and SIFT, in  LDLR, APOB and 
IDOL,  in cases and controls   
Variant Selection   FCH Controls   
OR 
(95% CI) P Value 
Missense <1%   10 3   
2.4  
(0.59-11.4) 0.25 
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Figure 3.1  Multiple Sequence Alignment of LDLR . Multiple Sequence 
Alignment of LDLR amino acid sequence from 6 species, namely: Human, 
Rhesus Monkey, House Mouse, Cattle, Chicken and Chinese Hamster.  
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Figure 3.2  Multiple Sequence Alignment of APOB. Multiple Sequence Alignment of 
APOB amino acid sequence from 6 species, namely: Human, House Mouse, Chicken 
Rat, Cat and White-tufted-ear marmoset. APOB sequence is from amino acid 1231 to 
4563. 
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Figure 3.3. Multiple Sequence Alignment of the IDOL protein. Multiple 
Sequence Alignment of IDOL amino acid sequence from 6 species, namely: 
Human, House Mouse, Chicken, Rat, Cattle, Rat and Pacific Walrus.  
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Chapter 4: Results II — Resolving genetic etiology of hypercholesterolemia in 
Mutation Negative Familial Hypercholesterolemia patients 
 
4.1 Study subjects 
Individuals with Familial Hypercholesterolemia have abnormally elevated 
cholesterol levels. I performed a case control study in which 44 Familial 
Hypercholesterolemia Mutation Negative (FH/M-ve) patients were cases and 44 Familial 
Hypercholesterolemia  Mutation Positive (FH/M+ve) patients were controls. The cases 
and controls were matched for age and sex.  I hypothesized that FH/M-ve patients have a 
significantly greater accumulation of LDL-C raising SNPs, as assessed by the genetic risk 
score, than FH/M+ve patients. This hypothesis was first tested in a British study (48). 
However, my study was the first to test this hypothesis in a Canadian population and also 
served as an independent replication study. 
I also performed an independent study where all the coding regions of APOE 
were in 95 APOE FH/M-ve patients. For the FH/M-ve resequencing study, all 44 of the 
FH/M-ve patients from the FH case control study were included in the FH/M-ve APOE 
resequencing study. APOE was sequenced to identify any potential FH-causing mutations 
as a recent collaborative study has showed an APOE variant to FH-causing (data not yet 
published). 
 
 
 
126 
 
 
 
4.1.1 Patient demographics of Mutation negative Familial Hypercholesterolemia 
patients and Mutation positive Familial Hypercholesterolemia patients 
In Tables 4.1 and 4.2, the clinical attributes of patients from the FH case-control 
study and APOE re-sequencing study are given, respectively. Paired t-tests were 
performed to compare clinical characteristics between cases and controls; paired t-test 
was used because the cases and controls were matched. Paired t-tests were conducted 
using SAS Enterprise guide version 4.3 software, with a nominal level of significance of 
P <0.05. 
4.2 LDL-C genetic risk score 
12 of the 37 LDL-C raising SNPs identified by GLGC were genotyped in 44 
FH/M-ve cases and 44 FH/M+ve controls. For each FH patient, the LDL-C genetic risk 
score was calculated as follows:  The LDL score was the sum of the product of the risk 
allele and beta coefficient (or standardized regression coefficient). The beta coefficient 
essentially represents the standardized regression coefficient for the risk allele. The beta 
coefficient is representative of the effect size (i.e. estimate of how much the risk allele is 
raising LDL-C). Table 4.3 shows the beta coefficients from GLGC (43) recalculated to 
mmol/L and the beta coefficients for APOE (100). Table 4.3 shows the standardized 
regression coefficient for all the risk alleles used to calculate the LDL-C genetic risk 
score (48).  
For example if an FH patient had two copies of the rs2479409 risk allele 
(PCSK9), one copy of the rs629301 risk allele (CELSR2) and ε4ε4, the LDL-C genetic 
risk score would be calculated as follows: 
(0.052*2)+(0.15*1)+ 0.2= 0.45 
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4.2.1 List of LDL-C genetic risk score in Mutation Negative  Familial 
Hypercholesterolemia patients and Mutation  Positive  Familial  
Hypercholesterolemia patients 
 
The GLGC weighted LDL-C genetic risk scores for the 44 FH cases and their 
matched controls are all given in Table 4.4. The information in Table 4.4 was obtained 
from our UK collaborators.   All the 88 FH patients were genotyped  for the 12 SNPs and 
the LDL-C  genetic risk score was calculated  for each patient  by our UK collaborators  
(Professor Steve Humphries, British Heart Foundation Laboratories,  Institute for 
Cardiovascular Science,  University  College  London,  United  Kingdom). 
Table 4.2 gives partial information on patient demographics for APOE  
resequencing. All the FH/M-ve patients were collected over the years in the Hegele lab; 
some of the patients were from other sources. So, information clinical information on all 
95 patients could not be obtained, however, I found clinical information on 59 of the 95 
patients (62% of patients) (Table 4.2) 
 
4.3 Test for accumulation   of LDL-C  SNPs 
Normality tests showed that the LDL-C genetic risk scores for FH/M-ve cases and 
FH/M+ve controls  were not normally  distributed;  they were skewed  (normality  test 
results are shown in Table 5 in the Appendix).  Because cases and controls were paired, 
the LDL-C  genetic  risk scores were also paired.  Therefore,  the Wilcoxon  Signed-Rank 
test was used to statistically determine whether the mean LDL- C genetic risk score was 
higher in FH/M-ve  cases than in FH/M+ve  controls, because  it is the most appropriate 
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test to use to compare  the mean of paired data that are not normally distributed.  Table 
4.5 shows results from Wilcoxon's signed rank test. Even though the mean LDL-C  
genetic risk score was higher  in FH/M-ve cases than in FH/M+ve controls,  this 
difference  in mean LDL-C  genetic risk score was not statistically significant  (P=0.43)  
(Table  4.5). Table 4.6 shows all the descriptive statistics for the mean LDL-C  genetic  
risk scores in FH/M-ve  cases and FH/M+ve  controls 
 
4.4 Comparison of LDL-C  genetic  risk scores to other ethnically  different  cohorts 
The LDL-C  genetic  risk scores from my Canadian case control  cohort was then 
compared  with two other different  populations,  namely,  British  and Belgian 
subpopulations (48). Information on the British and Belgium cohort is from Talmud  et al 
(48).  Table 4.7 shows the mean LDL-C genetic risk scores, along with the p-values for 
the mean differences between cases and controls in the three different  populations.  
Table 4.7 also shows the sample size of the case-control cohort in the three populations.  
In all three cohorts, the mean LDL-C genetic risk score was greater in FH/M-ve cases 
than in FH/M+ve controls.   
The mean LDL-C genetic risk scores of the cases and controls of the Canadian  
cohort  are unequivocally comparable  to the mean LDL-C  genetic risk scores of cases 
and controls  of the UK and Belgium cohort.  Unlike the Canadian cohort, the sample size 
of the UK and Belgian cohorts is considerably larger  (Table  4.7) and the differences  in 
mean LDL-C  genetic risk scores between FH/M-ve cases and FH/M+ve controls were 
significant in both the UK and Belgian cohort  (Table 4.7). Post-hoc power calculations 
showed that the British and Belgium cohorts were sufficiently powered and the Canadian 
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cohort was underpowered. Figure 4.1 shows how statistical power is a function of 
sample size.  
 
4.5 APOE resequencing in FH/M-ve patients 
Another recent collaborative study involving the Hegele lab and the Genest lab at 
McGill University identified an amino acid deletion mutation in APOE  that segregated 
with the hypercholesterolemia phenotype in a family with Familial Hypercholesterolemia 
(FH). This mutation was designated as  APOE  Leu167del and was considered to be FH 
causing  as it co-segregated with the FH phenotype in LDLR mutation negative 
individuals   across  multiple generations  in the affected family.  Because this example 
showed that mutations in APOE could cause an FH-like phenotype, the three coding 
regions of APOE  were sequenced  in 95 Canadian FH/M-ve  patients  to identify any 
possible  FH-causing  mutations.  The APOE  Leu 167 del was not found in this Canadian 
FH/M-ve  cohort. Table 4.8 shows all the variants that were found by Sanger sequencing.  
Intronic, silent and missense  variants  were found.  I performed in silico prediction 
analysis of the rare missense variants found  in the Canadian  FH/M-ve  cohort: these 
were the APOE : p.L46P and p.A91 T variants.  These were absent from other databases.  
Only the p.L46P variant was predicted  to be deleterious  by PolyPhen-2  (Table 4.9). 
Therefore, in Canadian FH patients who are negative for mutations in genes such 
as LDLR, APOB and PCSK9, there appears to be other genetic factors involved, 
including: 1) a trend towards a higher polygenic LDL-C genetic risk score; and 2) 
evidence for rare variants in APOE.  The relatively small sample size here was consistent 
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with a pilot project to test these hypotheses; larger sample sizes will be needed to 
determine whether these findings can attain statistical significance. 
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Population FH M+ FH M- p-value 
n 44 44 N/A 
Female,% 56.8 56.8 N/A 
Age, years 47.5±1.8 48.3±1.8 0.03 
BMI, kg/m
2 29.1±1.0 28.8±1.0 0.67 
TC, mmol/L 9.35±0.37 7.40±0.32 <0.0001 
LDL-C, mmol/L 7.36±0.3 5.24±0.3 <0.0001 
HDL-C, mmol/L 1.25±0.05 1.24±0.05 0.93 
TG, mmol/L 1.73±0.15 2.05±0.14 0.1 
Tendon xanthoma present, % 20.5 2.27 0.0097 
Table 4.1 Baseline characteristics (mean+SEM or percentage) of FH patients with and 
without a mutation in the FH case-control project 
 
Note: BMI, Body Mass Index; TC, Total Cholesterol; LDL-C, Low Density 
Lipoprotein Cholesterol; HDL-C; High Density Lipoprotein Cholesterol; TG, 
Triglyceride. Mean values of clinical attributes are represented as mean ± standard 
deviation. LDL-C level is not accurately calculated using the Friedewald equation for 
HTG patients when plasma TG concentration exceeds 4.5 mmol/L 
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Characteristic value 
n 59 
Female,% 50.8 
Age, years 44.2 ±2.01 
BMI, kg/m
2 27.3±0.96 
TC, mmol/L 7.70±0.52 
LDL-C, mmol/L 5.04±0.3 
HDL-C, mmol/L 1.27±0.26 
TG, mmol/L 1.93±0.12 
  
Table 4.2 Baseline characteristics (mean+SEM and percentages) of 59 of the 95 FH 
patients without a mutation for APOE resequencing project. 
 
Note: BMI, Body Mass Index; TC, Total Cholesterol; LDL-C, Low Density 
Lipoprotein Cholesterol; HDL-C; High Density Lipoprotein Cholesterol; TG, 
Triglyceride. Mean values of clinical attributes are represented as mean ± standard 
deviation. LDL-C level is not accurately calculated using the Friedewald equation for 
HTG patients when plasma TG concentration exceeds 4.5 mmol/L 
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Table 4.3.  The standardized regression coefficient of the risk alleles for various SNPs (43).  
CHR 
 
SNP 
 
Gene 
 
Risk allele Standardized regression 
coefficient 
   
 
 1 rs2479409 PCSK9 G 0.052 
1 rs629301 CELSR2 T 0.15 
2 rs1367117 APOB A 0.1 
2 rs4299376 ABCG8 G 0.071 
6 rs1564348 SLC22A1 T 0.014 
6 rs1800562 HFE G 0.057 
6 rs3757354 IDOL C 0.037 
11 rs11220462 ST3GAL4 A 0.05 
14 rs8017377 KIAA1305 A 0.029 
19 rs6511720 LDL-R G 0.18 
19 rs429358 APOEψ  
 19 rs7412 APOEψ  
 19  APOE ε2ε2 -0.9 
19  APOE ε2ε3 -0.4 
19  APOE ε2ε4 0.2 
19  APOE ε3ε3 0 
19  APOE ε3ε4 0.1 
19  APOE ε4ε4 0.2 
Ψ APOE weights (100) 
The standardized regression coefficients were representative of effect size of risk alleles. 
 The LDL-C genetic risk score was calculated for each FH patient by calculating the sum  
of the products of standardized regression coefficients and the count of risk alleles. 
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Sample.ID of 44 
FH/M- patients    
   
GLGC Weighted 
LDL-C genetic risk 
score 
Sample.ID of   
44 FH/M+ 
patients 
     
GLGC Weighted  
LDL-C genetic risk  
score 
726 -0.045590899 90 -0.00188777 
9035 0.307008016 573 0.420015515 
4242 0.385621928 1123 0.5805534 
366 0.640031031 2457 0.603568657 
9075 0.72723041 4177 0.648461339 
250 0.773467804 796 0.655340056 
8784 0.783811739 2062 0.674993534 
1746 0.814067752 9979 0.730799069 
367 0.871476596 1999 0.747349366 
3895 0.885880527 3420 0.840186191 
8555 0.892086888 3606 0.846909748 
8836 0.892940263 1905 0.865451254 
9884 0.923454874 175 0.873028187 
8983 0.926299456 787 0.873648823 
3477 0.928032066 8832 0.877424358 
6455 0.972071372 55 0.877941556 
5965 0.972329971 846 0.907680372 
683 1.006206361 8783 0.910886992 
8728 1.021903283 877 0.9256271 
8831 1.02560124 8712 0.929919834 
8534 1.039824152 2453 0.933540212 
3939 1.046547711 363 0.952935091 
4789 1.057667442 393 0.966382207 
1095 1.076027928 5614 0.971476596 
1339 1.093612619 1844 0.976208947 
169 1.098448409 3635 0.979570725 
3646 1.107240755 5791 0.980087923 
9885 1.124644426 11 0.987070079 
8797 1.127747607 6310 1.024566847 
1460 1.133436772 124 1.034134988 
8954 1.134652185 825 1.038712179 
1813 1.137574346 8557 1.065606413 
Table 4.4 GLGC Weighted LDL-C genetic risk scores for all the FH patients in 
the FH case-control study 
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8704 1.138091543 8967 1.072071372 
3457 1.147323506 140 1.08215671 
1805 1.150426687 154 1.089475044 
8625 1.166976983 5665 1.105766744 
8852 1.228782001 592 1.127928626 
 
5732 1.231186966 8504 1.179131108 
521 1.235505559 554 1.210343935 
6302 1.242229117 495 1.226014998 
8691 1.292655804 4625 1.227825187 
8982 NA 810 1.28541505 
1761 NA 650 NA 
628 NA 560 NA 
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Statistic FH/M-ve FH/M+ve P-value 
Mean 0.96±0.27 0.92±0.24 0.43 
Table 4.5. Mean (±SD) for LDL-C genetic risk score for Canadian case-control 
cohort 
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Statistic FH/ M - v e  FH/M+ve 
Mean  0.96 0.92 
Standard Deviation 0.3 0.2 
Median 1.03 0.95 
Standard Error 0.044 0.038 
Table 4 . 6. Descriptive statistics for LDL-C genetic risk score for t h e  
Canadian case-control cohort 
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Cohort FH/M- FH/M+ n  P-value 
UK  1.0±0.2 0.95±0.2 640 0.0014 
Belgium 0.99±0.19 0.92± 0.2 736 4.0xl0-6 
Canada 0.96±0.27 0.92±0.23 88 0.45 
Table 4 . 7. Mean weighted LDL-C  genetic  risk score (±SD) for UK, Belgium  and 
Canadian  Case-Control Cohort 
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Figure 4.1 Representation of level power as a function of sample size. As 
sample size increases, the power to detect statistical significance increases. 
Post hoc power calculations showed that British cohort sufficiently powered, 
while Canadian cohort was underpowered. 
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Variant SNP identifier MAF(%) Minor  allele carriers 
c.43 +64C>T rs.143063029 0.53 1 
p.S40S - 0.53 1 
p.L46P rs769452 0.53 1 
p.A91T  - 0.53 1 
p.A217A rs.72654468 0.53 1 
c.43+78G>A rs.769449 13.7 25 
p.C130R rs.429358 16.8 32 
p.R176C rs.7412 3.16 5 
Table  4.8. List of all variants found in 95 Mutation  Negative  Familial  
Hypercholesterolemia patients  that were sequenced  for APOE 
 
141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variant 
 SIFT prediction 
SIFT score 
 PolyPhen-2 prediction 
Polyphen-2 score 
 
p.L46P Tolerated 0.11 Possibly damaging 0.949 
p.A91T Tolerated 0.36 Benign 0.092 
Table 4.9 Rare missense variants found in APOE  in 95 FH/M-ve  patients 
that  were resequenced 
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Chapter 5: Results III—Association of DIET1 SNPs with Hypertriglyceridemia 
 
5.1 Study subjects  
 Study subjects were individuals clinically diagnosed with one of the 4 
Fredrickson polygenic hypertriglyceridemia (HTG) phenotypes, namely, Type 2B (MIM 
144250), Type 3 (107741), Type 4 (144600) or Type 5 (144650). The majority of control 
subjects were healthy normolipidemic individuals (96%) and the remaining controls were 
FH patients without HTG (4%). FH patients were included as controls to partially correct 
for the increased total cholesterol phenotype that is seen in some HTG  patients. Table 
5.1 shows the clinical attributes of the case-control cohort for the DIET1 analyses. There 
was a total of 463 HTG cases. 
 Out of all these 463 hypertriglyceridemia patients, all Familial Combined 
Hyperlipidemia (FCH) (Frederickson Type 2B) patients (n=159) and all Familial 
Hypertriglyceridemia (FHTG) (Fredrickson Type 4) patients (n=128) were used for the 
independent case-control study that tested for association of the PSMD9 gene region with 
hypercholesterolemia.  Testing this association aimed at identifying any common variants 
associated with the cholesterol component of FCH because of a recent publication in 
which the PSMD9 locus had been associated with hypercholesterolemia (65)  
 
5.2 Genotyping Results 
 HTG cases and controls had been genotyped for SNPs across the genome using 
Affymetrix version 6.0 microarrays, as stated in section 2.5 of the Materials and Methods 
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section. The specific subset of these genotypes within the DIET1 region was used for the 
association analysis with HTG.  The DIET1 region in mice corresponds to the genomic 
coordinates chr 10:19,377,700 to 20,063,500 in the hg19 human genome build. This 
corresponds to chr 10: 19,417,706 to 20,103,506 genomic coordinates in the hg18 human 
genome build. The hg18 version of genome build in the human genome was used 
throughout DIET1 analyses because the GWAS data (70) were based on hg18. I 
hypothesized that the DIET1 region is associated with triglyceride levels in humans, 
because the mouse DIET1 gene was associated with triglyceride levels in mice.  If 
correct, the frequency of SNPs in DIET1 region should differ between HTG cases and 
normotriglyceridemic controls.  
 The DIET1 region corresponds to the 19,417,706 to 20,103,506 hg18 human 
genome coordinates. Since I was only interested in the DIET1 region, statistical analyses 
was only performed on SNPs in the DIET1 region from the GWAS data. Logistic 
regression was performed to test for association of SNPS in DIET1 region and 
triglyceride (TG) level; logistic regression essentially tests whether any SNP allele or 
genotype has a different frequency in cases relative to controls.  
Because of linkage disequilibrium, SNPs outside the 19,417,706 to 20,103,506 
DIET1 regions were selected; SNPs from hg18 19,317,706 to 24,003,506 human genomic 
coordinates on chromosome 10 were selected for logistic regression. In total, 4,808 SNPs 
were present within this expanded range. Logistic regression was adjusted for the 
following covariates:  sex, body mass index (BMI), diabetes status and population 
substructure. 
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5.3 List of most highly associated SNPs in DIET1 locus with HTG  
 Since there were 4,808 SNPs genotyped in the 19,317,706 to 24,003,506 hg18 
DIET1 region, the Bonferroni corrected p-value, below which  an association is 
considered statistically significant, is (0.05/4,808) 0.00001. Bonferroni correction is an 
over-conservative form of adjusting  p-values for multiple testing, where each association 
analysis of each SNP is essentially a ‘test’. Table 5.2 shows the top 5 five SNPs most 
highly associated with TG levels, in the DIET1 region. 
 The most highly associated SNP with TG (i.e. smallest p-value) was rs2499065 
(P=0.0008). Since the DIET1 region in mice has currently not been annotated in the 
human genome, not much information on the rs2499065 variant presently exists; so it is 
not known whether the variant is intronic, silent, nonsense or amino acid changing.  
Even though the p-value of the rs2499065 variant does not reach the overly-
conservative p-value of 0.00001, it is still worth reporting the variant (as well the 
remaining top 4) because a substantial proportion of the 4,808 SNPs are in Linkage 
Disequilibrium (LD). So, in reality the SNPs that are actually associated due to some 
biological relationship with TG (and not due to LD) are likely much fewer than 4,808, 
although the precise number cannot be estimated. So this only makes the Bonferroni 
corrected p-value over-conservative as there are in actuality fewer ‘tests’. 
 For the adjusted logistic regression, the rs2499065 variant had an OR of 1.4 with 
a 95% confidence interval that did not include 1.0 (1.1-1.6) (Table 5.2). The remaining 
SNPs, from the adjusted logistic regression, also had ORs above 1.0 with 95% 
Confidence Interval (CI) that did not include 1.0 (Table 5.2). Figure 5.1  summarizes the 
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findings from the DIET1 analyses.  The data suggest that there might indeed be an 
association between SNPs in the DIET1 region and TG; follow up experiments would be 
very reasonable for a future graduate student project. 
 
5.4 PSMD9 and cholesterol 
 Testing whether PSMD9 is associated with hypercholesterolemia in FCH was 
conducted in an identical manner for DIET1 analyses. The cases were FCH patients and 
controls were FHTG patients; so the same data from Johansen et al (70) were used. The 
hg19 human genomic coordinates for PSMD9 is on chromosome 12: 122,326,646-
122,355,771; the hg18 human genomic coordinates of PSMD9 is chromosome 12: 
120,811,029 -120,840,154 and the hg18 human genomic coordinates of PSMD9 were 
used because the GWAS data from Johansen et al (70) were obtained when hg18 had 
been the current version of the human genome build. 
 Since we were only interested in the PSMD9 region, statistical analyses were 
only performed on SNPs in the PSMD9 region from the GWAS data. Logistic regression 
was performed to test for association of SNPS in PSMD9 region and 
hypercholesterolemia; logistic regression essentially tests whether any SNP allele or 
genotype has a different frequency in cases relative to controls.   
Because of LD, SNPs outside the 120,811,029 -120,840,154 region were selected; 
SNPs from the hg18 chr 12: 120,711,029 -120,940,154 human genomic coordinates were 
selected for logistic regression. In total, 134 SNPs were present within the chromosome 
12 120,711,029 -120,940,154 region in hg18. Logistic regression was adjusted for the 
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following covariates:  sex, body mass index (BMI), diabetes status and population 
substructure. 
The most highly associated SNP from this region with FCH was rs1795964 
(P=0.08). The Bonferroni-corrected p-value is (0.05/134) 0.0004. However, it is still 
worth reporting the variant as a good proportion of the SNPs are in Linkage 
Disequilibrium. So the SNPs that are actually associated due to some relationship with 
hypercholesterolemia (and not due to LD) are fewer than 134. So this only makes the 
Bonferroni corrected p-value over-conservative as there are in actuality fewer ‘tests’. 
Nevertheless, it is unlikely that rs1795964 is playing a role in dyslipidemia susceptibility 
because the 95% Confidence interval of its OR includes 1.0 (Table 5.3) 
According to NCBI, the rs1795964 SNP is a SNP that is found in the intronic 
region of a gene named SET domain containing 1B (SETD1B); SETD1B gene product is 
a component of a histone methyltransferase complex (102), so an obvious mechanistic 
connection to dyslipidemia is unclear. Figure 5.2 summaries the PSMD9 findings. 
 
5.5 GLGC-identified LDL-C raising SNPs 
 The Global Lipids Genetic Consortium (GLGC) identified 37 SNPs that affects 
LDL-C levels (43). The list of these 37 SNPs is shown in Table 5.4; (43). The SNPs 
listed in the table are the SNPs most highly associated with LDL-C. For instance 
rs2131925, which is in the ANGPTL3 gene, is a SNP primarily associated with TG levels 
but is also associated with other lipid variables. So, the "best SNP" is taken to be the SNP 
most strongly associated with a particular lipid, in cases where there are multiple 
associations. For instance, the "best SNP" in the ANGPTL3 example is rs3850634 
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because it is most strongly associated with LDL-C. Because Table 5.4 mainly shows 
SNPs that affect specifically LDL-C levels, it is slightly modified from Table 1 in (43).  
 The same GWAS data for FCH cases and HTG controls from (70) was used for 
two analyses: (i) to test for association between each of the 37 LDL-C SNPs and LDL-C 
levels in FCH cases and FHTG controls; and (ii) to determine whether more of risk 
alleles of the 37 SNPs accumulate in cases relative to controls. I tested for association of 
each of the 37 SNPs to see if any of these SNPs that affect LDL-C levels in the 
population also affects LDL-C levels in FCH cases. I performed the risk score analyses to 
see if a larger number of risk alleles from the 37 LDL-C associated SNPs accumulate in 
cases relative to controls. 
 
5.5.1 Test for association of the 37 SNPs 
Logistic regression was performed as in Section 5.4. The 37 SNPs shown in Table 
5.4 were tested in 159 FCH cases and 128 HTG controls. The Bonferroni corrected p-
value was (0.05/37) 0.001. Table 5.5 shows the results from logistic regression. The two 
SNPs with the smallest (i.e. most significant) p-values were rs629301 (P=0.04) and 
rs3757354 (P=0.05). The SNP with the smallest p-value but highest OR was rs1367117 
(OR=1.34) (P=0.12).  
 
5.5.2 Test for accumulation of all SNPs for LDL-C genetic risk score 
 I hypothesized that FCH cases would have a greater accumulation of LDL-C 
raising alleles relative to the HTG controls. Therefore, all 37 LDL-C raising SNPs were 
tested to see if FCH patients have a more accumulation of LDL-C associated risk alleles 
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and thus a higher genetic risk score. The unweighted LDL-C genetic risk score was used 
for comparison. Since the unweighted LDL-C genetic risk score was not normally 
distributed, the Wilcoxon Rank Sum test was used. The mean LDL-C genetic risk score 
was greater in FCH cases than in HTG controls at a rate almost approaching statistical 
significance (P=0.054). 
 
 
Summary 
The results of the association analysis of DIET1 with TG, PSMD9 and cholesterol 
and LDL-C genetic risk score (GRS) and hypercholesterolemia show suggestive positive 
trends that are close to, or of borderline statistical significance.  The relatively small 
sample size here was consistent with a pilot project to test these hypotheses; larger 
sample sizes will be needed to determine whether these trends can attain statistical 
significance. 
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Clinical attribute HTG cases Controls 
n 463 1197 
Female,% 30.7 40.4 
Age, years 50.9±13.0 47.8±11.1 
BMI, kg/m
2 29.9±4.9 26.4±4.6 
TC, mmol/L 8.2±3.9 5.3±1.3 
LDL-C, mmol/L - 3.4±1.2 
HDL-C, mmol/L 0.9±0.3 1.4±0.4 
TG, mmol/L 14.3±1.8 1.1±0.7 
Table  5.1. Baseline characteristics (mean+SEM) of 463 HTG cases and 1197controls. 
 
Note: BMI, Body Mass Index; TC, Total Cholesterol; LDL-C, Low Density 
Lipoprotein Cholesterol; HDL-C; High Density Lipoprotein Cholesterol; TG, 
Triglyceride. Mean values of clinical attributes are represented as mean ± standard 
deviation. LDL-C level is not accurately calculated using the Friedewald equation 
for HTG patients when plasma TG concentration exceeds 4.5 mmol/L 
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Figure 5.1. Representation of the top 5 SNPs in the 10p12.31 
chromosome region using the UCSC genome browser template. (a) 
Because UCSC has not released its Linkage disequilibrium (LD) map 
for the hg19 genome build, the hg18 genome build was used to show 
the LD pattern of SNPs in the region corresponding to the DIET1 gene 
in humans in the European population. LD map is a representation of 
SNPs that are in LD with each other across the genome. Since SNPs are 
in LD with SPNs physically close, LD occurs in LD ‘blocks’. The 
“CEPH (CEU) from phased genotypes” refers to the LD pattern for the 
European population. The 19,417,706-20,103,506 hg18 coordinates 
correspond to the hg19 19,377,700-20,063,500 coordinates. P-values 
from logistic regression adjusted for sex, BMI, diabetes status and 
population substructure are in the parentheses next to SNP ID. For the 
LD blocks in the European population, the intensity of the colour is 
proportional to the LD measure; the red colour represents a stronger LD 
measure than the less intense lavender purple colour. (b) is a zoomed in 
image of (a) that better shows which LD block the top SNPs are in. The 
green dotted lines show which LD block the top SNPs belong to. 
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Figure 5.2. Representation of the rs1795964 variant in the 
12q24 chromosomal region using the UCSC genome browser 
template. Because UCSC has not yet released its linkage 
disequilibrium (LD) map for the hg19 genome build, the hg18 
genome build was used to show the LD pattern of rs1795964 non-
coding SNP in the European population. The “CEPH (CEU) from 
phased genotypes” refers to the LD pattern for the European 
population.  For the LD blocks in the European population, the 
intensity of the colour is proportional to the LD measure; the red 
colour represents stronger LD measure than the less intense 
lavender purple colour. The blue dotted line shows which LD 
block the rs1795964 belongs to. 
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SNP Effect Size  Risk allele Nearby genes Chromosome 
rs12027135 -1.1 T LDLRAP1 1 
rs2479409 2.01 G PCSK9 1 
rs3850634 -1.59 T ANGPTL3 1 
rs629301 -5.65 T SORT1 1 
rs2807834 -1.09 G MOSC1 1 
rs514230 -1.13 T IRF2BP2 1 
rs1367117 4.05 A APOB 2 
rs4299376 2.75 G ABCG5/8 2 
rs12916 2.45 C HMGCR 5 
rs6882076 -1.67 C TIMD4 5 
rs3757354 -1.43 C IDOL 6 
rs1800562 -2.22 G HFE 6 
rs3177928 1.83 A HLA 6 
rs11153594 -0.89 C FRK 6 
rs1564348 1.95 C LPA 6 
rs12670798 1.26 C DNAH11 7 
rs217386 -1.17 G NPC1L1 7 
rs2126259 -2.22 C PPP1R3B 8 
rs1030431 0.95 A CYP7A1 8 
rs2954022 -1.84 C TRIB1 8 
rs11136341 1.4 G PLEC1 8 
rs649129 2.05 T ABO 9 
rs1129555 1.08 A GPAM 10 
rs174583 -1.71 C FADS1-2-3 11 
rs964184 2.85 G APOA1-C3-A4-A5 11 
rs11220462 1.95 A ST3GAL4 11 
rs11065987 -0.97 A BRAP 12 
rs1169288 1.42 C HNF1 12 
rs2332328 1.17 T NYNRIN 14 
rs247616 -1.45 C CETP 16 
rs2000999 2 A HPR 16 
rs7225700 -0.87 C OSBPL7 17 
rs6511720 -6.99 G LDLR 19 
rs10401969 -3.11 T CILP2 19 
rs4420638 7.14 G APOE-C1-C2 20 
rs2902941 -0.98 A MAFB 20 
Table 5.4 List of 37 GLGC identified SNPs that affect LDL-C levels in the general 
population 
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rs909802 1.41 T TOP1 20 
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SNP Gene OR(95% CI) p-value 
rs629301 SORT1 0.63 (0.41-0.98) 0.04 
rs3757354 IDOL 0.65 (0.42-0.99) 0.05 
rs1367117 APOB 1.34 (0.90-1.90) 0.12 
Table 5.5 Results from testing for association, using logistic regression, of the 37 
GLGC-identified LDL-C SNPS  
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Chapter 6: Discussion 
 
 Hypercholesterolemia is a classical major risk factor for cardiovascular disease 
(CVD), the most common cause of mortality in North America. Therefore, having 
Familial Hypercholesterolemia (FH) (Fredrickson Type 2A) or Familial Combined 
Hyperlipidemia (FCH) (Fredrickson Type 2B) puts an individual at risk for CVD 
development because of the hypercholesterolemia that is characteristic to both 
dyslipidemias. The etiology of hypercholesterolemia can be either environmental and/ or 
genetic. The underlying theme of all three projects comprising my thesis was to better 
understand the genetic etiology of hypercholesterolemia, with the heaviest focus on better 
understanding the genetic basis of hypercholesterolemia in FCH.  In the course of this 
work, I therefore investigated patients with FCH, but also those with FH and with 
Familial Hypertriglyceridemia (HTG) (Fredrickson Type 4).  
The overall hypothesis of my first study was that FCH could actually represent 
the simultaneous co-existence of FH and FHTG. My second study focused on FH and in 
particular non-classical genes that could be linked in some cases, such as APOE and also 
the polygenic LDL-C genetic risk score (comprised of SNPs).  My third study focused on 
non-classical genetic determinants of HTG and hypercholesterolemia using GWAS data. 
So, the work done independently on FH and HTG, in essence converge towards further 
understanding the two phenotypes that are characteristic of FCH, namely 
hypercholesterolemia and hypertriglyceridemia. 
Knowing the genetic basis of diseases is a major upstream step in understanding 
the biochemistry underlying the disease, which can consequently lead to implementation 
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of better diagnoses and better treatment. For instance, the Nobel-Prize winning discovery 
of the genetic basis of FH has led to the understanding of the disease at the biochemical 
level (39) and has also led to the development and implementation of LDL-C lowering 
drugs(18). Better diagnosis leads to better prognosis, as shown by Kaplan-Meier survival 
curves that showed better survival rate for FH patients on statin treatment (63).  
The main goal of my first study was to better understand the genetic basis of 
hypercholesterolemia in FCH, which is the most common genetic dyslipidemia in the 
North American population.  FCH is also the principal dyslipidemia in 20% of 
individuals with coronary heart disease (CHD) (103). The genetic etiology of HTG is 
better understood than the hypercholesterolemia component in FCH, due in large part of 
previous work from the Hegele lab. Previous work  has explained 42% of genetic 
variation of HTG for the four Fredrickson polygenic HTG-associated phenotypes 
(Fredrickson Type 2B, Type III, Type 4 and Type V) (71). Low plasma levels of high 
density lipoprotein cholesterol (HDL-C), which are strongly associated with CVD risk, is 
also often characteristic of FCH (104). None of my projects focused on low HDL-C, 
perhaps fortunately since the direct role of HDL-C in causing CVD and CHD is recently 
facing questions (20). 
My second study, which was composed of two sub-projects, was aimed at 
resolving the genetic etiology of hypercholesterolemia in FH patients, in whom the 
hyperlipidemia was not due to the any of the four known FH causing genes.  The first 
sub-project of my second study tested whether the LDL-C genetic risk score was higher 
in Mutation Negative Familial Hypercholesterolemia (FH/M-ve) patients relative to 
Mutation Positive Familial Hypercholesterolemia (FH/M+ve) patients; in other words, 
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the first sub-project tested whether the genetic etiology of FH could be polygenic. The 
second sub-project of the second study aimed at looking for other rare monogenic causes 
of FH among  patients in whom FH was not due to the any of the four known FH causing 
genes. Towards this goal, APOE was sequenced in the second sub-project. 
For the first sub-project of the second study, I hypothesized an alternate genetic 
etiology for FH could be the accumulation of LDL-C raising SNPs. In the British study 
from our collaborators at University College, London (48), they were the first to test this 
hypothesis in a UK and Belgian cohort. So, my study was both the first to test this 
hypothesis in the Canadian population and also served as a replication study of theirs. I 
was also interested in the results of the second sub-project, because I reasoned that 
whatever caused hypercholesterolemia in FH/M-ve patients could also be cause 
hypercholesterolemia in FCH. So, my FH findings could converge to specify future 
directions on further studies on FCH. 
For the third study of my thesis, a Genome Wide Association Study (GWAS) in 
hyperlipidemia patients and healthy controls was performed using data previously 
obtained (70). This data represents a wealth of data for various follow-up genetic 
analyses to test new hypotheses regarding hyperlipidemia. In particular I used this data 
for all three sub-projects of my third study. Note, this data studied 1197 healthy controls 
and 463 HTG cases (70). These HTG cases were patients with polygenic HTG, namely, 
FCH (Fredrickson Type 2B), Familial HTG (Fredrickson Type 4), Familial 
dysbetalipoproteinemia (Fredrickson Type III) and Mixed Dyslipidemia (Fredrickson 
Type V).  
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The DIET1 gene in mice (also called Diet1) has been associated with HTG. . 
Synteny refers to similar genes present in similar chromosomal locations between species 
and the syntenic DIET1 region has not been well-annotated in humans.  Association of 
the syntenic DIET1 region with HTG has not previously been evaluated. So, for the first 
sub-project of the third study, I was interested in finding whether or not DIET1 plays a 
significant role in HTG in humans, by searching for any highly associated SNPs in the 
DIET1 region. All the polygenic HTG patients from (70) were studied as my cases and all 
the healthy normolipidemic patients from (70) were my controls. As mentioned earlier, 
the Hegele lab has identified a large proportion of the genetic basis of HTG; 42% of 
susceptibility to HTG, encompassing Type 2B, Type III, Type 4 and Type V Fredrickson 
dyslipidemias is due to a combination of common SNPs and heterozygous rare variants. 
So, I was also interested in the first sub-project of the third study to see if I could further 
add to the explained proportion of the genetic basis of HTG (which is also the other 
characteristic biochemical phenotype of FCH).  
The second sub-project of the second study aimed at identifying whether the 
genomic region harboring the PSMD9 gene is associated with hypercholesterolemia in 
FCH, given that this region has recently been associated with hypercholesterolemia (65). 
For the third sub-project of the third study, the same GWAS data from FCH 
patients and HTG patients was used in a case-control study, where FCH patients were 
defined as cases and HTG patients were defined as controls. I hypothesized that the 37 
SNPs that affect LDL-C levels in the general population would also affect LDL-C levels 
in FCH, especially since the genetic architecture of FCH is increasingly appreciated as 
being polygenic. Out of the total of 463 HTG cases, FCH patients (n=159) were our cases 
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and HTG patients (n=128) were our controls. So, I tested for association of the 37 SNPs 
with LDL-C levels in FCH. Then we tested for whether FCH patients have a higher 
genetic LDL-C genetic risk score, where the LDL-C genetic risk score was calculated 
using the effect sizes of the 37 GLGC identified SNPs (43). 
Even though my second and third studies focused on FH and HTG, respectively, 
findings from the latter two projects can lead to future directions for studying the two 
phenotypes (i.e. hypercholesterolemia and hypertriglyceridemia) that are the defining 
biochemical phenotypes in FCH. 
 
6.1 Findings from resequencing of candidate genes in FCH 
Before I undertook my first project, the genetic basis of hypercholesterolemia in 
FCH was poorly understood in the field. The first researchers to describe and characterize 
Familial Combined Hyperlipidemia (FCH) (103) described the disorder to be an 
autosomal dominant disorder that was the most common dyslipidemia in humans (68). 
Since  FCH was proposed in the 1970's by Goldstein to be an autosomal dominant 
disease, researchers in the field have believed FCH was due to a single gene. Despite 
decades of heroic efforts, a single gene could not be found for most cases of FCH. Thus, 
by default, FCH was then considered  to be  polygenic, although there was no direct 
evidence for this idea until recently (69). 
The hypothesis of my first project was that individuals with FCH have a greater 
accumulation of heterozygous rare and potentially deleterious mutations in the three 
Autosomal Dominant Hypercholesterolemia (ADH) causing genes, namely LDLR, APOB 
and PCSK9. We did not focus on ARH because (i) FCH does not show an autosomal 
recessive pattern and (ii) only a minute percent of the total population of FH is caused by 
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recessive mutations in ARH. Since work from the Hegele lab has previously explained the 
genetic etiology of hypertriglyceridemia (HTG) in FCH, I hypothesized that FCH could 
be a condition where individuals have polygenic susceptibility to HTG in combination 
with FH-causing mutations. My study was the first to sequence the three known ADH 
causing genes in a case-control setting. My study was also the first to utilize individuals 
with HTG  as controls for studying genetic basis of hypercholesterolemia in FCH. Sanger 
sequencing, which is a Nobel Prize winning method (105), is still the gold standard for 
identifying  novel and known mutations. Our study was the first to Sanger sequence 
LDLR, APOB and PCSK9 genes in both FCH cases and age- and sex-matched HTG 
controls.  
The ratio of rare missense variants for LDLR was 7 to 4, giving rise to an OR of 
1.2 with a confidence interval that included 1.0. The comparable ORs were 0.74 and 0.69 
for APOB and IDOL, respectively and the 95% confidence interval included 1.0 for both 
genes. No analyses could be done for PCSK9 as no variants were found. Post hoc power 
calculations showed that the studies had a statistical power to detect small effects that 
was well below 80%. Therefore lack of significant results in my study can be explained 
by low power. Not having a definite idea of the power of my type of study is a limitation 
as effect sizes (as represented through ORs) of rare variants accumulating in candidate 
genes cannot be determined a priori, especially since my study was the first to perform 
this type of analysis. Realistically, finding appropriate sized samples from a single centre 
that would provide satisfactory statistical power is impractical, as samples of such 
patients are not easy to assemble. Nevertheless it is still worthwhile attempting such 
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studies, on the chance that there is a large biological effect that might be detectable with a 
relatively small sample.  Again, the effect size was unknown a priori in my study. 
Since I did not perform any functional work on any of the variants found, a 
literature search was performed on all 31 rare missense variants that were observed in the 
case-control studies to determine if any of the variants had already been functionally 
evaluated. I performed a literature search to date (June 1, 2013) by searching the National 
Center for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov/) 
and Human Gene Mutation Database (HGMD) (http://www.hgmd.cf.ac.uk/ac/index.php). 
  
6.1.1 Findings from literature search of all 31 missense variants found in my study 
LDLR: p.T705I 
Loux et al, were the first to report this variant in a French family: a proband, and 
father and sister had the LDLR: p.T705I variants and were all FH patients (106). LDLR:  
p.T705I is a mutation occurring in the O-linked sugar domain of LDLR (106). Despite the 
fact that the LDLR:  p.T705I variant tends to segregate in families(107) (106), Brussgaard 
et al mentioned that the role of LDLR:  p.T705I in FH has been controversial (107). So 
Graham et al investigated the LDLR: p.T705I variant by screening the LDLR: p.T705I in 
207 normolipidemic controls (108). Throughout the literature, the LDLR: p.T705I variant 
has been said to be in linkage disequilibrium (LD) with an intronic variant in of exon 7 
(rs72658861) (109) (108). The rs72658861 variant and the LDLR: p.T705I variant were 
also in LD in our FCH cases.  Likewise, the LDLR: p.T705I variant could also be in LD 
with an actual causative FH-causing mutation, which could explain why the p.T705I 
variant has been shown to segregate in FH families (106). Graham et al concluded that 
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the LDLR: p.T705I does not cause FH because it was found in normolipidemic controls 
at a population frequency of greater than 1% , which is above the cut-off frequency for 
defining a variant to be a mutation. In 2008, Leigh et al updated the University College 
London, UK database for Low Density Lipoprotein Receptor Familial 
Hypercholesterolemia database and agreed that the LDLR: p.T705I variant was 
considered a non-FH causing (110). LDLR: p.T705I was found in 2 of our 
normocholesterolemic HTG controls. So, with our data and literature search on the 
LDLR: p.T705I variant, the bulk of the data favour LDLR: p.T705I being non-causative 
of FH. 
 
LDLR: p.G-2R 
Amsellems et al (111) were the first to discover the LDLR G-2R variant in a male 
FH patient. This patient inherited the LDLR:p.G-2R variant from his father, who did not 
have FH and also inherited an LDLR: p.V502M variant (rs28942080) from his mother, 
who had FH. LDLR: p.V502M was not seen in my study. The LDLR: p.V502M was first 
reported in Hobbs et al in an FH patient, but with no other information (112). Romano et 
al (113) showed that the LDLR: p.V502M variant lowers LDLR activity through 
functional studies. So, it is very likely that the FH male patient with the LDLR: p.G-2R, 
in Amsellems et al, had FH because of the LDLR: p.V502M variant he inherited from his 
FH mother and not the LDLR: p.G-2R variant he inherited from his non-FH father.  
Amsellems et al did not report any functional work for the LDLR: p.G-2R variant, 
but they suggested that based on the structural and functional knowledge of LDLR gene, 
it is very likely the LDLR: p.G-2R variant is disease causing (111). For instance , the -2 
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position is conserved in mammals and is found in the signal peptide domain of LDLR 
(111) thus making it likely to be a disease causing variant. Fouchier et al (114) were the 
first to report the LDLR: p.G-2R variant in a Dutch Population. Fouchier et al simply 
reported the occurrence of the variant and did not provide any information on whether the 
variant segregated with FH phenotype (114). Amsellems et al reported that all the novel 
mutations they found segregated with the FH phenotype and were not found in 150 
chromosomes of normolipidemic individuals (i.e. 75 normolipidemic individuals) (111). I 
also did not find the LDLR: p.G-2R in our normocholesterolemic controls. Nevertheless, 
functional work for LDLR: p.G-2R, which is currently non-existent in the literature, 
would be needed in order to confidently characterize  it as an FH-causing variant. So I do 
not consider LDLR: p.G-2R to be an FH-causing mutation. 
 
LDLR: p.G314S 
 Hobbs et al were the first and so far only to report the LDLR: p.G314S variant in 
literature (115). Their functional studies showed that the LDLR: p.G314S variant lowers 
LDLR activity. Since, I found only one FCH patient with the LDLR: p.G314S variant 
with no occurrences in the FHTG controls, I consider the LDLR: p.G314S variant to be 
probably causative of the hypercholesterolemia seen in this single FCH patient. 
 
LDLR: p.D333V 
 Hobbs et al were the first to report the LDLR: p.D333V variant (115) and showed 
that the variant lowers LDLR activity through their functional studies.  The LDLR: 
p.D333V variant was initially found in an FH individual. The LDLR: p.D333V variant 
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has also been mentioned in non-hyperlipidemia studies. In Liljedahl et al (116), the 
LDLR: p.D333V variant, along with other variants, was used in evaluation and 
comparison of microarray technologies. In Andreotti et al (117) the LDLR: p.D333V 
variant, along with other known LDL-C raising variants was shown to be associated with 
biliary tract cancers (117). So The LDLR: p.D333V variant was used because it was 
considered to be pathogenic, although not necessarily for hypercholesterolemia. Based on 
literature findings and because I found the LDLR: p.D333V variant in only FCH cases, I 
consider this variant to be possibly causative of the hypercholesterolemia seen in the 
FCH patients. 
 
LDLR: p.L561P 
 The Hegele lab was the first to report the LDLR: p.L561P variant and this variant 
was found in an FH individual (118). Wang et al did not perform any functional work on 
the LDLR: p.L561P variant (118). So I cannot definitively conclude that this variant is 
causative of hypercholesterolemia, even though I found this variant only in FCH cases. 
 
LDLR: p.C677G 
 This variant to date (June 2013) could not be found in the HGMD 
(http://www.hgmd.cf.ac.uk/ac/index.php ), NCBI(http://www-ncbi-nlm-nih-
gov.proxy2.lib.uwo.ca/snp/?term=%28%28ldlr[Gene+Name]%29+AND+11231152[Base
+Position]%29+AND+19[Chromosome] ), Ensembl 
(http://uswest.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g=ENS
G00000130164;r=19:11200038-
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11244492;v=rs147509697;vdb=variation;vf=38263839#missense_variant_tablePanel ) 
and 1000 Genomes 
(http://browser.1000genomes.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g
=ENSG00000130164;r=19:11200038-
11244492;t=ENST00000558518;v=rs5931;vdb=variation;vf=1894#missense_variant_tab
lePanel) databases. So, while this variant is novel, no functional work has been performed 
and thus I cannot conclude that it is causative of hypercholesterolemia in our FCH cases. 
 
LDLR: p.V806I 
  Hobbs et al (115) found the LDLR: p.V806I variant in an FH individual; this 
variant showed lowered LDLR activity through their functional work. Lombardi et al 
(119) were the first to report the LDLR: p.V806I variant in an FH patients from the Dutch 
population. Zakharova et al (120) was the first to report the LDLR: p.V806I variant in a 
Russian population. Zakharova et al mentioned that the LDLR: p.V806I position is found 
in the internalization signal whose sequence is NPVY, where V is not conserved. So 
Zakharova et al mentioned that the substitution of Valine for Isoleucine may not affect 
LDLR function as the V in the NPVY internalization signal is not conserved (120). 
However, Zakharova et al did not perform any functional work to disfavour the LDLR: 
p.V806I variant being causative of FH. Also, the range of species used for their multiple 
sequence alignment may differ from the species I used for multiple sequence alignments. 
My multiple sequence alignment showed that the LDLR: p.V806I position was conserved 
across species in which LDLR is said to be conserved according to NCBI (Figure 3.1).  
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Laurie et al reported the pathogenicity of the variant to be uncertain (121). In 
2010, Huijgen et al  (122) classified the LDLR: p.V806I variant as non-pathogenic 
because they cited Huijgen et al cited Defesche et al (123), Fouchier et al (114, 124) and 
Lombardi et al (125).  
Interestingly, Defesche et al (123) reported the LDLR: p.V806I variant in an FH 
patient but did not perform any functional work that would disfavour the variant being 
causative of FH  and cited sources  that did not even report the LDLR: p.V806I variant. 
These sources were Lombardi et al (125), Graham et al(108), Jensen et al (126) and 
Weiss et al (127).  Fouchier et al (114, 124) reported the LDLR: p.V806I variant in FH 
patients but did not perform any functional work to disfavor the LDLR: p.V806I variant 
being causative of FH. Lomabrdi et al did not even mention the LDLR: p.V806I variant 
(125).  In 2012, Huijgen et al (128) reported the LDLR: p.V806I variant to be non-
pathogenic based on a criteria that was non-functional based. 
Interestingly, from my literature search, the LDLR: p.V806I variant was 
essentially considered being non-causative of hypercholesterolemia, although most 
authors did not perform any functional work to support this. The only source that 
supported the LDLR: p.V806I variant being causative of FH performed functional work 
where the variant lowered LDLR activity (115). I also found the LDLR: p.V806I variant 
only in cases. Since the weight of evidence favours the LDLR: p.V806I variant as being 
causative of hypercholesterolemia, I consider the LDLR: p.V806I variant to be likely 
causative of hypercholesterolemia in the FCH cases. 
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LDLR: p.T41M 
 Fouchier et al (114) were the first to report the LDLR: p.T41M mutation in a 
Dutch FH patient. However, I found this variant in only one HTG control subject. No 
functional work has been reported on this variant. So I cannot conclude that this variant is 
causative of FH more, especially since it was found  only in normocholesterolemic HTG 
controls. 
 
LDLR: p.A585S 
Sun et al (129) were the first to report the LDLR: p.A585S in an FH patient. 
Through some functional work, Sun et al predicted the effect of various variants they 
found in FH patients to be either mild or severe. However, Sun et al did not classify the 
functional effect of LDLR: p.A585S variant (130) (129). Since the LDLR: p. A585S 
variant only occurred in our normocholesterolemic controls, I consider it to not be 
causative of hypercholesterolemia in FCH. 
The APOB gene product is the apolipoprotein that carries the hydrophobic lipid 
(cholesterol) contents of the LDL particle through the bloodstream. The interaction of 
ApoB with LDLR is vital for the internalization of LDL-C into the cells. Therefore, 
mutations in APOB that disrupt APOB-LDLR binding will prevent LDL-C from being  
internalized, which results in hypercholesterolemia. In my first project, I wanted to see if 
there was an accumulation of FH-causing variants in APOB in the FCH cases. 
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 APOB: p.C1395Y, p.T3799M, p.I2286V, p.S1586T, p.V4101M 
  These variants have each been reported in the dbSNP database, which is part of 
the NCBI database (http://www.ncbi.nlm.nih.gov/snp/ ). To date (June 2013), no papers 
could be found citing these variants in the dbSNP database. 
 
APOB: p.E2539K, p.M2331I, p.M4293V, p.R1662W, p.S3252G, p.T3020R, 
p.T4457M,  p.E2539D,  p.R2192C,  p.S3267P and p.S4403T 
 Our lab was the first to report these variants, that were discovered by Johansen et 
al (71) in patients with polygenic Fredrickson HTG phenotypes (i.e. Fredrickson Type 
2B, Type III, Type 4 and Type V). Sequencing of the target regions of APOB in all of the 
FCH patients and most HTG controls was already performed in Johansen et al (71).  
Sequencing of the target regions of APOB in the remaining of the 94 FHTG patients was 
performed in my first study. So the patients’ sequence data from Johansen et al (71) and 
my first study were combined for subsequent analyses. No papers cited these variants in 
the dbSNP database (http://www.ncbi.nlm.nih.gov/snp/) and so no functional work was 
reported in literature. 
  
APOB: p.R3500W 
 Gaffney et al (31) were the first to report the APOB: p.R3500W variant. Gaffney 
et al screened hypercholesterolemic patients for mutations at position 3500 in APOB. 
APOB: p.R3500Q was the first APOB mutation established to cause FH (31). Gaffney et 
al compared the effect of APOB: p.R3500Q variants and the APOB: p.R3500W on the 
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APOB-LDLR interaction. Gaffney et al showed both variants bound defectively, found 
no difference in effect of the two mutations and concluded the APOB: p.R3500W variant 
is causative of hypercholesterolemia. Since I only found the APOB: p.R3500W variant in 
FCH cases, the APOB: p.R3500W variant very likely explained hypercholesterolemia in 
our FCH cases. 
 
APOB: p.K1615R 
 This variant to date (June 2013) could not be found in the HGMD 
(http://www.hgmd.cf.ac.uk/ac/index.php ), NCBI (http://www.ncbi.nlm.nih.gov/snp/), 
Ensemble 
(http://www.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g=ENSG
00000084674;r=2:21224301-21266945#missense_variant_tablePanel ) and 1000 
genomes 
(http://browser.1000genomes.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g
=ENSG00000084674;r=2:21224301-21266945#missense_variant_tablePanel ) databases. 
So, this variant is novel and since no functional work was done on this variant, I cannot 
definitively conclude that it is causative of hypercholesterolemia. 
 
APOB: p.Q3404E 
The functional effect of the APOB : p.Q3405E variant has been contradictory 
throughout literature. Findings from Pullinger et al support that APOB: p.Q3405E does 
not cause hypercholesterolemia (131). In contrast, findings from Gaffney et al (132) 
support the idea that the APOB: p.Q3405E variant causes hypercholesterolemia.  
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Pullinger et al used fibroblast binding assays from 11 normolipidemic controls, 7 
heterozygous APOB: p.Q3405E individuals and 1 homozygous APOB: p.Q3405E 
individual. There was no statistical difference in binding affinity in the 3 groups (131) 
Gaffney et al studied growth of U937 cells from 23 normolipidemic individuals 
and 13 APOB: p.Q3405E individuals as a measure of LDL binding affinity. Gaffney et al 
found 13 heterozygous APOB: p.Q3405E individuals at a frequency of 1.4% and 1 
homozygous APOB: p.Q3405E variant at a frequency of 0.1%. They compared APOB: 
p.Q3405E mutant cells with cells cultured from normolipidemic individuals. They 
showed that the mean (± SD) cell growth from normolipidemic individuals was 1.1 ± 
0.32 units. The mean (± SD) cell growth from APOB: p.Q3405E individuals was 0.77± 
0.24 units and they reported the difference in mean growth rates to be statistically 
significant (P=0.004).  
High triglyceride levels lower the affinity of LDL for its receptor (132) and in 
Gaffney et al, a triglyceride level of 2.3mmol/L was defined as the upper limit of the 
normal range (132). After controlling for HTG, by removing HTG individuals, Gaffney 
et al still reported significantly lower LDL binding affinity (P=0.009) attributable to the 
APOB: p.Q3405E variant(132). However, Figure 5 from Gaffney et al showed a 
considerable discrepancy in cell growth for two separate assays done for the same 
severely HTG individual, who was removed to control for HTG. This huge variability 
from the same patient may lead to questioning of the reliability of cell growth values, 
even when controlled for HTG, for APOB: p.Q3405E individuals who had only a single 
assay performed. Table 1 in Gaffney et al reports the mean triglyceride level for the 13 
APOB: p.Q3405E individuals to be 2.5 mmol/L, which is 0.2 mmol/L above their upper 
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limit for normal TG level range. So, it can be argued that this mean TG level could bias 
the significantly lower cell growth in cells derived from APOB: p.Q3405E individuals. 
Also, in the selection of study subjects, Gaffney et al stated that patients were referred to 
them and were not pre-screened. So, it is possible that some of these 13 APOB: 
p.Q3405E individuals actually had FCH, in which HTG is part of the definition. 
Gaffney et al could not rule out the possibility of other (now) known FH causing 
mutations that were not detected. For instance, association of gain of function mutations 
in PCSK9 with clinical FH was discovered in 2003 (133), which was well after Gaffney 
et al, who published their data in 1998. So, Gaffney et al could not have screened for FH 
causing gain-of-function mutations in PCSK9. So, it remains possible that the 
significantly lower cell growth found in APOB: p.Q3405E individuals was actually due 
to other unmeasured or undetected variants and not to APOB: p.Q3405E.  
Pullinger et al proposed that the APOB: p.Q3405E variant does not cause 
hypercholesterolemia because the APOB: p.Q3405E variant segregated independently of 
hypercholesterolemia in a family diagnosed with FH (131).  Gaffney et al also reported 
no statistical difference in U937 cell growth from three family members, in which the 
proband and proband’s mother had the APOB: p.Q3405E genotype but the proband’s 
brother did not have the APOB: p.Q3405E genotype. The U937 cell growth of all three 
family members was all comparable to U937 cell growth from healthy individuals (132). 
Gaffney et al screened 200 normolipidemic individuals for the APOB: p.Q3405E variant 
and found it in 4 of the 200 normolipidemic individuals. Despite reporting information 
that disfavours APOB: p.Q3405E being causative of hypercholesterolemia, Gaffney et al 
stated that the extra negative charge brought about the APOB: p.Q3405E variant may 
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alter the structural biology of APOB in such a way that hypercholesterolemia may result 
downstream (132). However, that statement was merely a suggestion or speculation.  The 
balance of all the experimental findings do not support the idea that APOB: p.Q3405E is 
FH-causing,. 
Gaffney et al and Pullinger et al are two papers in literature that discuss the 
APOB: p.Q3405E variant in detail.  In my study, the APOB: p.Q3405E variant was only 
found in one normocholesterolemic HTG control and was not found at all in FCH cases. 
After evaluating all the findings from Gaffney et al and Pullinger et al along with only 
finding the APOB: p.Q3405E variant in HTG controls, I would argue that the balance of 
evidences favours the idea that APOB: p.Q3405E does not raise LDL-C levels.  
 
IDOL: p.R372W and p.V339I 
 These variants were not reported in HGMD 
(http://www.hgmd.cf.ac.uk/ac/index.php). These variants were reported in the dbSNP 
database (http://www.ncbi.nlm.nih.gov/snp/). No papers cited these variants in the dbSNP 
database and so no functional work was reported in literature.  I cannot definitively 
conclude whether either one is associated with hypercholesterolemia. 
 
IDOL: p.C31Y 
 This variant to date (June 2013) could not be found in the HGMD 
(http://www.hgmd.cf.ac.uk/ac/index.php ), NCBI (http://www.ncbi.nlm.nih.gov/snp/), 
1000 Genomes 
(http://browser.1000genomes.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g
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=ENSG00000007944;r=6:16129356-16148479#missense_variant_tablePanel ) and 
Ensembl 
(http://www.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g=ENSG
00000007944;r=6:16129356-16148479#missense_variant_tablePanel ) databases.  So, 
because this variant is novel and since no functional work was done on this variant, I 
cannot definitively conclude that it is causative of hypercholesterolemia. 
 
PCSK9 
 Finally, with respect to PCSK9, given the rarity of mutations in this gene across 
the entire population of FH patients, it is perhaps not surprising that I did not find any 
variant in PCSK9 in my study. 
 
All rare variants in FCH considered cumulatively 
My literature search of the variants that I found suggests that there was an 
accumulation of known functionally verified variants in FCH cases at a p-value almost 
approaching statistical significance (P=0.09). No known functionally verified variant was 
found in controls and 4 known functionally verified variants was found in cases namely 
LDLR: p.G314S, p.D333V,p.V806I and APOB: p.R3500W variants. These variants likely 
explain hypercholesterolemia in those particular FCH patients, which make up about 3%  
The results of the re-sequencing of FH candidate genes in FCH cases and FHTG 
controls indicates non-significant trends that suggest that dysfunctional rare variants 
accumulate in cases relative to controls.  The relatively small sample size here was 
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consistent with a pilot project to test these hypotheses; larger sample sizes will be needed 
to determine whether these trends attain statistical significance. 
  
Limitations of sequencing strategy to identify rare variants 
 I only looked at the coding regions of LDLR, coding regions of IDOL, only exons 
26 to 29 in APOB and only exon 7 in PCSK9. So I cannot rule out potential disease-
causing variants outside these regions. Previous studies have shown that disease causing 
variants can be non-exonic (134) and SNPs from GWAS studies have shown that it is 
SNPs in non-coding regions that are associated with disease traits (43) — all of which are 
in line with findings from the ENCODE project that showed that most variants that 
control protein biochemistry are non-coding (135) .  
 However, I am still confident in the approach taken to test my hypothesis because 
it has been long established that non-synonymous rare variants are most likely to be 
disease causing (136). There have been ‘success stories’, where the discovery of missense 
rare variants being causative of a disease resulted from the approach where only coding 
regions were analysed (137) (138). One such success story that involved analyzing 
exonic regions is the discovery the ANGPTL3 gene being causative of Familial Combined 
Hypolipidemia (137). 
 Most of the missense rare variants I found were either exclusive in FCH cases or 
FHTG controls; only the LDLR: p.T705I and IDOL: p.V339I were found in both FCH 
cases and controls. So, it is possible that the effect sizes of the other 29 missense rare 
variants vary, and the standard chi Square test is insensitive, since it assumes all missense 
rare variants to have an equal effect size.  
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Variant 
 
 
 
Variant 
identifier 
 
 
 
MAF  
Functionally verified 
in literature as 
causative of 
hypercholesterolemia 
 
 
 
References 
 
 
 
Population  
LDLR: p.T705I rs45508991 0.0065 No Loux et al (106), 1992 
Brussgaard et al(107), 
2006 
Graham et al (108), 
2006 
Leigh et al (110), 2008 
Cases: 1 
Controls: 2 
LDLR: p.G-2R rs147509697 0.0022 No Amsellems et al (111), 
2002 
Fouchier et al (114), 
2005 
Cases:1 
Controls:0 
LDLR: 
p.G314S 
CM920439 0.0022 Yes Hobbs et al (115), 1992 Cases:1 
Controls:0 
LDLR: 
p.D333V 
rs5930 0.0022 Yes Hobbs et al (115), 1992 Cases:1 
Controls:0 
LDLR: p.L561P CM014578 0.0022 No Wang et al (118), 2001 Cases:1 
Controls:0 
LDLR: 
p.C677G 
N/A 0.0022 No NOVEL Cases:1 
Controls:0 
LDLR: p.V806I rs137853964 0.0022 Yes Hobbs et al (115), 1992 
Lombardi et al (119), 
2000 
Zakharova et al (120), 
2005 
Huijgen et al (122), 
2010 
Huijgen et al (128), 
2012 
Cases:1 
Controls:0 
LDLR: p.T41M CM055350 0.0022 No  Fouchier et al (114), 
2005 
Cases:0 
Controls:1 
LDLR: 
p.A585S 
rs72658868 0.0022 No Sun et al (129) Cases:0 
Controls:1 
APOB: 
p.C1395Y 
rs568413 0.0022 No NOVEL Cases:1 
Controls:0 
APOB: 
p.E2539K 
rs1801696 0.0022 No Johansen et al (71), 
2010 
Cases:1 
Controls:0 
APOB: 
p.M2331I 
CM105023 0.0022 No Johansen et al (71), 
2010 
Cases:1 
Controls:0 
APOB: 
p.M4293V 
CM104782 0.0022 No Johansen et al (71), 
2010 
Cases:1 
Controls:0 
APOB: 
p.R1662H 
rs151009667 0.0022  Johansen et al (71), 
2010 
Cases:1 
Controls:0 
Table 6.1 Complete list of 31 missense rare variants observed in FCH-FHTG 
cohort and information from published research on these variants 
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APOB: 
p.R3500W 
rs144467873 0.0022 Yes Gaffney et al (31), 
1995 
Cases:1 
Controls:0 
APOB: 
p.S3252G 
rs12720854 0.0043 No Johansen et al (71), 
2010 
Cases:2 
Controls:0 
APOB: 
p.T3020R 
rs61742323 0.0022 No Johansen et al (71), 
2010 
Cases:1 
Controls:0 
APOB: 
p.T3799M 
rs61744153 0.0022 No NOVEL Cases:1 
Controls:0 
APOB: 
p.T4457M 
rs12713450 0.0065 No Johansen et al (71), 
2010 
Cases:3 
Controls:0 
APOB: 
p.I2286V 
rs584542 0.0022 No NOVEL Cases:1 
Controls:0 
APOB: 
p.E2539D 
rs149306841 0.0022 No Johansen et al (71), 
2010 
Cases:0 
Controls:1 
APOB: 
p.K1615R 
N/A 0.0022 No NOVEL Cases:0 
Controls:1 
APOB: 
p.Q3405E 
rs1042023 0.0043 No Pullinger et al (131), 
1996 
Gaffney et al (132), 
1998 
Cases:0 
Controls:2 
APOB: 
p.R2192C 
rs141641980 0.0022 No Johansen et al (71), 
2010 
Cases:0 
Controls:1 
APOB: 
p.S1586T 
rs61742247 0.0022 No NOVEL Cases:0 
Controls:1 
APOB: 
p.S3267P 
rs12720855 0.0022 No Johansen et al (71), 
2010 
Cases:0 
Controls:1 
APOB: 
p.S4403T 
rs72654426 0.0022 No Johansen et al (71), 
2010 
Cases:0 
Controls:1 
APOB: 
p.V4101M 
rs1801703 0.0022 No NOVEL Cases:0 
Controls:1 
IDOL: 
p.R372W 
rs141183183 0.0022 No NOVEL Cases:1 
Controls:0 
IDOL: p.V339I rs142124143 0.0043 No NOVEL Cases:1 
Controls:1 
IDOL: p.C31Y N/A 0.0022 No NOVEL Cases:0 
Controls:1 
 
 
 
 
 
 
 
 
 
 
 
 
Note: MAF, Minor allele frequency (defined as the frequency of the minor allele ≥ 0.01 in our combined 
FCH-FHTG cohort. 
 LDLR, Low Density Lipoprotein Receptor (gene);APOB, ApolipoproteinB-100 (gene); MYLIP, Myosin 
Regulatory Light Chain Interacting Protein (gene). 
References refer to papers that cite the variants. 
Population refers to how many of our cases and controls the variant was found in. 
N/A, Not Applicable; N/A was reported under variant identifier when variant was novel. N/A was 
reported under References when there was no research article citing the variant. 
Where variants did not have a dbSNP ID (i.e. rs ID), the HGMD accession ID was given as a variant 
identifier (which are the numbers prefixed with the letters CM) 
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6.1.2 In silico analyses of missense variants 
 The effects of all 31 missense rare variants from the candidate genes studied were 
predicted in silico using PolyPhen-2 and SIFT;  results are shown in Chapter 3. Missense 
rare variants predicted to be deleterious both PolyPhen-2 and SIFT were only found in 
cases for LDLR, namely LDLR: p.G314S, p.D333V, p.L561P and p.C677G variants, of 
which the LDLR: p.G314S and LDLR: p.D333V variants were accurately predicted as 
being likely dysfunctional (Table 3.8). This is because these two variants were predicted 
to be deleterious when functional work showed reduced LDLR activity. In contrast, the 
LDLR: p.V806I has been shown to reduce LDLR activity but was predicted to be 
tolerated by SIFT (Table 3.8) thus indicating an inaccurate in silico prediction. However, 
only PolyPhen-2 predicted the LDLR: p.V806I variant to be deleterious— even though 
p.V806I (SIFT score 0.06) marginally escaped being predicted as deleterious, since a 
SIFT score of 0.05 or lower is predicted as being deleterious (Table 3.8).  
 For APOB, 4 missense rare variants were predicted to deleterious by both 
PolyPhen-2 and SIFT in FCH cases. These variants were the APOB: p.R1662H, 
p.R3500W, p.S3252G and p.T3799M variants of which the APOB: p.R3500W variant 
was predicted accurately. In HTG controls, 2 missense rare variants were predicted to 
deleterious by both PolyPhen-2 and SIFT, which namely were the APOB: p.K1615R and 
p.S3267P variants. With respect to being causative of hypercholesterolemia, these 
predictions are very likely to be inaccurate since the variants were found in only 
normocholesterolemic controls. 
 For IDOL, the p.R373W and p.C31Y variants were predicted to be deleterious by 
both PolyPhen-2 and SIFT, and were found in cases and controls, respectively. Since the 
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literature did not report any functional work on these variants, I cannot comment on the 
accuracy of in silico predictions. With respect to being causative of 
hypercholesterolemia, the in silico prediction for the IDOL p.C31Y variant is likely to be 
inaccurate because controls are normocholesterolemic. 
The discrepancies in predictions of PolyPhen-2 and SIFT, in variants across 
candidate genes, could result from differences in algorithms and weighting priorities 
given to certain features by the two softwares. 
For each of the candidate genes, Multiple sequence alignment (MSA) was done in 
order to visually analyze amino acid conservation in the region of each rare missense 
variant (Figures 3.1-3.3). For MSA of each candidate gene, 6 species were used for MSA. 
In the first 4 species, the gene, according to NCBI, was conserved; in the last two species, 
the candidate gene was not considered to be conserved.  In general, some of the amino 
acid positions of the rare missense variants that I studied were completely conserved and 
others were not conserved. 
After looking at MSAs of LDLR, the change of amino acid to the basic arginine at 
position -2 can create electrostatic bonds with nearby acidic amino acids (shown in green 
squares) that may negatively affect protein activity (Figure 3.1). These electrostatic bonds 
may be unfavourable in the sense that it could negatively affect protein activity. Protein 
activity could also be negatively affected due to the absence of Glycine and not 
necessarily the presence of Arginine, especially since Glycine is the amino acid that 
allows most three dimensional freedom.  
The LDLR: p.T41 position is conserved in the 4 species that show the strongest 
LDLR  conservation. The conservative mutation to a Methionine may not affect LDLR 
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activity and thus may explain why the LDLR T41M variant was found in a 
normocholesterolemic control (Figure 3.1). 
The LDLR: p.G314 position is fully conserved across species. This mutation was 
shown to lower LDLR activity. This could be due to the lack of a Glycine at the LDLR 
G314 position, especially since Glycine is the amino acid that allows three dimensional 
freedom the most. This lowered activity could also be due to a non-hydrophobic amino 
acid such as Serine at the (Figure 3.1). 
The LDLR: p.D333 position is also fully conserved across species and mutation to 
the hydrophobic Valine has been shown to lower LDLR activity functionally. This 
lowered activity may be due to disruption of electrostatic bonds with nearby basic amino 
acids (shown in blue squares) (Figure 3.1).  
The LDLR: p.C677 position is fully conserved and mutation to a Glycine may 
disrupt disulphide bonds with nearby Cysteines (shown in blue squares) (Figure 3.1). 
For all the missense rare variants in LDLR, APOB and IDOL the amino acids in 
blue squares represent amino acids that could have disrupted electrostatic interactions 
with amino acids at mutant positions. Amino acids at mutant positions are in red squares. 
Amino acids in green squares represent amino acids that could have formed electrostatic 
interactions with amino acids at mutant positions. The possible formation and/or 
disruption of electrostatic bonds could be unfavourable in that it may lower protein 
activity. Amino acids in blue squares also represent amino acids that could have 
disulphide bonds formed or broken—which could negatively affect protein activity.  
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Limitations of bioinformatic analyses 
 In silico predictions in and of themselves are not enough to determine whether an 
amino acid changing variant is causative of a disease. Literature has shown that 
predictions by PolyPhen-2 and SIFT are inaccurate; the concordance with functional 
studies, when performed, is only 50-60% (139). This is because variants that have been 
shown to be deleterious functionally were predicted to be non-deleterious and conversely, 
variants that have been shown to be non-deleterious functionally were predicted as 
deleterious (139). This discrepancies could be because the in silico programs do not take 
into consideration other aspects of protein biochemistry such as post-translational 
modification, protein-protein interactions, etc (139). Therefore, in silico predictions can 
be considered ‘just slightly better than chance’ and cannot not be used in clinical 
decisions such as diagnosis, therapeutics and prognosis. Nevertheless, in silico analyses 
of missense variants are a useful tool in the investigation of variants along with other 
information such as structural information, biological information, etc. In silico analyses, 
along with other information, can also be useful in the prioritizing of those variants to test 
functionally. So the information from in silico predictions of the 31 missense rare 
variants, as well as the MSA of the 3 candidate genes, would be useful for any future 
projects involving functional validation of the variants. 
 
6.2 Findings from Familial Hypercholesterolemia Mutation Negative (FH/M-ve) 
subjects and Familial Hypercholesterolemia Mutation Positive (FH/M+ve)  
My second study was composed of two collaborative projects, namely (i) the  
resequencing of APOE  in FH/M-ve patients to look for possible undetected deleterious 
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mutations and (ii) testing whether FH/M-ve patients (cases) have a higher LDL-C genetic 
risk score than  FH/M+ve subjects (controls). In the second collaborative study, the 
hypothesis had been first tested by our collaborators in the UK. So, my second 
collaborative study not only served as a replication study, but was the first study to test 
the hypothesis in the Canadian population. 
In the first collaborative project of my second study, not a single potentially 
deleterious APOE mutation was found in the 95 FH/M-ve patients. However, our 
collaborators for this first study found APOE c.L167 del variant that segregated in an FH 
family and this APOE Leu 167 del variant was found to be causative of FH (data yet to be 
published). Their finding has now made APOE the fifth FH-causing gene. Our 
collaborator’s findings is an example of a serendipitous discovery of another FH–causing 
gene as it is very likely that our collaborator’s FH family is one of only few families in 
the world to have FH due to the APOE Leu 167 del mutation. To date (June 2013) an 
APOE Leu 167 del mutation has only been reported in one other large family as being 
causative of FH (60). Therefore, it is not surprising that our 95 FH/M-ve patients did not 
show any deleterious mutation. The second collaborative project of my second study 
showed that FH/M-ve patients had a higher mean LDL-C genetic risk score than  
FH/M+ve controls, meaning that the FH/M-ve patients have a greater accumulation of 
risk alleles. However, in my sample this greater accumulation was not statistically 
significant. The effect sizes and absolute values of the mean LDL-C genetic risk scores 
that I observed for FH/M-ve cases and FH/M+ve controls were comparable to those 
reported in our collaborators' FH/-ve cases and FH/M+ve controls, respectively (Table 
4.7). However, post hoc power calculations showed that our UK collaborators had 
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sufficient statistical power, while the sample size in my study did not afford sufficient 
statistical power to detect a difference of this magnitude in the mean values  (Table 4.7). 
So, our lack of statistical significance is likely due to restricted sample size and not due to 
lack of biological effect. In essence, my studies in the Canadian FH population replicated 
our UK collaborators' finding that an alternate polygenic etiology (as in the accumulation 
of risk alleles) can cause FH, thus making it both a polygenic and a monogenic disease. 
 
6.3 Findings from analyses of GWAS data 
Finally, I applied some of the GWAS data from (70) for all 3 projects that made 
up my third study. The aim of the first project of my third study was to identify if the 
DIET1 locus is associated with polygenic HTG in humans, because  DIET1 is associated 
with HTG in mice. The second and third projects of my third study used only the FCH 
patients and HTG patients in (70) as cases and controls, respectively. The aim of my 
second project was to test whether the PSMD9 locus, which was recently reported to be 
associated with hypercholesterolemia, is associated with hypercholesterolemia in FCH.  
The third project had two aims: (i) to test for association of the 37 GLGC-identified SNPs 
with hypercholesterolemia in FCH; and (ii) to test for accumulation of the 37 GLGC-
identified LDL-C risk alleles in FCH cases relative to controls. 
Association analysis of all the SNPs in the DIET1 region with HTG did not reach 
the overly conservative Bonferroni-corrected p-value, thus I could not say that the DIET1 
region was associated with HTG in humans. The true p-value would likely be much less 
strict than the Bonferroni corrected p-value, since many SNPs at this locus were in 
linkage disequilibrium; however the LD was largely uncharacterized in this region, I 
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could not estimate what the appropriate correction should be, and so used the Bonferroni 
correction as my default approach. Limitations of the first project was sample size, as 
typical GWAS studies have very large sample sizes (79) (70). Nevertheless, I am still 
confident in testing whether the DIET1 locus is associated with HTG in humans, since 
nothing was known about this unannotated region in humans previously, and also 
because my findings will be a useful starting point in future analysis of this region. If and 
when more is learned about the DIET1 region in humans, it is likely that fewer SNPs 
would be tested for association, which would increase the statistical power since the 
adjustment of the nominal p-value would be less strict. Because my results might be 
useful for future analyses, I  still reported 5 SNPs with the strongest associations — albeit 
all non-statistically significant (Table 5.2). 
In my second project, I found that the most highly associated SNP —albeit not 
statistically significant— in the PSMD9 region with FCH was the rs1795964 SNP 
(P=0.08). So it is possible that this region plays a role in hypercholesterolemia in FCH. 
However, the second project was similarly limited with respect to statistical power, 
because only subset of subjects from the database in (70) was used. However, as with the 
first project, the information could be useful for future studies. 
Finally, I tested for association of each of the 37 GLGC-identified SNPs in the 
first part of my third project. The top three SNPs with strongest associations were all well 
below the Bonferroni the corrected p-value (Table 5.6). Since these 37 SNPs were not in 
LD, the Bonferroni corrected p-value is not overly conservative. Here I may not have 
detected any significance because of limited statistical power due to sample size. 
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Nevertheless, my findings would be valuable for future larger-sized meta-analyses 
studies that could include our samples.  
My findings for the second part of the third project showed that there is a greater 
accumulation of risk alleles in FCH cases relative to controls at a rate borderline of 
statistical significance (P=0.054). Given the sample size, the inclusion of the 37 SNPs 
increased statistical power compared to testing each of the 37 SNPs individually. So, if I 
had the opportunity to study a few more patients, the p-value could have been well below 
0.05. In essence, the 37 SNPs that affect LDL-C levels in the general population also 
appear to affect LDL-C levels in FCH. This is in line with the concept that the genetic 
etiology of FCH is polygenic (66). 
 
6.4 Conclusions 
Findings from my first study have shown that the presence of HTG and FH-
causing mutations can interact to produce an FCH phenotype. In other words, my 
findings suggest that FCH can sometimes indeed result from the co-existence of FH and 
HTG genetic susceptibility. My finding of the LDLR: p.G314S, p.D333V, p.V806I and 
APOB: p.R3500W variants in the FCH cases supports the idea that rare FH-causing 
mutations are over-represented in FCH. My first study was the first of its kind. However, 
a similar—yet far from identical— study was performed by Civeira et al (140), where 
LDLR and APOB variants (203 LDLR variants and 4 APOB variants) were genotyped in 
only 143 unrelated FCH patients (140). Civeira et al found LDLR mutations in his FCH 
population. However, their study, unlike mine, was uncontrolled and so variants they 
found could also have been present in normocholesterolemic controls, including healthy 
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individuals and individuals with HTG. For instance, Civeira et al stated that none of the 
mutations they found were reported in normolipidemic individuals and one of the LDLR 
variants the genotyped was LDLR: p.T705I (140). Civeira et al also stated that the variant 
they genotyped were reported to be causative of FH (140). From our extensive literature 
search on each of our 31 LDLR missense rare variants, we discovered that there were 
variants reported to cause hypercholesterolemia in the HGMD database, when extensive 
literature search did not confirm those variants being causative of hypercholesterolemia 
such as the APOB: p.Q3405E, LDLR: p.T705I and LDLR: p.G-2R variants. Thus having 
sequence information from controls, which Civeira et al did not have, helped in our 
assessment of whether a variant was possibly causative of hypercholesterolemia. For 
instance, I found the same LDLR: p.T705I that Civeria et al found and interpreted as 
being FH causing, in our normocholesterolemic HTG controls, which helped me discard 
LDLR: p.T705I as being causative of hypercholesterolemia in FCH. 
Even though the understanding of the genetic etiology of FCH in the field shifted 
from being autosomal dominant to polygenic, no one had confidently disprove that FCH 
is caused by FH causing mutations because no one ever sequenced the three well known 
FH causing genes.  ‘Absence of evidence (not knowing for sure that 
hypercholesterolemia in FCH is due to FH-causing mutations) is not evidence of absence 
(FCH is not due to FH-causing mutations)’. But the findings from my first study indicate 
that FCH is for the most part not due to FH causing mutations. Despite the fact that post 
hoc power calculations showed low statistical power for my first study, if the 
hypercholesterolemia in FCH had indeed been due to FH-causing mutations, my sample 
size would have been sufficiently powered. This is because, hypothetically speaking, had 
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I tested the same hypothesis in 138 FH cases and 94 controls, I would have had a greater 
accumulation of missense rare variants in our cases.  
Findings from my second study support the idea that while FH is mainly 
monogenic, there are some cases in which there is a polygenic cause. For instance, 
findings from my study suggest that it might be warranted to test for greater accumulation 
of the 37 GLGC- identified LDL-C risk alleles in FH cases relative to healthy controls, 
especially when a mutation in any of the known genes is absent, since the genetic 
etiology of FH can sometimes be polygenic.  
The biological macromolecules such as carbohydrates, proteins, lipids and nucleic 
acids are vital to human existence. So, it is not unreasonable that many genes are 
involved in the metabolism of these macromolecules, including lipids. Many genes are 
involved in cholesterol metabolism, thus mutation in such genes can lead to a clinical 
presentation of hypercholesterolemia. Therefore, findings from the APOE collaborative 
project would support searching for other possible monogenic causes of FH using next 
generation sequencing technologies, such as whole exome sequencing, in FH/M-ve 
cohorts.  
 Findings from testing for accumulation of the 37 LDL-C risk SNPs in FCH cases 
as well as findings from my first study show that genetic etiology of 
hypercholesterolemia in FCH, like in FH, can be monogenic and polygenic. Findings 
from testing for accumulation of the 37 LDL-C risk SNPs in FCH cases and findings 
from testing for accumulation of 12 of the 37 LDL-C SNPs in FH/M-ve cases show that 
the polygenic etiology of hypercholesterolemia in FCH and FH are similar in some 
patients. 
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All of these findings have shown that genetic definition of a disease, including 
monogenic diseases, cannot be too rigid, which might help clinicians make a better 
diagnosis, especially if it can be shown that these different etiologies predict a different 
prognosis or different response to treatment. My findings also support the idea that 
personalized medicine might one day be the standard of care for patients with 
hyperlipidemia, especially since the genetic etiology of a these diseases cannot be 
‘generalized’ into a single cause. From an economic aspect, this would also encourage 
researching ways of making personalized medicine cost-effective. 
All of my findings strongly support extending such investigative approaches to 
other monogenic diseases, where the causative gene does not explain the disease in some 
minority of cases. Finally, the findings from my studies support a new way of thinking 
and a different approach in unraveling the genetic etiology of monogenic and polygenic 
lipid disorder and perhaps other related diseases in the field. 
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Appendix 
 
 
Variant SNP MAF Cases (n=138) Controls (n=94) 
p.G-2R rs147509697 0.002165 1 0 
p.C6C rs2228671 0.09307 29 14 
p.T41M NR 0.002155 0 1 
c.190,+56G/A rs3745677 0.07576 22 13 
c.313,+69C/T rs56084625 0.01082 2 3 
c.314,-50T/C rs10423288 0.002155 0 1 
c.940,+16G/A rs72658859 0.002155 0 1 
c.940,+36G/A rs13306513 0.02851 8 5 
c.941,-39C/T rs55792959 0.01078 2 3 
p.G314S NR 0.002165 1 0 
c.1060,+7T/C rs2738442 0.002155 0 1 
c.1060,+10G/C rs12710260 0.4286 113 85 
c.1060,+49C/T NR 0.002155 0 1 
c.1060,+59A/C rs55642005 0.002155 0 1 
c.1061,-82G/C rs41301947 0.002155 0 1 
c.1061-8T/C rs72658861 0.002174 1 0 
p.D333V NR 0.002174 1 0 
p.C347C rs113669610 0.002174 1 0 
p.A370T rs11669576 0.05 12 11 
c.1373,+29C/A NR 0.002174 1 0 
p.N407N NR 0.00431 0 2 
c.1359,-54C/T rs6413505 0.00431 1 1 
c.1359,-30C/T rs1003723 0.4353 117 85 
p.R450R rs5930 0.4095 165 109 
c.1774,-87G/A NR 0.002155 0 1 
p.P518P rs5929 0.05435 20 5 
c.1705,+56C/T rs4508523 0.1354 40 22 
c.1706,-81C/T rs41307025 0.006466 1 2 
c.1706,-69G/T rs7259278 0.1358 41 22 
c.1706,-55A/C rs2738447 0.4203 162 107 
c.1706,-10G/A rs17248882 0.006466 2 1 
p.L554L rs1799898 0.1293 35 25 
p.L561P NR 0.002155 1 0 
p.N570N rs688 0.4353 118 84 
Table 1.  List and description of all variants identified in all 18 exons and promoter 
of LDLR and the minor allele counts in cases and controls 
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p.T576T NR 0.002155 1 0 
p.A585S rs72658865 0.002155 0 1 
c.1846,-78C/G rs116959285 0.04762 13 9 
p.N619N rs5926 0.00431 0 2 
p.V632V rs5925 0.4351 118 83 
p.C677G NR 0.002183 1 0 
c.2140,+5G/A rs72658867 0.00655 1 2 
p.T705I rs45508991 0.006466 1 2 
p.R723R rs5927 0.263 203 136 
c.2312,-71G/A rs17249358 0.006466 1 2 
c.2312,-47G/A rs41306974 0.03097 6 8 
c.2312,-28G/A NR 0.002155 0 1 
c.2389+41C/A rs72658868 0.006637 1 2 
c.2389+46C/T rs2738460 0.2633 76 43 
c.2389+47G/A rs13306501 0.03319 8 7 
c.2389,+51C/T rs145293532 0.002165 1 0 
p.V806I rs137853964 0.002165 1 0 
c.2548,-53G/A rs6413503 0.006466 1 2 
c.2548,-42A/G rs6413504 0.4697 130 87 
3'UT+19G/A rs56270417 0.004329 2 0 
3'UT+52G/A rs14158 0.2294 62 44 
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Variant SNP identifier MAF Cases (n=138) Controls (n=94) 
 p.T4533 rs72654427 0.002155 1 0 
 p.T4457M rs12713450 0.006466 3 0 
 p.A4454T NR 0.04095 8 11 
 p.S4403T rs72654426 0.002155 0 1 
 p.S4311N rs1042034 0.194 44 46 
 p.M4293V NR 0.002155 1 0 
 p.I4287V rs72654423 0.01293 5 1 
 p.R4243T rs1801702 0.0194 7 2 
p.V4238A NR 0.01078 2 3 
p.E4154K rs1042031 0.1724 46 34 
 p.V4101M rs1801703 0.002155 0 1 
 p.Y4089 NR 0.002155 1 0 
c.11788+150C>T rs12713523 0.002155 0 1 
 p.T3799M NR 0.002155 1 0 
 p.R3611Q rs1801701 0.06034 15 13 
 p.T3540 rs12713558 0.002155 1 0 
 p.R3500W Reported 0.002155 1 0 
 p.Q3405E rs1042023 0.00431 0 2 
 p.L3350 rs1799812 0.002155 0 1 
p. S3267P rs12720855 0.002155 0 1 
 p.S3252G rs12720854 0.00431 2 0 
 p.Y3071 NR 0.002155 0 1 
 p.T3020R rs61742323 0.002155 1 0 
 p.N3008 NR 0.002155 0 1 
 p.P2794L rs72653095 0.01078 4 1 
 p.P2712L rs676210 0.1897 43 45 
p.I2689 rs6413458 0.01724 5 3 
 p.L2594 NR 0.002155 1 0 
 p.E2539D NR 0.002155 0 1 
 p.E2539K rs1801696 0.002155 1 0 
 p.L2511 rs72653093 0.00431 1 1 
 p.T2488 rs693 0.4871 124 102 
 p.M2331I NR 0.002155 1 0 
 p.V2286I rs584542 0.002155 1 0 
 p.D2285 NR 0.4935 127 102 
Table  2.  List and description of all variants identified in exons 26 and 29 APOB 
in and minor allele count in cases and controls   
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 p.R2192C NR 0.002155 0 1 
 p.H2040 rs143222685 0.002155 0 1 
 p.H1896R rs533617 0.02586 5 7 
 p.N1887S rs1801699 0.01293 3 3 
 p.P1875 NR 0.002155 1 0 
 p.R1662H NR 0.002155 1 0 
 p.K1615R   0.002165 0 1 
 p.S1586T rs61742247 0.002165 0 1 
p. F1428 rs12720847 0.002155 1 0 
p.C1395Y rs568413 0.002155 1 0 
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Variant       SNP identifier MAF Cases (n=138) Controls (n=94) 
5'UTR,-56G/T rs3765234 0.04565 17 4 
c.87+60G/A rs1076632 0.004348 1 1 
p.C31Y New 0.002174 0 1 
c.279,-31A/G rs34444721 0.002174 1 0 
c.464,+80T/C rs143656216 0.01957 1 8 
p.I202L rs79992066 0.3978 92 185 
c.663,-33A/G rs2072783 0.1413 38 27 
p.V339I rs142124143 0.004348 1 1 
p.N342S rs9370867 0.4696 121 95 
p.R372W rs141183183 0.002174 1 0 
p.C391 rs1060901 0.09565 19 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.  List and description of all variants identified in the 7 exons of IDOL 
in and minor allele count in cases and controls   
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Normality Test p-value 
Shapiro-Wilk <0.0001 
Kolmogorov-Smirnov 0.0112 
Cramer-von Mises <0.0050 
Anderson-Darling <0.0050 
 
 
Normality Test p-value 
Shapiro-Wilk 0.0004 
Kolmogorov-Smirnov <0.0100 
Cramer-von Mises <0.0050 
Anderson-Darling <0.0050 
 
Normality tests was done on the LDL-C genetic risk score for Familial 
Hypercholesterolemia (FH) mutation negative patients (a) and FH mutation positive 
patients (b). In Normality tests, p-value less than 0.05 means that the null hypothesis 
(which states that the data are normally distributed) means that the data are not normally 
distributed). So, Normality tests showed that the LDL-C genetic risk scores were not 
normally distributed. 
 
 
Table 4.  Normality tests for LDL-C genetic risk score for (a) FH Mutation 
negative patients and (b) FH Mutation positive patients 
a 
b 
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